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Classic techniques designed to understand bacterial gene regulation in vitro are still
used today to elucidate genetic mechanisms and pathways. However as much as we
can learn from in vitro studies of bacterial behaviour, it is impossible to fully recreate
the complex and multifaceted environment the bacterium faces in vivo. To this end
the development of techniques to allow us to study gene regulation in vivo is
important as these can then be applied to dissect bacterial pathogenesis and should
uncover novel therapeutic targets.
Recombinase in vivo expression technology (RIVET) provides a heritable irreversible
marker of gene activity in the host and has been applied recently to discover genes
important for bacterial virulence in the host. The aim of this project was to develop a
novel RIVET system using genes from the enterohaemorrhagic Escherichia coli
0157:H7 (EHEC) ftm operon and the beta-lactamase reporter gene (bid). This system
was named FR1VET (Jim recombinase in vivo expression technology)
The basis to FRIVET is a completely synthetic operon placed in single copy in the
EHEC chromosome at the Jim locus. The arabinose (ara) inducible promoter was
tested in the system initially to validate the system in vitro. The key aim of these in
vitro tests was to understand the working tolerances of the FRIVET operon and define
appropriate control points. Emphasis was placed on 'setting' the system and
controlling the levels of recombination achieved.
Construction of the FRIVET operon on allelic exchange vectors and subsequent
exchange into a Shiga-like toxin negative EHEC strain was successful. In vitro tests
using the ara promoter proved the system functioned as intended and was
experimentally stable. When EHEC promoters, in particular LEE5, were tested in
vitro, considerable difficulty was encountered in controlling levels of recombination
and setting the system to the off status. This is essential for any use of the system to
examine gene expression in vivo. Therefore the emphasis of future work must be on
defining appropriate measures for controlling in vitro activity of chosen promoters
when preparing constructs for in vivo challenges.
With appropriate modifications the FRIVET system has the potential to produce
valuable data about EHEC gene expression in the host and therefore to contribute to
our understanding of the complex regulation required to establish colonisation,
maintain infection and induce pathology in vivo.
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The introduction to this thesis will be divided into three distinct sections. Section 1.1 will
outline Escherichia coli 0157:H7; its pathogenesis and the major virulence factors
deployed in its natural host as a commensal and in humans as a pathogen. Section 1.2
will focus on the fim operon, an important fimbrial cluster in uro-pathogenic Escherichia
coli. The FRIVET system is constructed using a number of important genes from the fim
operon. Section 1.3 describes in vivo expression technology and its evolution over the
past decade. Section 1.4 outlines the fim recombinase in vivo expression technology
(FRIVET) system and details its construction methods and uses. Section 1.5 summarises
the main aims of the thesis.
1.1.1 - Escherichia coli 0157:H7
Escherichia coli 0157:H7 is a serotype of Enterohaemorrhagic Escherichia coli (EFIEC)
responsible for sporadic outbreaks of gastro-intestinal disease in humans. It was first
identified and associated with human disease in 1982 in an outbreak in the USA (Riley et
al, 1983). Since then outbreaks of haemorrhagic colitis (HC) and diarrhoea associated
with E. coli 0157:H7 have occurred mainly in Europe, Japan and North America and E.
coli 0157:H7 has emerged as a major cause of diarrhoeal illness and paediatric renal
failure. E. coli 0157:H7 associated deaths are thought to be in the region of 60 from
74,000 cases per annum (Mead et al, 1999).
The main routes of infection are faecal contamination of food or dairy products, direct
contact with colonised ruminants and water supply contamination. The largest E. coli
0157:H7 outbreak to date occurred in Sakai, Japan in 1996 with over 6000 school
children infected. The outbreak was associated with faecal contaminated white radish
sprouts from a single farm (Michino et al, 1999). However, person to person spread can
also occur in outbreaks (Naylor et al, 2005). Patients that develop HC can develop more
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serious sequelae such as haemolytic uraemic syndrome (HUS) and thrombocytopaenic
purpura (TTP). The prevalence of HUS appears to be higher in the young and the elderly.
The natural reservoir of E. coli 0157:H7 is the ruminant, and recently the terminal
rectum (TR) has been identified as a specific colonisation site of attachment for E. coli
0157:H7 (Naylor et al, 2003). Experimental and natural infection studies in cattle results
in the efficient colonisation of the intestinal tract and persistent shedding of E. coli
0157:H7 in the faeces for several weeks post inoculation (Naylor et al, 2003; Wray et al
2000). Importantly, E. coli 0157:H7 colonisation and infection in cattle seems to be
asymptomatic except in very young calves (Dean-Nystrom et al, 1997).
To date the complete genome sequences of two E. coli 0157:H7 strains have been
reported. The first sequenced strain was isolated from the E. coli 0157:H7 disease
outbreak in 1983 termed E. coli 0157 EDL933 (Perna et al., 2001), the second sequenced
strain was responsible for the large outbreak previously mentioned in Japan in 1996,
termed E. coli 0157 Sakai (Hayashi et al., 2001).
The molecular mechanisms utilised by E. coli 0157:H7 to colonise the ruminant host are
not fully understood to date. E. coli 0157:H7 is able to form distinct attaching and
effacing lesions (A/E) on tissue culture cells (Nataro and Kaper, 1998) and intestinal
epithelium in vitro (Phillips et al, 2000) characterised by localised clearance of brush
border microvilli, actin cytoskeleton recruitment, pedestal formation and intimate
bacterial attachment. Recent studies have also demonstrated that E. coli 0157:H7 forms
A/E lesions at the TR site of colonisation (Naylor et al, 2005). Important virulence
factors involved in this process will be discussed in detail below. Briefly, the intimate
attachment seen in A/E lesions is a result of a translocated effector protein inserting itself
into the host cell membrane and acting as a receptor for the bacterial adhesin, intimin. As
a consequence of this interaction the effector protein was
termed the translocated intimin receptor (Tir). Studies have shown that (a) Intimin is an
important adhesin for colonisation in a variety of ruminant models (Cornick et al, 2002;
Dean-Nystrom et al, 1998; Woodward et al, 2003) and (b) mutations in Tir impact on
calf colonisation (Vlisidou et al, 2006), suggesting a vital role for these proteins in
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ruminant colonisation and a strong link between the formation of A/E lesions and
ruminant persistence. Other T3SS secreted proteins and their role in host colonisation
and pathogenesis will be discussed below.
The importance of other bacterial proteins in E. coli 0157:H7 host persistence continues
to be elucidated. Conflicting data on the importance of ToxB, a homologue of
Efal( EHEC factor for adherence) from EHEC 0111:H-, as an important colonisation
factor on cultured epithelial cell lines but not in ruminant infection studies has been
published (Stevens et al, 2004; Tatsuno et al, 2001). Much of the work into E. coli
0157:H7 genes involved in colonisation has focused on a small subset of potentially
important virulence genes encoding a bacterial type III secretion system (T3SS) and an
array of regulators, effectors and adhesins. Recently, a signature tagged mutagenesis
study revealed 59 genes required for intestinal colonisation in young calves, many of
which associated with the T3SS. E. coli 0157:H7 appears to contain 2 distinct sets of
genes encoding the structural genes for a T3SS:
• The LEE - Locus of Enterocyte Effacement
• ETT2 - E. coli type III secretion system 2
The importance of the LEE in E. coli 0157:E17 pathogenesis is well documented and will
be discussed below. The function of ETT2 however is less well understood. Although it
appears to be non-functional as a T3SS, studies have shown that mutations in ETT2
regulatory genes appear to upregulate genes on the LEE (Zhang et al, 2004). This
indicates a level of cross talk between regulators from distinct gene clusters.
1.1.2 - The Locus of Enterocyte Effacement (LEE)
The formation of A/E lesions by E. coli 0157:H7 is a complex process with multiple
levels of regulation. The translocation of key effector proteins responsible for the A/E
histopathology is carried out by the T3SS. Bacterial T3SS utilise a multiprotein basal
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apparatus spanning the inner and outer membranes, and a 'needle' complex, extending
from the basal apparatus, which injects proteins into the host cell. The genes encoding
the E. coli 0157:H7 T3SS are contained on a 43kb pathogenicity island termed the Locus
of Enterocyte Effacement (LEE). The LEE was first described in Enteropathogenic E.
coli (EPEC) (McDaniel et al, 1995) and was sequenced shortly afterwards (Elliot et al,
1998). The E. coli 0157:H7 LEE contains a substantially lower GC content (39% vs.
51%) than the rest of the E. coli 0157:E17 chromosome suggesting the acquisition of the
LEE by horizontal gene transfer (Khan et al, 2003). Although similar in structure and
function there are two main differences associated with the EPEC LEE and the E. coli
0157:H7 LEE. Firstly studies have shown the cloned LEE from EPEC confers the
ability to form A/E lesions in E. coli K12 but the LEE from E. coli 0157:H7 is unable to
confer this ability to the same strain (Elliot et al, 1999). Additionally the E. coli
0157:H7 LEE is larger than its EPEC version due to the presence of a 7.5kb prophage at
the right hand end (Perna et al, 1998). The importance of this prophage in determining
the regulation of the E. coli 0157:H7 LEE is yet to be elucidated.
A total of 41 open reading frames (ORF's) have been discovered in the E. coli 0157:H7
LEE (Perna et al, 1998) and the majority are organised into 5 distinct operons: LEE1,
LEE2, LEE3, LEE4 and tir. However other genes known to have a role in the formation
of A/E lesions and the regulation of the LEE lie outwith this pathogenicity island and will
be discussed below. The LEE is shown diagrammatically in Fig 1.1.
The LEE1, LEE2 and LEE3 operons contain the genes encoding the structural proteins
required for the T3SS basal apparatus (Elliot et al, 1998). It has been postulated that E.
coli 0157:H7 can differentially regulate the LEE operons to create a 'primed' state, in
which the bacterium produces the T3SS basal apparatus but represses the production of
secreted effector proteins. The T3SS is represented diagrammatically in Fig 1.2.
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Fig 1.1















Genetic organisation of the LEE pathogenicity island from E. coli 0157:H7
1.1.3 - Ler - LEE Encoded Regulator
The first gene in the LEEl operon is ler (LEE encoded regulator). Ler, an H-NS
homologue, acts as a positive regulator of the LEE2, LEE3 and tir operons as well
positively regulating its own expression by removing H-NS repression of the LEE, an
action that seems to require GrlA and upstream IHF binding (Laaberki et al, 2006; Elliot
et al, 2000; Bustamante et al, 2001; Mellies et al, 1999; Friedberg et al, 1999). It also
seems that ler can respond to adverse environmental changes through the activity of the
stress response sigma factor RpoS in conjunction with the non coding RNA DsrA
(Laaberki et al, 2006) as well as the quorum sensing molecule QseA (Sperandio et al,










The type III secretion system (T3SS) from E. coli 0157:H7. The basal apparatus and
needle complex is comprised of proteins encoded by the LEE. The LEE also encodes
translocated effector proteins that can be secreted through the needle complex and into the
host cell. EspA forms a hollow protein filament extending from the needle complex. EspB








LEE1 LEE2 LEE3 tir LEE4
Positive and negative regulators of the ler gene. The yellow arrows represent factors that
influence ler expression. The direct consequence of ler expression is the upregulation of the
LEE1, LEE2 and LEE3 operons and the production of the T3SS. LEE4 and tir are also
upregulated by Ler, although to a lesser extent than LEE1, LEE2 and LEE3.
1.1.4 - LEE4 Operon
The LEE4 operon encodes the translocated bacterial proteins EspA, EspD, EspB and
EspF as well as the cytoplasmic protein SepL, and the T3SS needle complex protein,
EscF. The EspA protein forms a hollow filament that elongates the needle complex on
the T3SS and allows the efficient secretion of the other LEE4 translocated proteins EspB
and EspD into the host cell (Knutton et al, 1998). EspB and EspD have been shown to be
targeted to the host cell membrane by EPEC and EHEC and the proteins are thought to
form a pore in the host cell membrane that completes the conduit from the bacterial T3SS
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via the EspA filament through which translocated proteins can pass (Wachter et al, 1999,
Wolff et al, 1998, Kresse et al, 1999, Daniell et al, 2001).
The sepL, espA, espB and espD genes are transcribed from a single promoter at sepL and
the resultant RNA is subject to post-transcriptional regulation (Roe et al 2003). This post
transcriptional control of LEE4 effector proteins was revealed by comparing transcription
activity from the LEE4 promoter and the production of EspA filaments. Whilst the
expression of the LEE4 promoter remained stable the expression of EspA filaments was
heterogenous (Roe et al 2003). Additionally, espADB mRNA levels were measured and
found to be inversely proportional to EspA and EspD production. That is, the cells
secreting low amounts of EspA and EspD contained higher levels of espADB mRNA,
providing further evidence of the post transcriptional control of LEE4.
It is clear therefore that the LEE4 operon is under an alternative control procedure to the
LEE 1,2,3 operons. This indicates a stratagem employed by the bacterium where the
basal apparatus of the T3SS may be constructed already following Ler activation of the
LEE1,2,3 operons but the secretion of effector proteins and the formation of the EscF
needle and EspA hollow filament takes place at another time point and under different
control. The use of in vivo expression technologies will help us to elucidate these levels
of control.
1.1.5 - LEE5 Operon
The LEE5 operon comprises of the tir, cesT and eae genes encoding for the Tir, CesT and
intimin proteins respectively and is transcribed from a single promoter at tir (Sanchez-
SanMartin et al, 2001). Intimin is an outer membrane surface protein that binds to Tir on
the surface of the host cell (Kenny et al, 1997).
There are at least five antigenically distinct subtypes of intimin: a, p, y, 8, and e, each
exhibiting sequence variation in their C-terminal cell binding domains (Adu-Bobie et al,
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1998) and tissue specific tropism (Reece et al, 2001). E. coli 0157:H7 expresses Intimin
7, a subtype shown to effect tropism to follicle associated epithelium (FAE) in humans
and cattle (Phillips et al, 2000; Naylor et al, 2003). Additionally the role of intimin as an
adhesin for host cell receptors such as nucleolin (Sinclair and O' Brien, 2002) has been
shown and there is speculation that intimin may act as the initial adhesin for E. coli
0157:H7 colonisation in the host, although the mechanisms of intimin binding in vivo to
host cell receptors is not well known. The 'middle' gene in the tir operon encodes the
chaperone, CesT which has been shown to interact with Tir, enabling efficient transfer
through the T3SS (Elliot et al, 1999; Creasey et al 2003)
Tir has been shown to be translocated into the host cell via the T3SS where it inserts into
the host cell membrane and binds to intimin expressed on the bacterial cell surface The
Intimin-Tir interaction is required for the subsequent actin cytoskeleton rearrangement
and pedestal formation characteristic of A/E lesions (Kenny at al, 1997). Actin re¬
organisation proceeds as Tir couples with N-WASP (neural Wiskott-Aldrich syndrome
protein), a process that requires the bacterial translocated protein, TccP (Tir-cytoskeleton
coupling protein, aka EspFu) (Campellone et al, 2004; Garmendia et al, 2004), although
in vivo studies have shown that tccP mutants can form A/E lesions to some extent
suggesting an alternative pathway for actin recruitment by Tir in the host cell (Vlisidou et
al, 2006).
Tir has been shown to be essential for intestinal colonization in E. coli 0157:H7 rabbit
models (Ritchie et al 2003) bovine calf and lamb models (Vlisidou et al, 2006) and in
rabbit EPEC models (Marches et al 2000). A recent study has shown that E. coli
0157:H7 shows heterogenous expression of the tir operon and that the same subset of
cells expressing tir also express intimin on their cell surface (Roe et al, 2004), this co¬
ordinate expression shows that intimin is only expressed on the cell surface when Tir is
being produced, suggesting that the main function of intimin is an adhesin for Tir, and
not as an initial adhesin for E. coli 0157:H7 colonisation. Furthermore the same study
showed that the subset of bacterial cells expressing tir were the same subset of cells that
produced EspA filaments on their cell surface and furthermore, it is likely that factors
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outside the LEE are responsible for this regulatory control (Roe et al, 2004). This
provides important evidence that the expression of the LEE4 and the tir operons are co-
ordinately controlled at the single cell level.
Interestingly, EPEC does not appear to exhibit the same heterogeneity of expression for
LEE4 and tir, rather EPEC tir expression was homogenous for a given population. The
differences in LEE4 and tir regulation between the two strains may be caused by the
ETT2, which is present in E. coli 0157:H7, but absent in EPEC (Roe et al, 2004).
1.1.6 - Map (mitochondrial-associated protein)
The map gene is transcribed from a different promoter to that of the tir operon (Kenny
and Jepson, 2000). Map is a translocated effector protein, secreted into the host cell via
the T3SS and the activity of CesT. In EPEC it has been shown to target the host cell
mitochondria where it disrupts mitochondrion activity (Kenny and Jepson, 2000). The
precise function ofMap in E. coli 0157:H7 pathogenesis in vivo is yet to be determined.
Transcription studies in E. coli 0157:H7 using gfp have shown the same heterogenous
expression for map as for LEE4 and tir; however unlike LEE4 and tir, which appear to be
co-ordinately controlled, the subpopulation expressing map was different to the
subpopulation expressing LEE4 and tir (Roe et al, 2004) indicating different timing of
map activation in the overall colonisation process. This result also indicates that map is
under the control of a different regulatory pathway than tir and LEE4.
1.1.7 - Other LEE encoded effector proteins
Other translocated effector proteins encoded on the LEE include: EspF; EspH, EspG and
EspZ/SepZ. EspF has shown to have a role in EPEC in disrupting barrier function in host
cells and in inhibiting macrophage uptake (Quitard et al, 2006), however the role of EspF
in E. coli 0157:H7 is less clear (Viswanathan et al, 2004). Studies have shown a similar
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function but redundancy of EspF via extra non LEE coded factors again highlighted the
different modes of regulation for EPEC and E. coli 0157:H7. EspH appears to play a key
role in action cytoskeleton modulation (Tu, et al, 2003). EspG does not seem to be
involved directly in A/E lesion formation but has shown to be responsible for disruption
of the host cell microtubules (Shaw et al, 2005).
A role for EspZ (renamed from SepZ) in E. coli 0157:H7 pathogenesis is yet to be
determined, but in EPEC EspZ has been shown to be localized beneath pedestals in
proximity to Tir. Elowever, EspZ translocation is thought to occur after pedestal
formation and is not essential for Tir activity (Kanack et al, 2005).
1.1.8 - Non-LEE encoded effector proteins
As well as the LEE encoded effectors, a variety of non LEE encoded virulence factors for
E. coli 0157:EI7 and EPEC have been characterised. Cycle inhibition factor (Cif) has
been shown to disrupt the host cell growth cycle and modulates the host cell actin
cytoskeleton (Marches et al, 2003), but does not appear to be required for A/E lesion
formation.
The nleA (Non-LEE encoded) gene is present in E. coli 0157:H7 on a prophage and is
not required for A/E lesion formation but seems to have a tropism to the host cell golgi
apparatus (Gruenheid et al, 2004). Interestingly nleA was found to be present in 86% of
clinical EHEC isolates (Mundy et al, 2004). The aforementioned TccP (EspFu) is also
present on a prophage and recently another prophage encoded effector protein, EspJ was
found to play a role in host persistence, but not A/E lesion formation (Dahan et al 2005).
A recent study on the Sakai genome elucidated 39 putative Nle's (Tobe et al, 2006),
indicating that E. coli 0157:H7 has a large array of effector proteins, many as yet
uncharacterised.
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1.1.9 - E. coli 0157:H7 adhesins
The precise role of adhesins in the pathogenesis of E. coli 0157:H7 is still unclear. It is
logical to presume that initial attachment to preferred tissue types or sites by E. coli
0157:H7 may be mediated by fimbrial adhesins, with the formation of A/E lesions
perhaps a direct consequence of bacterial binding. However as yet the fimbriae involved
are unknown.
The sequencing of two E. coli 0157:H7 strains has identified at least 16 putative fimbrial
clusters. Some of these such as the type 1 fimbrial operon, are well characterised, and
many clusters are at least partially conserved in other E. coli strains. In a recent study
analysing E. coli (3157:117 fimbrial operons only four clusters were found that were
specific to E. coli 0157:H7 (Low et al, 2006). Of the four clusters, the functions of two
are unknown. The remaining two clusters show similarity to the long polar fimbriae
(LPF) described initially in Salmonella enterica serovar Typhimurium (S. Typhimurium)
(Baumler and Heffron, 1995). LPF in S. Typhimurium have been shown to mediate
attachment to the follicle associated epithelium (FAE) of murine Peyer's patches
(Baumler et al, 1996). FAE is present at the terminal rectum of cattle, and therefore it
may be possible that LPF in E. coli 0157:H7 mediates initial binding to the FAE at this
site but to date there is no evidence that this occurs in vivo.
A signature tagged mutagenesis (STM) study on E. coli 0157:H7 in calves highlighted an
E. coli 0157:H7 gene showing homology to a fimbrial usher that lay within a cluster
designated loc8, also shown to be important in calf colonisation (Dziva et al, 2004). A
recent study has characterized this cluster (renamed F9) in E. coli 0157:H7. Induction of
F9 expression led to increased binding to bovine GI tissue for E. coli K12, but reduced
binding for E. coli 0157:H7, perhaps as a result of the induced F9 fimbriae interfering
with T3SS formation and/or function (Low et al, 2006).
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1.1.10 - Shiga Toxin
The main virulence factor for E. coli 0157:H7 for human infections is shiga toxin (Stx)
and it is this toxin that is responsible for the serious symptoms of E. coli 0157:H7
infection such as HUS and HC (Nataro and Kaper, 1998). There are two types of Stx:
Stxl and Stx2 and both are encoded on lysogenic phages. This fact, coupled with the
discovery that Stx can be detected in cattle faeces (Ball et al, 1994) seems to suggest a
role for Stx in the successful colonisation of cattle, despite the apparent lack of
pathogenicity shown by E. coli 0157:H7 in this host. EHEC strains may carry and
express only Stxl, only Stx2 or both. Stx toxins are compound toxins formed of a 32kDa
'A' subunit and a pentameric 'B' subunit made up of 7.7kDa monomers. The A subunit
is the active domain entering the host cell and inhibiting protein synthesis and the B
subunit mediates binding to specific receptors on the host and aids translocation of the
toxin into the host cell (O'Loughlin and Robins-Browne, 2001).
Stx has been shown to bind to a specific glycolipid receptor: globotriaosylceramide (Gb3)
on the host cell surface (Lingwood, 1996). As a result of this specific binding the
distribution of Gb3 receptors is crucially important. The development of HUS in patients
infected with E. coli 0157:H7 is due to the renal damage caused by the shiga toxin and it
is no surprise that renal tissue has a high concentration of Gb3 receptors. Significantly
the different infection paths of E. coli 0157:H7 in cattle and humans may be partly
caused by variation in Gb3 receptor level expression. Studies have shown that while
human intestinal tissue does not express high levels of Gb3, tissue types in the cattle
intestinal tract have been shown to express Gb3 (Hoey et al, 2002). The expression of
Gb3 at these sites in cattle may prevent dissemination of Stx to sub epithelial areas,
exposing the host to Stx mediated tissue damage.
It is clear that Stx has an important role to play in both human disease and cattle
colonisation. Key factors such as the distribution of Gb3 receptors and the different
immunomodulatory effects shown by Stx between hosts may explain the differences seen
in E. coli 0157:H7 pathogenicity in cattle and humans. Recent work has indicated that
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Stx increases E. coli 0157:H7 binding in mice intestine (Robinson et al, 2006) and
downregulates interleukin expression on bovine epithelial cells (Mahajan, A. personal
communication). Studies indicate this could be due to an increase in a eukaryotic
receptor for intimin (Robinson et al, 2006).
1.2.1 - The fun operon
Attachment to host tissue is a key step in bacterial pathogenesis. Bacterial pathogens
have acquired a wide range of adhesins that can be expressed at the appropriate time
during the infection process. Escherichia coli can produce over 15 different fimbrial
adhesins depending on serotype and pathotype. In the case of uro-pathogenic E. coli
(UPEC) adhesins are key virulence factors that allow the bacterium to bind specific
receptors on the urinary epithelium and resist removal during urination. One of the main
fimbrial adhesins associated with UPEC is type 1 fimbriae, which bind to a-D-mannose
receptors and mediate binding and invasion of bladder epithelial cells (Martinez et al,
2000).
Bacterial cells have also been shown to express type 1 fimbriae at crucial stages of a
murine model of cystitis, in a recent study cystitis strains mutated for type 1 fimbrial
production were attenuated in a murine cystitis model (Snyder et al, 2006) and bacterial
cells made constitutive for type 1 fimbriae were more pathogenic (Gunther et al 2002).
Bacterial attachment via type 1 fimbriae has been shown to induce IL-8 secretion in
mucosal cells, indicating a pro inflammatory response from the host to these organelles
(Godaly et al 1998) and studies have provided a link between type 1 fimbrial expression
and Crohn's disease (Boudeau et al, 2001).
Type 1 fimbriae, like many E. coli expressed fimbrial adhesins, exhibits phase variation.
Phase variation means that at a particular point in time only a subset of the bacterial
population will express the fimbriae leading to a heterogeneous population. The
biological significance of this process for the bacterium is still a topic of debate. The
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population as a whole can remain 'primed' for attachment at any one time without the
danger of complete eradication by the host's immune defences. If the population was
homogenous in either way, the bacteria may miss an opportunity to bind to host cells by
not having the fimbriae expressed on their surface or alternatively may be cleared from
the host completely if the entire population expressed the adhesin.
Type 1 fimbriae are encoded by the fim operon located at 98 minutes on the E. coli K-12
chromosome. E .coli 0157:H7 possesses the fim operon but does not express the
fimbriae due to a 16bp deletion in the fimS region (Roe et al, 2001). The fim operon is
polycistronic, containing nine genes, seven of which encode for structural or export
components {fimAICDFGH), the remaining two: fimB and fimE, encode site specific
recombinases that regulate expression of the operon. In between the regulators and the
structural genes is a 314bp invertible DNA element known as the fim switch that can be
in the 'on' or 'off orientation. Importantly, the fun switch contains a promoter at one
end so that in one orientation (on) it can drive expression of downstream genes. FimB
and FimE invert the fim switch and in the on orientation the fimA-H operon is expressed,
whereas in the opposite (off) orientation the promoter points away from fimA and directs
the transcription of a rapidly degraded antisense copy offimE. The genetic organisation




Genetic organisation of the fim operon on the E. coli chromosome. fimB and fimE are the
site specific recombinase genes that regulate the orientation of the fim switch. The
promoter embedded in the fim switch (shown here in the 'on' orientation) directs
transcription of the downstream structural genes: fimA-H.
fimB fimE
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The inversion of the fim switch is under the direct control of the two site specific
recombinases encoded by fimB and fimE (Klemm. 1986), the inversion from 'on' to 'off
is predominately controlled by FimE whereas FimB mediates inversion in both directions
(Gaily et al. 1996). FimB and FimE belong to the lambda integrase family of site
specific recombinases and share 52% amino acid identity, indicating evolution from the
same ancestor (Blomfield, 2001). Each recombinase contains a tetrad of conserved
amino acids and mutations of these amino acids result in loss of activity (Burns et al 2000,
Smith and Dorman, 1999).
In addition to the activity of the two recombinases, fim switch inversion is also controlled
by two site specific DNA binding proteins: IHF (integration host factor) and Lrp
(Leucine responsive regulatory protein) but inversion appears to be repressed by HNS
(Spears et al. 1986). In rich culture media at 37°C FimB mediated inversion occurs at a
frequency of between 10"3 and 10"4 per cell per generation. FimE mediated inversion is
much more frequent in the range of 0.3 per cell per generation (Gaily et al. 1993) in rich
media. Thus in E. coli K-12 MG1655 high frequencies of inversion from 'on' to 'off
result in a largely afimbriate population in the order of 3% (Blomfield et al 1993),
however incubation in static culture selects for fimbriate bacteria that allow the bacterial
population to form a pellicle, or surface layer, using cell-cell type 1 fimbriae-mediated
binding.
The fim switch invertible element is flanked by two 9bp inverted repeats, termed IRL and
IRR. FimB and FimE bind to these half sites, and, via the formation of Holliday
intermediates, catalyse the recombination of the fim switch. Other DNA binding proteins
are important for this activity. IHF binds to two distinct sites within the fun region. The
first site is near the IRR and is thought to introduce a sharp bend in the DNA bringing the
inverted repeats closer together (Blomfield et al 1997). The second site is outwith the fim
switch and is located between the IRL and the 3' end offimE. As this site is not involved
with DNA looping much speculation has arisen about its function. The effect of IHF
binding to this site is thought to play a part in determining FimB specificity (Blomfield
2001) but inconsistencies in various studies attempting to elucidate this could be
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attributed to HNS binding at a site overlapping with this IHF site as it is known that HNS
does play a role in determining FimB specificity (O' Gara and Dorman, 2000).
Mutations in the ihf genes have a 15,000 fold effect on fimE mediated inversion
compared to an 80 fold effect on fimB mediated inversion (Blomfield et al 1997), but
interestingly mutations in the IHF binding sites have a similar effect for fimB
recombination as with the mutation of the ihf genes, but show much less of an effect on
fimE recombination. The binding sites of IHF are shown in Figure 1.5.
The other main DNA binding protein associated with fim inversion is Lrp. Inversion of
the fim element is stimulated by branched chain amino acids particularly leucine and
requires the binding/unbinding of Lrp to three sites within the fim switch (Gaily et al,
1993, Roesch and Blomfield, 1998). The binding of Lrp to two sites (sites 1 and 2)
activates FimB and FimE recombination in a similar manner to IHF by introducing bends
in the DNA, but Lrp binding to the third site (site 3) has been shown to inhibit fim
switching (Roesch and Blomfield, 1998). Studies have shown that leucine promotes the
dissociation of Lrp from site 3, presumably to allow recombination in the presence of
exogenous amino acids. Additionally, mutations in site 3 that prevent Lrp binding result
in high levels of recombination, even in the absence of amino acids (Roesch and
Blomfield, 1998) indicating a loss of amino acid regulation offim switch inversion. The
Lrp binding sites are shown in Figure 1.5.
The DNA binding protein, HNS, is an important element in the control offim switching.
Mutations in hns result in increased fimE and fimB transcription levels (Olsen et al, 1998;
Olsen and Klemm, 1994) indicating HNS acts as an inhibitor of fim recombinase gene
expression and HNS has been shown to bind to fimE and fimB promoter regions (Olsen et
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Binding sites of Lrp, IHF and HNS to the fim switch region. The fim switch is shown in the
'on' orientation.
It has been found that fimB has two distinct promoter sites (Schwan el al, 1994). The
presence of two promoters could be strain specific. Additional levels of control of fimB
expression have been found and lie far outside the characterised fim region. A recent
study has shown the importance of the large (1.4kb) intergenic region upstream offimB
including the yjhATS operon. Researchers found distant 'cis' acting regulatory elements
were essential in fimB expression. Mutations in various regions elucidated two regions
lying over 500bp upstream of fimB that control FimB mediated recombination via
repression offimB expression. Additional sequences proximal to yjhA were also shown
to be important (El-Labany et al, 2003).
N-acetylneuraminic acid (sialic acid) was also shown to suppress fimB expression (El-
Labany et al, 2003). It is hypothesised that the bacterium recognizes and responds to
sialic acid, by suppressing type 1 fimbrial production, therefore limiting potential
clearance by the host immune system. Further research by the same group has shown the
differential binding to regions 1 and 2 by two distinct regulators: NanR and NagC. NanR
is responsive to sialic acid, whereas NagC is responsive to GlcNAc, a metabolite of sialic
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acid. The two regulators have also been shown to provide methylation protection at both
regions respectively (Sohanpal et al, 2004). Bacterial cells are unable to synthesise sialic
acid, but can freely scavenge GlcNAc from the environment or synthesise it from sialic
acid, alternatively the bacterium can recycle cell wall components including GlcNAc.
Sialic acid is released as part of the host inflammatory response potentially providing the
bacteria with a marker for the host immune response. Therefore signals arising from
within the cell and from the environment are both part of the same regulatory circuit.
The level offimB transcription is tightly controlled as part of a complex regulation map
in order to suppress the pro inflammatory response to the production of type 1 fimbriae.
It seems logical that bacteria would have evolved to limit type 1 fimbrial expression to
when necessary, i.e.when presented with the target receptor of choice.
The high frequency of FimE mediated recombination compared to the relatively low
frequency of recombination for FimB, means that any slight drop in the levels of FimE
recombination would markedly effect the 'off to 'on' recombination balance. FimB acts
to turn the cell from 'off to 'on' and FimE activity defines the period of time the Jim
switch remains 'on'. It must be surmised therefore that fimE would be under very tight
regulation.
It has been shown that the transcription of fimE can inhibit the frequency of FimB
mediated recombination (O' Gara and Dorman, 2000), a level of control that requires
HNS, and that the transcription offimE is increased when the fim switch is in the 'on'
orientation but levels of FimE activity are undetectable when the fim switch is in the 'off
orientation (Kulasekara and Blomfield, 1999). Essentially the orientation of the fim
switch changes the stability of the fimE transcript. This effect, termed 'orientational
control' (Kulasekara and Blomfield, 1999), no doubt exists to minimise the exposure of a
bacterial cell to the host immune system by keeping the population largely afimbriate.
Bacterial cells initially switch from the 'off to the 'on' orientation resulting in the
fimbriae being produced and raising levels offimE transcription. FimE levels will be low
at this point but as the levels of FimE start to rise transcription of the Jim structural genes
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will be inhibited by FimE mediated switching from 'on' to 'off and by direct
transcriptional inhibition in 'on' cells. In the 'off orientation fimE transcription levels
will drop off, the bacterial cell will stop producing the fimbrial structural genes and the
population as a whole will become more afimbriate. The control of fim expression
therefore involves strong fimE feedback control to alter fim switching and phase variation
levels.
1.2.2 - Bacterial adhesin 'cross-talk'
The large number of adhesins deployed by E. coli can depend on the pathotype and these
are associated with certain serotypes. The sequenced UPEC strain CFT073 for example
has been shown to contain as many as 12 fimbrial clusters (Snyder et al, 2005).
The ability of a bacterial population to respond to different environments and to change
phenotype in response to new environmental factors can be extremely important in
setting up a successful colonisation or infection. Bacteria that can deploy a number of
different adhesins depending on environmental signals will have a significant advantage
in survival in a new host compared to bacteria that have lost the ability to produce
multiple different surface adhesins.
For the bacteria that have a number of functional adhesins, the regulatory circuits
between these genetic loci are of importance. Producing fimbriae and other surface
structures has a high energy cost for the bacterium and it would be disadvantageous to
produce all the adhesins it can, all the time. Whilst it is important for the bacterial
population as a whole to generate adhesin and antigenic heterogeneity, an individual
bacterium must tightly regulate it's surface structures to ensure the optimum combination
is produced to allow successful proliferation in the host.
The regulation or 'cross-talk' between fimbrial adhesins is dependant on environmental
signals as well as regulatory genes present in the fimbrial loci themselves. It is more
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efficient for the bacterium to produce a regulator that acts in a positive manner on its own
set of adhesin genes but also acts to suppress or upregulate other fimbrial cluster genes.
In the case of type 1 fimbriae the regulatory product from the pap operon: PapB, has been
shown to suppress fim switching by acting directly to inhibit FimB mediated switching,
whilst increasing fimE expression in vitro (Holden et al, 2001; Xia et al, 2000). The pap
operon contains genes encoding for P pili and is also subject to phase variation, although
via dam methylation at key GATC sequences rather than an invertible element as with
fim. As PapB acts to upregulate the production of its native P pili, the cross-talk net
result is the production of P pili and the switching off of type 1 fimbrial production.
Array studies have also shown that during UTI infection type 1 fimbriae are upregulated
but P pili are downregulated, suggesting 'cross-talk' during the infection process (Snyder
et al, 2004).
The same group has shown recently that type 1 fimbriae can have regulatory affects on
the pap operon using phase locked 'on' mutants of UPEC strain CFT073 in microarray
assays (Snyder et al, 2005). This result is not surprising as the negative cross-talk
exhibited by the pap operon on the fim operon may be reciprocated to some degree. The
actual mechanism by which the fim operon inhibts P pili production remains to be
elucidated, but as with the pap operon regulator PapB, the fim recombinases: FimB and
FimE are likely to be involved, with some evidence pointing to a role for FimE (Snyder
et al, 2005).
Whilst understanding the regulation of type 1 fimbriae and P pili is important in our
search for key virulence factors in a pathogens genome, we must also seek to understand
the regulatory networks and circuits that each adhesin cluster may be a part of.
Individually each cluster has complex regulatory pathways that govern the production of
their specific surface structure; however regulators and genes from these operons may
also play a crucial role in the regulatory pathways of other adhesin clusters.
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In this way a bacterial cell can respond to environmental signals in a co-ordinated and
energy efficient manner. Perhaps, more importantly, the bacterial population as a whole
can maintain antigenic heterogeneity, a state that may be essential for evading the host
immune system and for establishing and maintaining a successful infection.
1.3.1 — in vivo Expression Technology
Our increased knowledge of bacteria and their pathogenesis over the last century has
mainly been due to defined experiments designed to study bacteria under laboratory
controlled conditions. As such, control of the bacterial environment has allowed
researchers to glean the maximum amount of data from each experiment and to construct
hypotheses that can be proven or not in a defined manner. Bacterial responses to changes
in their environment such as iron depletion and pH (Olson, E.R., 1993) have identified
virulence factors essential for bacterial survival and persistence in the host.
It is clear however that even the more complex in vitro experiments cannot recreate the
complexity and dynamics of an in vivo habitat. For bacteria to be successful in a
particular biological habitat, complex regulatory systems have evolved at a genetic level
and such complexity may be beyond the scope of laboratory based assays to unravel.
Genes that have little or no activity in a laboratory screen may be critical to the
persistence of the bacterium in the host, likewise, genes that appear vital in an in vitro
assay may well play little or no role in vivo.
To this end, strategies for studying bacterial genetics in vivo have become important.
Advances in gene fusion and reporter fusion technology allow researchers to analyse
gene function 'quietly' without significant disruption to the fitness of the bacterium.
Researchers have used this technology to design novel systems for isolating genes
activated in vivo.
In vivo expression technology (IVET) was first described in 1987. A group from the UK
successfully used a promoterless chloramphenicol resistance gene and a promoter trap
23
library of the plant pathogen Xanthomonas campestris to identify genes activated in vivo
(Osbourn et al 1987).
The first use of IVET for an animal pathogen was in 1993 when Mahan et al defined a
promoter trap system resulting in the identification of Salmonella Typhimurium genes
expressed in vivo (Mahan et al 1993). The basis behind this form of IVET was the use of
compromised strains carrying mutations in genes responsible for the biosynthesis of
purines: the purA gene. The attenuated strain is not able to grow in the in vivo
environment unless this gene is expressed. A promoter trap library was used to create
gene fusions with a promoterless purA gene. Promoters induced in the environment now
allow the expression of the purA gene and can complement the deficiency. To ensure
that the induced promoter was not constitutively expressed, the lacZ gene was linked to
the fusion to allow screening of the recovered bacteria for in vitro expression. Bacteria
that produced beta-galactosidase were discarded from the study. Thus only genes that
were in vivo induced (i.v.i.) were included in the final analysis. Importantly this form of
IVET established three principles:
The purA and lacZ fusion must be stably inserted in single copy into the
Salmonella typhimurium chromosome. This avoids the inherent
problems with using reporter strains carrying multicopy plasmids.
A functional copy of the wild type virulence gene must be retained so
as not to affect the fitness of the bacterium in the environment.
To ensure only i.v.i. genes are analysed, a reporter gene for screening
promoter activity in vitro must be used.
This form of IVET is characterised by its auxotrophy based selection. Many IVET
studies followed that used this selection method, all of which required the
complementation of a promoterless gene essential for survival in the environment.
Another example of purA IVET was used to identify i.v.i. genes in a murine model of
Pseudomonas aeruginosa (Handfield et al 2000). The difficulty in obtaining purA
mutants in some bacteria has led to the use of other essential genes for auxotrophy IVET.
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Genes such as galU (Lai et al 2001) and inhA (Dubnau et al 2002) required for galactose
metabolism and mycolic acid biosynthesis respectively have been used to identify i.v.i.
genes. Genes that are involved in pathogenesis have also been used as a reporter and
screening method, for example the hly gene in Listeria monocytogenes (Gahan and Hill,
2000). The obvious specific disadvantage of auxotrophy IVET is the need to construct an
auxotrophic mutant, which may be extremely difficult for some bacteria.
The original IVET experiment (Osbourn et al 1987) used a promoterless chloramphenicol
acetyltransferase (cat) gene as a marker of in vivo induced expression. IVET based on
antibiotic resistance is an important variant that expands the range of bacteria that can be
used (Rediers et al 2005). The cat gene was also used in IVET studies of Shigella
flexneri (Bartoleschi et al 2002), Yersinia enterocolitica (Young and Miller, 1997) and
Helicobacterpylori (Angelini et al., 2004) amongst others.
A promoterless tet gene was used in an IVET study on Porphyromonas gingivalis (Wu et
al., 2002). Antibiotic resistance IVET bypasses the need for an auxotrophic mutant and
allows the temporal study of expressed i.v.i. genes but brings disadvantages of its own,
chiefly the need to administer the antibiotic to the host system during the experiment.
The administering of an antibiotic to the host may alter the environment enough to give
false readings for the bacteria, the host itself may be affected by the antibiotic as can be
the case with plants (Osbourn et al., 1987) and achieving the correct concentration of
antibiotic at the relevant sites may be difficult.
A disadvantage with both auxotrophy and antibiotic resistance IVET is the inability to
identify genes that are expressed weakly or temporally during the experiment. Such
genes never survive the rigorous selection required in the environment and are missed in
any subsequent screen. Bacterial persistence and infection is a complex process
genetically, requiring many levels of control. Certain genes may be of vital importance
to this process yet remain undiscovered if using traditional IVET systems.
25
1.3.2 - Recombinase in vivo Expression Technology
As such a major modification was made to the IVET method. In 1995 a research group
produced a publication outlining this new method (Camilli and Mekalanos, 1995). They
described using a promoterless site specific DNA resolvase, TnpR under control of a
promoter trap library. If expressed, the resolvase would mediate recombination between
two resl sites, removing the DNA between the sites. Using a murine model of Vibrio
cholerae infection the group placed a tetracycline resistance gene in between the resl
sites. Expressed promoters drove production of TnpR, which mediated recombination at
the resl sites, removing the tetracycline resistance gene resulting in a permanent and
heritable marker of promoter activity. Replica plating could now determine any
tetracycline sensitive strains. To isolate only i.v.i genes, tetracycline was used as a
selection pressure during the construction of the strains. This ensured that any
constitutively expressed promoters would be removed from the study before inoculating
the mice.
This new form of IVET was named recombinase based in vivo expression technology
(RIVET) and is represented diagrammatically in Figure 1.6. The RIVET method has also
been used to isolate i.v.i. genes in Staphylococcus aureus infection of mice (Lowe et al.,
1998).
As RIVET was developed it was found that the lack of a positive selection method meant
the laborious task of replica plating the recovered strains to look for sensitivity to the
antibiotic selection. The addition of a second reporter gene that could be used for
positive selection solved this problem. Merrell et al used the sacB gene (Merrell and
Camilli, 2000), the product of which (levansucrase) converts sucrose into the toxic levan
form, placed alongside the tet gene in between the resl sites to create a resl-tet-sacB-
resl cassette. Bacteria that expressed the resolvase during the study will gain the ability









Diagrammatic representation of a RIVET experiment. Expression from Px produces TnpR.
TnpR mediates recombination between the resl sites, excising the tet gene. The strain is
now tetracycline sensitive.
Other research groups have used a cat gene, disrupted by the tet gene flanked with res
sites. Strains expressing TnpR during the study will excise the tet cassette and become
chloramphenicol resistant, quiescent strains will retain the resistance to tetracycline.
This new form of RIVET, called selectable in vivo expression technology (SIVET) was
used to study induced lysogens of shiga toxin (STX) in shiga toxin producing
Escherichia coli strains (STEC). By using SIVET the researchers could count
proportions of a population that had expressed the tnpR gene under the phage promoter
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Pr. The advantage of using a positive selection method when searching for a very low
percentage of resolution (as with spontaneously induced prophages) is clearly
demonstrated in this study as researchers could screen populations for chloramphenicol
resistance. Using standard culture conditions the researchers found a spontaneous
induction rate of 1 in 20 000 lysogens carrying the Stx-1 encoding phage and 1 in 7000
carrying the Stx-2 encoding phage per cell generation (Livny and Friedman, 2004), a
figure greater than that of non STX encoding phages. The methodology of SIVET is
represented diagrammatically in Figure 1.7.
Fig 1.7
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RIVET is a much more sensitive method than auxotrophy IVET or antibiotic resistance
IVET. Promoters that are weakly expressed or temporally controlled can still be studied.
The other main disadvantage with RIVET however was the loss of potentially important
genes during the construction process. Due to the systems sensitivity any virulence genes
that also have activity in vitro will result in a strain that resolves before inoculation and
cannot be constructed. Missing these genes out during the in vivo screen could lead to
difficulties in unravelling the complex genetic cascades used by the bacterium in the
environment.
Researchers working with the water-borne pathogen Vibrio cholerae were faced with the
problem that two of the well known virulence genes for V. cholerae infection: cholera
toxin (CT) and toxin co-regulated pilus (TCP) are produced in vitro. In order to proceed
with in vivo studies using the respective subunit genes: ctxA and tcpA the researchers
developed a 'tuned' RIVET system. (Lee et al 1999) By modifying the ribosome binding
site (RBS) of the tnpR gene the researchers were able to suppress translation initiation at
the RBS for any transcription level. Using an oligonucleotide primer, single nucleotide
changes at three positions in the RBS were generated using PCR. The resulting library
was screened using the iron repressible irgA promoter. This was cloned upstream of tnpR
within the genome of a V cholerae strain containing the resl-tet-resl cassette. The
resultant library was then cultured in the presence of varying iron concentrations. Three
strains were isolated that gave reduced resolution compared to wild type. Each strain was
used to test the ctxA and tcpA promoters in LB broth and AKI broth, a medium that is
known to induce the V. cholerae toxR regulon (Iwanaga et al., 1986). One of the strains
tested did not resolve in LB broth but did resolve in AKI broth, and as a result was
chosen for the study (Lee et al., 1999).
Previous forms of IVET were distinctly promoter 'hunting' methods. By using promoter
trap libraries, novel i.v.i genes could be found. However this form of 'tuneable' RIVET
allows researchers to investigate the importance of specific bacterial promoters in vivo
and study the interplay between specific promoters and other virulence genes.
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Researchers could now ask specific questions of virulence genes and their individual
roles within an infection model.
The use of 'tuneable' RIVET as a screening method was outlined in 2005. Researchers
used the same principles as the 'tuneable' RIVET but used a promoter trap library of V.
cholerae to screen for /.v./.genes in a murine model of infection (Osorio et al., 2005).
Two main modifications were made. Firstly the tet gene previously flanked by the resl
sites was omitted and replaced with two new reporter genes: neo and sacB. The neo gene
confers resistance to Kanamycin and the sacB gene has been described above. This
allowed researchers to select positively for resolved strains by growing on sucrose
containing media after recovery. Strains still in possession of a sacB gene will be unable
to grow. Sucrose resistant strains can then be tested for sensitivity to Kanamycin. The
addition of this secondary selectable reporter removes the tedious negative screening
associated with earlier RIVET studies using replica plating.
The second modification in this study was a preselection step designed to eliminate
partially resolved strains. Each starting fusion strain was grown in LB overnight to
stationary phase and diluted serially onto sucrose and non sucrose containing LB. Only
strains resolved to less than 0.1% were included in the study. This new form of tuned
RIVET dispenses with many of the drawbacks of the original form of RIVET whilst still
retaining the ability to identify low level or transiently expressed i.v.i. genes. Only 35%
of recovered resolved strains in the original RIVET study were true i.v.i genes (Camilli
and Mekalanos, 1995) whereas 85% of the recovered strains were true i.v.i. genes in the
tuned form ofRIVET (Osorio et al., 2005).
RIVET has also been used to identify the regulators of virulence genes. By using the
tuned RIVET method with key V. cholerae promoters: toxT and ctxA, as seen previously
(Lee et al., 1999) and STM technology, researchers were able to screen V. cholerae
strains for regulators of these two known virulence genes (Lee et al., 2001).
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1.4 -fim Recombinase in vivo Expression Technology
IVET and RIVET have proven to be useful tools to help unravel bacterial activity in vivo.
A well established animal model and ease of genetic manipulation has allowed such
activity to be elucidated in a wide range of bacteria. Using the principles of IVET and
RIVET, I propose a different method of RIVET, for use with Escherichia coli 0157:H7
and its natural ruminant bovine host. This new method: fan recombinase in vivo
expression technology (FRIVET) utilises genes taken from the fan operon in E.coli with
an antibiotic reporter system. By using fim operon genes under the control of specific
EHEC promoters, FRIVET could allow more control and flexibility than previous IVET
or RIVET methods.
Two key alleles from the fan operon are used: fimB and fimS. As has been mentioned
previously fimS (also referred to as the fim switch) is an invertible DNA element
containing a promoter sequence for downstream fim structural genes. These structural
genes are only transcribed when fimS is in the correct orientation ('on'), a factor partially
under the control of fimB, a site-specific recombinase that binds to fimS causing
inversion primarily from 'off to 'on'.
By using a promoterless fimB gene fused transcriptionally to a variety of EHEC
promoters we can control the inversion offimS and consequently the transcription of any
downstream genes. In place of the fan structural genes we will place the antibiotic
resistance gene bla (producing beta-lactamase, conferring resistance to ampicillin) as a
reporter gene for the FRIVET system.
The EHEC promoters to be used will attempt to cover a wide range of the EHEC
virulence determinants. As such we will use a number of key promoters from the LEE
which have been shown to be important for EHEC virulence and pathogenesis.
Additionally we will use promoters for EHEC specific adhesin clusters, flagella
regulation and other EHEC promoters that may generate interesting data in vivo.
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Each FRIVET construct will first be engineered on a temperature sensitive allelic
exchange vector. Once the final construct is made with the correct promoter in place
upstream offimB the construct will be placed in single copy at the fim locus in place of
the native fim operon in the category 2 Shiga toxin negative strain: ZAP193.
Importantly the deletion of the fim operon and thus the ability to produce type 1 fimbriae
from our FRIVET strains will not have a negative impact on the bacterium's
pathogenicity in the host animal. Studies have shown that despite possessing a copy of
the fim operon, E. coli 0157:H7 does not produce type 1 fimbriae due to a 16bp deletion
in the fimS region (Roe et al, 2001). We can confidently surmise therefore that type 1
fimbriae do not play a role in E. coli 0157:H7 pathogenesis and that our FRIVET strains
will not be impaired in their ability to adhere to host cell tissue due to the fim operon
deletion. However we must also be aware that the fim operon contains two site specific
recombinases: fimB and fimE. There is no evidence to suggest that FimB and FimE
production is deficient in E. coli 0157:H7 and therefore these proteins may play a role in
the regulation of other fimbrial operons or regulatory networks that are as yet unknown.
The basic FRIVET assay will proceed as follows:
• Activation of the specific promoter will result in FimB production
• FimB will mediate the inversion of the 'off fimS to the 'on' state
• The promoter in fimS is now 'lined up' and can now direct transcription of the bla
gene conferring ampicillin resistance on the cell
• Bacteria can be recovered and analysed by direct plating onto media with and
without ampicillin to obtain the percentage of the population resistant to
ampicillin
• This figure will correlate with the transcriptional activity of fimB and its EHEC
promoter during the assay
The FRIVET assay is shown diagrammatically in Figure 1.8.
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Fig 1.8
Diagrammatic representation of the FR1VET assay. Signals act on promoter X resulting in
transcription of fimB. FimB can then mediate recombination of fimS from the 'ofF
orientation to the 'on' orientation. The promoter in ftmS can now direct transcription of
the downstream bla gene. The cell now becomes ampicllin resistant.
A key part of the FRIVET system is the ability to control the orientation of fimS as
desired. Obviously there is a need to have the switch locked in the 'off orientation at the
start of the experiment, but the ability to control fimS orientation at other times has many
advantages. A feature of the RIVET method is the non-reversible nature of the resolution
event. After the excision of the resl-tet-resl cassette the bacterium becomes tetracycline
sensitive and remains so until manipulated otherwise. Thus each bacterium has one
chance to record the activity of its tnpR gene.
As an example, the extra level of control inherent to the FRIVET system will enable the
orientation of the switch to be reset for the whole population at any given timepoint.
After inoculating the animal model orally, an early time point sample is taken from a
point high in the gastro-intestinal (GI) tract and analysed for ampicillin resistance. At the
same point the orientation of the fim switch is reset to 'off for the remaining population
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still present in the animal model. Over the time course of a natural bacterial infection and
persistence study this process can be repeated all the way down the GI tract to the
terminal recto-anal junction, the identified site ofEHEC colonisation (Naylor et al, 2003).
A comparison between ampicillin resistance percentages at time/position point A can be
compared with time/position point B, C, D etc. This will allow conclusions to be made
regarding the necessary signals for that specific EHEC promoter being present in
different areas of the GI tract.
Each FRIVET construct can therefore provide a stable and hereditable readout of
promoter expression during a study but unlike RIVET the readout is not irreversible, but
can be controlled to fit the studies hypotheses. As such it will provide greater flexibility
than conventional RIVET for elucidating EHEC promoter activity in vivo.
The control of fimS orientation during an experiment will need an extra gene in the
FRIVET system. Studies have shown the complex interaction between the Type 1
fimbrial operon and the regulators of the E. coli pap operon. The pap operon contains
genes encoding P fimbriae in urinary pathogenic E. coli and has been shown to be
important in the development of pyelonephritis but its role is not fully understood. As
with type 1, the pap operon is phase variable but under DAM methylase control.
The effect of one of the pap operons regulators: PapB, and cross-talk with type 1 fimbriae
has been studied previously (Holden et al, 2001, Xia et al, 2000). PapB acts to inhibt
FimB mediated switching, although the mechanism for this action is not yet fully
understood, it is thought to be due to direct binding to the fim switch. Due to this we can
deploy PapB as our 'control' gene in order to lock our FRIVET fim switch in the present
orientation, allowing us to lock the switch in the 'off orientation whilst preparing the
inoculum as well as locking the switch in the position it is recovered in. This is an
important point as any unwanted FimB activity after recovery of the strain will result in
an artificially high ampicillin resistance proportion.
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To induce PapB, we will utilise the IPTG inducible promoters: /acUV5 and Ptac.
Constructs will be made for both promoters and placed in single copy at the lac locus in
the FRIVET strains. To 'reset' the fim switch during an experiment we can utilise the
fimE gene. FimE acts to turn the fim switch from the 'on' orientation to the 'off
orientation. By placing fimE under the same IPTG control instead ofpapB we can create
FRIVET strains designed to monitor a particular promoter's activity at points along the
GI tract.
By creating dual single copy strains we will avoid problems associated with maintaining
plasmids in our strains during in vivo assays whilst allowing full control over the
inoculum and the recovered strains.
The FRIVET system will provide an alternative to existing IVET and RIVET systems as
well as improving on their overall design. Its strengths lie in studying specific promoters
in their natural in vivo environment without the need for mutagenesis or overly toxic
reporter systems. The additional levels of control incorporated into the FRIVET system
sets it apart from existing IVET systems. Instead of having a defined start and finish,
FRIVET assays can be monitored at different time points and locations during the
infection process. Complex temporal regulation between promoters can be unravelled
and the process of attachment, immune evasion and proliferation can be elucidated. The
simplicity in screening the recovered bacteria for their promoter activity will allow higher
volumes of assays to be carried out and large amounts of data to be analysed.
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- Thesis aims
main aims of this thesis can be split into three distinct parts:
1) The construction of a working FRIVET synthetic operon. Using genes from
the fim operon and the bla gene, we must demonstrate that the fim switch is
invertible and that the promoter withinfimS can direct transcription of bla
2) The in vitro testing of the FRIVET system. This will start with the functional
testing of the operon itself using an inducible test promoter to define the
working limits of the operon and appropriate control methods. Secondly we
must define a suitable and reproducible screening system
3) The construction of experimental FRIVET strains for in vivo use. The E. coli
0157:H7 promoters initially used will be: lee5; fliC; Ipfl and loc8. The
resulting FRIVET strains will be assessed in vitro to determine the operons
functionality using various media and on cell lines.
To use constructed FRIVET strains in an in vivo experiment. The animal model
and strain to be used will be decided closer to the time. Current animal models
such as the sheep gut loop (ligated chambers in the ascending spiral colon) may
be deployed.
The final aim of the study is to functionally prove that the FRIVET system can be
used as an indicator of promoter activation in an in vivo environment. Ideally a
FRIVET in vivo experiment would involve inoculation of a natural bovine host
with a FRIVET test strain. Samples of bacteria collected and plated on SmacNal
plates (Sorbitol MaConkey Nalidixic acid) would be analysed for ampicillin
resistance levels. The prescence of ampicillin resistant colonies would indicate
the activation of the FRIVET system post inoculation.
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In this assay we can analyse the past activation of a promoter in the experimental
setting. The specific targeting of complex regulatory pathways and precise
temporal gene activation may however lie outwith the scope of this system as any
data recorded for the assay would give us a promoter activation record without
drawing accurate conclusions on the specific relevance of that activation
regarding E. coli 0157:H7 pathogenesis in the host. Further in vivo assays could
involve post mortem collection of bacterial samples at various lengths along the






2.1 - Table of Strains
Strain Description
ZAP 193 NCTC12900, stx, nalr
ZAP 193 sac/kan ZAP 193 Alac sac/kan
ZAP1 E. coli 0157:H7 Redhouse dairy outbreak strain
human isolate
E. coli AAEC185 F A supE44 hsdR17 mcrA mcrB endAl thi'1
AifimBEACDFGH) ArecA (Blomfield et al., 1991)
E. coli AAEC189 AAEC185 AlacZ (Blomfield et al, 1991)
E.coli MG1655 F- X- ilvG rfb50 rphl (Guyer, 1980)
ZAP541 ZAP 193 lac\]\5::papB
ZAP542 ZAP541 Afim sackan
ZAP543 ZAP542 ara::fimB::fimS::bla (pRQ15) fimS 'off orientation
ZAP544 ZAP193 ?tac::papB
ZAP545 ZAP544 Afim sackan
ZAP546 ZAP545 ara::fimB::fimS::bla (pRQ15) fimS 'off orientation
ZAP547 ZAP193 Afim
ZAP548 ZAP547 ara::fimB::fimS:\bla (pRQ15) fimS 'off orientation
ZAP550 ZAP545 lee5::fimB::fimS::bla (pRQIOl)
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2.2 - Table of Plasmids
Name Description Source
pRQi pAJR26 containing /acUV5 promoter This study
pRQ2 pRQl containing firnE cloned upstream of /acUV5
promoter
This study
pRQ3 pIB307 containing fim region left flanking region
(LFR) from ZAP193
This study
pRQ4 pRQ3 containing/w? region right flanking region
(RFR) from ZAP193
This study
pRQ40 pRQ4 containing sackan cassette for allelic
exchange
This study
pRQ5 pIB307 containing fim region LFR from ZAP1 This study
pRQ6 pRQ5 containing fim region RFR from ZAP1 This study
pRQ7 pRQ6 containing sackan cassette for allelic
exchange
This study
pRQ8 pAJR26 containing lac\J\5::papB fusion cut from
pHMG88
This study
pRQIO pACYC184 containing /acUV5 promoter This study
pRQll pRQ4 containing fimB from ZAP 193 This study
pRQ12 pRQl 1 containingJim switch from pMM36 This study
pRQ13 pRQ12 containing bla from pUC18 This study
pRQ15 pRQ13 containing ara promoter from pBAD18 to
create arar.fiimB fusion
This study
pRQ16 pRQl 1 containing fiim switch from NEC 120 This study
pRQ17 pRQ16 containing bla from pUC18 This study
pRQ18 pRQ17 containing ara promoter from pBAD18 to
create ara: :fimB fusion
This study
pRQ19 pAJR26 containing Ptac promoter from pACTAC This study
pRQ20 pRQ19 containing papB from MG1655 downstream
of Ptac promoter to create Ptacv.papB fusion
This study
pRQ23 pRQl 1 containing firm switch from pJL2 This study
pRQ24 pRQ23 containing bla from pUC18 This study
pRQIOl pRQ13 containing lee5 promoter from ZAP 193 to
create lee5::fimB fusion
This study
pRQ 102 pRQ13 containing fliC promoter from pTOPO lab
clone to create fliC::fimB fusion
This study





pRQ104 pRQ24 containing Ipfl promoter from ZAP 193 to
create Ipfl ::fimB fusion
This study
pRQ105 pRQ24 containing loc8 promoter from ZAP193 to
create loc8::fimB fusion
This study
pRQ30 pACYC::gfp+ containing ara promoter from
pBAD18 to create ara::gfp+ fusion
This study
pACTAC v.fimE pACTAC vector withfimE from MG1655 cloned
downstream of Ptac promoter
This study
pBAD18 E. coli plasmid cloning vector,
containing MCS downstream of the araBAD





pACYC184 E. coli plasmid cloning vector, low copy number. Cmr, (Sambrook,
1989)




pMM36 pACYC 184, fimS in on orientation (McClain et al,
1991)
pUC18 Small, high copy number cloning vector for E. coli (Yanisch-
Perron et al,
1985)
pHMG88 pACYC 184, lac\JY5::papB (Forsman et al,
1989)
pAJR26 pIB307 derivative containing the lacl and lacA genes
of ZAP 193
A.Roe
pAJR27 pIB307 derivative containing the lacl and lacA genes
of ZAP 1
A.Roe
pACTAC pACYC 184 containing Ptac promoter J.Emerson
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FRIVET Bla Diag ctgcaggcatcgtggtg







LFR up 5' cccaacgatgaacgttatcacg




FimS 5' BamYLl ccggatcccagaacaacgattgccagag
FimE 5' EcoKV gcggatatccagttaggagtactactattgtg
FimE 1 ccggatcccagttaggagtactactattgtg
FimE 2 ccggatccgacagtttggccccaattgtc
ara 5' Xbal gctctagagccaccagatgggcattaaacg
ara 3' Xbal gctctagagggtatggagaaacagtagagag









5' Ptac Xbal gctctagactgtgcaggtcgtaaatcac
3' Ptac Xbal gctctagagtgaaattgttatccgctcac
Loc8 5' gctctagagccatataaaccattagtagcc
Loc8 3' gctctagaatgtttgactttcataattctcc
5' GFP BamlKpnlSD ccggatccccgggtaccggaggccaccatggtgagcaagggcg
5'IRL Kpnl ccggtacctaaatacaagacaattgggg
3' IRRRawHI ccggatccccaaaagatgaaacatttgggg
3' IRR Kpnl ccggtaccccaaaagatgaaagatttgggg
5' IRL BamHl ccggatcctaaatacaagacaattgggg
3' GFP+ fuse ccgtatgtagcatcaccttcac
lacA 3' down catgccggatgcggctaatg
lacl up 5' cgccttatggcatgatagcg
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Antibiotics, when required, were added after sterilisation at the following final concentrations:






















Add 50g Sucrose to 150ml dH20, filter sterilise, and add to LB
M9 Medium
56.4g M9 minimal salts
10ml lMMgS04
2ml 1M CaCl2
20ml 5OX non-essential amino acids
10ml 100X non-essential amino acids
10ml 20% w/v glucose/glycerol
1000ml dH20
Filter sterilize



















150ml 15% v/v glycerol
Make up to 900ml with sterile dH20, autoclave




150ml 15% v/v glycerol
2.093g MOPS
Make up to 1000ml with sterile dH20, autoclave. Store at -20°C
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2.5 - Biochemical Techniques
2.5.1 - Poly Acrylamide Gel Electrophoresis
A 5% v/v acrylamide gel was prepared as follows: 7.75ml of sterile distilled H2O was pippetted
into a sterile sterilin. 1.25ml 40% v/v acyrlamide/bis and 1ml of 10 X TBE was added. A
BIORAD mini gell apparatus (Biorad, UK) was setup according to manufacturer's instructions
and filled with 1 X TBE running buffer. Before pouring lOOpl fresh Ammonium persulfate
(APS) and 5pl TEMED were added to the gel mix. Using a 10ml syringe the gel was poured
and left to set. Samples were added and run at 100V for approx. 50 minutes.
2.5.2 - Fluorstar measurement
Bacteria containing Fluorescent protein plasmids were grown in selected media to desired
OD6oo, and 20pl of culture was placed in 1 well of a black, flat bottomed 96 well plate (Nunc,
UK) alongside dFEO as a blank. The plate was transferred to the Fluostar Fluorimeter (BMG,
UK) at 37°C and measurements were taken according to manufacturer's protocol. A plasmid
containing a promoterless gfp+ gene was used as a negative control to set the gain for the
experiment.
47
2.6 - Molecular Biology Techniques
2.6.1 - Polymerase chain reaction (PCR)
Template for PCR reactions was prepared by suspending a single bacterial colony in lOOpl of
dH20 and boiling for 5 minutes. The lysate was pulsed 13,000rpm in a microcentrifuge for 10
sec. For PCR reactions using plasmid template a dilution of lpl of 1/100 plasmid preparation
was used. PCR's were carried out in 50pl reaction volumes containing lpl of template, 5 pi of
dNTP mix, lOOpmol of each primer, 5 pi of 10 X PCR buffer with 1.5mM MgCl2 (Roche, UK),
and 2.5U of Taq DNA polymerase (Roche, UK). PCR was carried out using a Hybaid
Thermocycler, and cycling conditions were as follows: denaturation at 94°C for 4 min,
followed by 30 cycles of denaturation at 94°C for 45 sec, annealing at specific temperature for
45 sec, and extension at 72°C for 60 sec, with a final extension at 72°C for 10 min. Products
were then held at 4°C or stored at -20°C.
2.6.2 - Agarose Gel Eletrophoresis
A 0.8% w/v agarose gel was made by addition of 0.4g molecular grade agarose (Sigma, UK) to
50ml of 1 X TBE. The solution was boiled in a microwave for 90 sec, allowed to cool to
approximately 60°C, and 1 pi of 1M Ethidium bromide added. The gel was then poured into a
gel cassette with comb (SLS, UK). Once the gel was set, it was placed in an electrophoresis
tank filled with 1 X TBE. For PCR diagnostics 2pl of PCR product was added to 7pl of MQ
H20 and lpl of 10 X DNA loading buffer (Invitrogen, UK). For restriction endonuclease
analysis 9pl of DNA sample was added to lpl of 10 X DNA loading buffer (Invitrogen, UK),
and the sample loaded onto the gel alongside a DNA marker, either lOObp ladder or a lkb
ladder (Invitrogen, UK). Electrophoresis was performed at 100V for approximately 30 minutes.
The gel was visualised using the UV setting on a Flowgen Multilmage cabinet using image
capture software (Flowgen, UK).
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2.6.3 - Plasmid Purification
Bacteria were grown overnight in 5ml LB with appropriate antibiotic at 37°C at 200rpm. A
Qiagen Qiaprep Spin mini prep kit (Qiagen, UK) was used according to the manufacturer's
instructions. For pIB307 and related plasmids 5ml of overnight culture was used. For medium
and high copy number plasmids 1.5ml was used. All plasmid preps were eluted in a final
volume of 50pl MQ FfO and stored at -20°C.
2.6.4 - DNA Purification from Enzymatic Analysis
DNA was purified from enzymatic reactions using the Qiagen Qiaprep spin DNA purification
kit (Qiagen, UK) according to the manufacturer's instructions. For initial restriction reactions
purified DNA was eluted in 40pl MQ H2O. Subsequent restriction reactions were eluted at a
volume of 10pl less than the starting volume of 40pl.
2.6.5 - DNA Purification from Agarose Gels
DNA was excised from agarose gels with a scalpel after visualisation on a UV transilluminator
(SLS, UK). The DNA was then extracted using the Qiagen Qiaprep spin Gel purification kit
(Qiagen, UK) according to manufacturer's instructions. Purified DNA was eluted in 30pl of
dH20.
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2.7 - DNA Manipulation
2.7.1 - Digestion of DNA with Restriction Endonucleases
For cloning, DNA restriction reactions were carried out in 50jlx1 volumes containing 20pl DNA,
24pl dFhO, 5pl reaction buffer, and lpl enzyme. Digests were incubated at 37°C water bath for
2 hours, purified using the Qiagen Qiaprep spin DNA purification kit (Qiagen, UK) and eluted
in 40pl MQ H2O. For restriction with a second enzyme 4pl reaction buffer and 1 pi enzyme
was added prior to incubation at 37°C for 2 hours. Reaction was purified again and eluted in
30pi MQ H20.
For diagnostic purposes, reactions were carried out in lOpl volumes, containing 8pl purified
plasmid, lpl of restriction enzyme (New England Biolabs, UK) and lpl of reaction buffer
(NEB, UK). Digests were incubated in a 37°C water bath for 2 hours and visualized on an
agarose gel.
2.7.2 - De-phosphorylation of DNA
Shrimp Alkaline Phosphatase (SAP) was used to dephosphorylate digested plasmid DNA to
prevent the plasmid self-ligating in ligation reactions. To dephosphorylate DNA, lpl of SAP
(NEB, UK) was added to restriction enzyme digest reactions for the final 30 mins at 37°C prior
to the final purification step.
2.7.3 - Ligation of DNA fragments
Digested DNA fragments and plasmids were visualised on a 0.8% w/v agarose gel. Using the
Hindlll DNA ladder (Invitrogen, UK) concentration of DNA was approximately calculated to
give a 3:1 ratio of DNA fragment to plasmid in a lOpl ligation reaction containing lpl of T4
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DNA ligase (NEB, UK) and lpl of 10 X ligase reaction buffer (NEB, UK). The reaction was
incubated at 15°C overnight.
2.8 - Genetic Manipulations
2.8.1 - Preparation of chemically competent cells
From a fresh overnight culture bacteria were inoculated into 50ml LB at 37°C shaking at
200rpm until an OD600 of 0.8. Culture was transferred to a 50ml falcon tube and cooled on ice
for 5 minutes. Bacteria were harvested at 4,000rpm for 10 minutes at 4°C, and re-suspended in
10ml of ice cold TFBI by gentle agitation. The cells were then harvested by centrifugation at
4,000rpm for 10 mins at 4°C and gently suspended in 2ml of ice cold TFBII. Competent cells
were stored at -20°C
2.8.2 - Preparation of electro-competent cells
From a fresh overnight culture bacteria were inoculated into 50ml LB at 37°C shaking at
200rpm until an OD600 of 0.8. Culture was transferred to a 50ml falcon tube and cooled on ice
for 5 minutes. Bacteria were harvested at 4,000rpm for 10 minutes at 4°C, and re-suspended in
25ml of ice cold 10% v/v glycerol. Bacteria were harvested as above and re-suspended in
12.5ml of ice cold 10% v/v glycerol, then harvested again and re-suspended in 2ml of 10% v/v
glycerol. Competent cells were stored at -20°C.
2.8.3 - Transformation of chemically competent cells
20pl of ligation reaction, or 1 pi of purified plasmid, was transferred into an aliquot of 1 OOpl
competent cells and incubated on ice for 30 minutes in a glass test tube. The mixture was then
transferred to a 42°C water bath for 60s, and then placed on ice. 250pl of SOC was added to the
mixture and incubated at 37°C (30°C for temperature sensitive plasmids) at 80rpm for 2 hours.
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200pl of the transformation reaction was then plated out onto LB plates with appropriate
antibiotic selction and incubated overnight at 37°C (30°C for temperature sensitive plasmids).
2.8.4 - Transformation of electro-competent cells
lpl of purified plasmid was added to 80pl of competent cells, and incubated on ice for 5
minutes. The mixture was transferred to a 1.5ml electroporation cuvette (Flowgen, UK) and
electroporated at 2.5kV. 1ml SOC was added immediately, and the suspension transferred to a
1.5ml eppendorf tube. The reaction was incubated at 37°C (30°C for temperature sensitive
plasmids) at 200rpm for 1 hour. 200pl was plated onto LB plates with appropriate antibiotic
selection and incubated overnight at 37°C (30°C for temperature sensitive plasmids).
2.8.5 - Allelic exchange
Allelic exchange strains containing the sackan cassette were made electrocompetent, and
transformed with the allelic exchange plasmid, with recovery of transformants at 30°C on LB
Chloramphenicol (LBC) and LB Kanamycin (LBK) plates. Ten colonies confirmed as
successful transformants were used to inoculate 50ml of LBC, and logarithmic growth was
maintained for 48 hours at 42°C with shaking at 200rpm. At this stage a diagnostic PCR can be
performed for primary integrates. After 48 hrs, a 1:500 dilution was made in LB and
logarithmic growth was maintained for 48 hours at 30°C with shaking at 200rpm. After 48
hours, the suspension was serially diluted and 200pl of 1CT5 and 1CT6 dilutions were used to
seed LB sucrose plates, which were incubated at 30°C for 24 hours. Succesful colonies on the
LB sucrose plates (indicating loss of the sacB gene) were replica plated onto LBC, LBK, and
LB agar plates. Colonies which were sensitive to chloramphenicol and kanamycin were
analysed with PCR to confirm exchange of the required DNA fragment with the sackan
cassette. The newly created strains were cultured and stored at -70°C. This method is an
extrapolation ofmethodology published previously (Blomfield et al, 1991).
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2.9 - FRIVET Techniques
2.9.1 - FRIVET 'on' to 'off switching assay
A confirmed 'on' colony is cultured in the presence of arabinose at a concentration of 0.04%
w/v to late exponential phase. The culture is then serially diluted in PBS and plated onto LB
agar for overnight incubation. Individual 'on' or 'off colonies are serially diluted in PBS and
replica plated onto LB/LBA plates. The 'off colonies can be isolated and stored at -70°C.
2.9.2 - FRIVET ampicillin resistance assay in vitro
From an overnight culture 50ml of appropriate media was inoculated to an OD(600) of 0.05.
Arabinose was added at varying concentrations. The control flask has no inducer added. At
required timepoints lOOpl samples were taken, diluted serially and lOOpl plated onto LB plates
and LB ampicillin (lOpglT). Plates were incubated at 37°C overnight. The colonies on each
plate were counted to give the relevant ampicillin resistant % for that flask.
2.10 - Large intestine ligated gut loop assay
Each sheep was determined free from E. coli 0157:H7 by examining faecal samples
before surgery using selective CHROM-agar (CHROMagar Microbiology, France). Each
sheep was sedated as described (Wales, A.D., et al, 2002). Briefly, each lamb was pre-
treated with Xylazine (Rompun 2%, Bayer) and then anaethetised with a combination of
diazepam (Valium, Roche) and ketamine (Ketaset, Fort Dodge) given intravenously.
After intubation, anaesthesia was maintained by inhalation with isoflourene in oxygen.
Twelve ligated intestinal loops, each roughly 10cm long were created by tying pairs of
encircling braided nylon ligatires around the spiral colon, maintaining the mesenteric
blood supply to each individual segment. A 2ml sample of each inoculum was injected
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into each loop with a 25 gauge needle. The injection site was sealed by thermocautery.
After inoculation, the intestine was replaced in the abdomen and the incision closed with
sutures. The sheep was maintained under anaesthesia. After 6h the ligated segments
were excised. The sheep was then killed with pentobarbitone. After removal from the
animal each loop was placed in PBS prior to processing.
Each loop in turn was isolated and cut open to reveal the faecal matter and endothelial
lining. The faecal matter and other loop contents were resuspended in PBS and serially
diluted in PBS before spread plating on SmacNal and SmacNalAmp plates. The
endothelial lining was scraped off using a spatula. After resuspension in PBS, the
scrapings were serially diluted in PBS and plated on SmacNal and SmacNalAmp plates.
Plates were incubated overnight at 37°C before counting the proportion of ampicillin
resistant colonies in each sample.
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Chapter 3
Construction of the FRIVET system
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3.1 - Deletion offim region from strains ZAP193 and ZAP1
The fim region will be deleted from strains ZAP1 and ZAP193 using an allelic exchange
vector containing fim flanking regions of homology on either side of the sac/kan cassette.
The flanking regions will be cloned into pIB307 one at a time and a separate exchange
vector will be constructed for each strain as flanking regions may contain sequence
differences. The sac/kan cassette will be used to allow exchange of the full FRIVET
constructs at a later date. An outline of the cloning strategy can be seen in Fig 3.2
As previously discussed the E coli 0157:H7 fim operon contains a 16bp deletion in the
fiimA gene that results in the inability to express type 1 fimbriae (Roe el al, 2001).
Therefore, crucially, by deleting this region we are not affecting the bacterium's natural
ability to bind receptors or aid in pathogenesis in the host. However as E. coli 0157:H7
does contain both characterised and uncharacterised fimbrial clusters, we must be aware
that other genes within the film operon may potentially play a role outside of the fim
operon and that deletion of these genes may have consequences in vivo for the
pathogenicity of the bacterium.
The region of homology downstream of fimH was designated the right flanking region
(RFR) and was defined as starting immediately after the stop codon for fimH. As has
been discussed the region of homology upstream of the fim operon, designated the left
flanking region (TFR) must contain the necessary fiimB control elements upstream of the
Jim operon. Therefore the start of the LFR can be defined as being approximately 700bp
upstream of the JimB transcriptional start site. The organisation of the regions of
homology can be seen in Fig 3.1
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Fig 3.1
Diagram outlining the positions of the LFR and RFR relative to fimB and fimH for the
FRIVET system
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Cloning strategy used for creation offim deletion vectors using temperature sensitive allelic
exchange vector pIB307 as a template. Vectors were constructed in AAEC189 prior to
single copy exchange into FRIVET strains.
Exchanging the sac/kan cassette at the fim locus will allow us to conduct a further
exchange at this site. Using the same flanking regions of homology FRIVET constructs
can be assembled between the LFR and RFR and exchanged into the fim locus.
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3.3- Cloning the fim operon left flanking region from ZAP193 into pIB307
The LFR of the fim operon was amplified by PCR from ZAP 193 with primers LFR1 and
LFR2 This fragment was digested with BamHl and SacI and ligated into the temperature
sensitive exchange vector pIB307 between the BamHl and Sacl restriction sites. The
pIB307 vector contains a single BamHl site and linearizes at 4.2kb. The cloning of the
LFR from ZAP193 introduces an extra 1.2kb. When putative clones are digested with
BamHl (Fig 3.3a) three clones (#1, #4, #6) linearized at 5.4kb.
To confirm the cloning of the LFR into pIB307 an Avail digest was performed on clones
#1, #4, #6 and a putative negative #2 using pIB307 as a negative control (Fig 3.3b). The
LFR introduces a novel Avail site. All four clones produced 2 bands at 1.7kb and 3.7kb
against the pIB307 single band at 4.2kb indicating the insertion of the LFR into pIB307 at
the correct site. Clone #2 produces the correct banding pattern for the Avail digest but
does not seem to linearize any larger than pIB307 and was excluded from further study.




BamHl digest of seven putative clones containing the LFR from ZAP193 compared against
plB307 (wt). Clones #1, #4 and #6 linearize 1.2kb larger than wt. M= Hindlll ladder.
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Fig 3.3b
M wt 1 4 6 2
Avail digest of clones #1, #4 and #6 against pIB307 and putative negative clone, #2 and
pIB307 (wt). Clones #1, #4, #6 and #2 all produced 2 bands compared to wt, consistent with
the cloning of the LFR into pIB307. M = Hindlll ladder.
Fig 3.3c
Ava
Vector map of pRQ3 showing the cloned LFR from strain ZAP193 and its novel Avail site
inserted into pIB307.
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3.4- Cloning thefim operon right flanking region from ZAP193 into pRQ3
The RFR from ZAP193 fim operon was amplified by PCR using primers RFR 1 and RFR
2. The resulting fragment was digested with Pstl and RawHI.and cloned into pRQ3 at
the BamHl and Pstl restriction sites.
Eight putative clones were subsequently analysed by restriction digest. The RFR
introduces a novel Avail site and all eight clones produced three bands at 1.7kb, 2.1kb
and 2.8kb (Fig 3.4b) compared to pRQ3 that produces two bands at 1.7kb and 3.7kb.
This indicates the correct cloning of the RFR into pRQ3. Clone #1 was taken forward
and designated pRQ4 (Fig 3.4a).
Fig 3.4a
Avail








Avail restriction analysis of eight putative pRQ3 clones containing the cloned RFR from
strain ZAP193. All eight clones exhibit the expected banding pattern of 1.7kb, 2.1kb and
2.8kb for a correct orientational insertion of the RFR. M = lkb ladder.
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3.5- Insertion of the sac/kan cassette between the LFR and RFR of pRQ4
The sac/kan cassette was gel excised from pDG28 and ligated into pRQ4 at the BamH\
restriction site. Two putative clones were digested with BamHl to excise the sac/kan
cassette (Fig 3.5a). One of the clones (#2) produced a band at 3.9kb, corresponding to
the correct size for the sac/kan cassette and 6.6kb corresponding to the pRQ4 backbone.
E. coli MG1655 strain AAEC189 was transformed with clone #2 and conferred
kanamycin resistance, confirming the correct cloning of the sac/kan cassette into pRQ4.





Zh//«HI excision analysis of two putative clones containing the sac/kan cassette from pDG28.






Diagrammatic representation of pRQ40 with the sac/kan cassette cloned between the LFR
and RFR
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3.6 - Cloning the fim operon right flanking region from ZAP1 into pIB307
The RFR of the fim operon from ZAP1 was amplified by PCR using primers RFR 1 and
RFR 2. This fragment was digested with BamHl and Pst\ and ligated into pIB307
between the BamHl and Pst\ restriction sites.
Three putative clones were subject to restriction analysis with BamHl and Avail and
compared against pIB307 (wt) (Fig 3.6a). All three clones linearized at 5.5kb compared
to 4.2kb for wild type pIB307 indicating the cloning of 1.3kb extra DNA. To confirm the
extra DNA cloned was the RFR an Avail digest was performed. All three clones
produced 2 bands at 2.8kb and 2.7kb. The RFR introduces a novel Avail site compared
to pIB307 which linearizes at 4.2kb with a single Avail site. All three clones therefore




M Wt 1 2 3 M wt 12 3
Three putative clones containing the RFR from ZAP1 digested using BamlAl and Avail
compared against pIB307 (wt). All three clones linearize 1.3kb larger than wt when
digested with BamYll and produce two bands of 2.8kb and 2.7kb compared to one band of




Vector map of pRQ5 showing the additional ^4vaII site on the RFR cloned from ZAP1 into
pIB307.
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3.7 - Cloning the fim operon left flanking region from ZAP1 into pRQ5
The LFR from the ZAP1 fim operon was amplified by PCR with the primers LFR 1 and
LFR 2. The PCR product was digested with Sad and BamUl and was ligated into pRQ5
between the BamHI and Sad restriction sites.
Twelve putative clones were analysed by restriction digest with Avail. The correct
cloning of the LFR into pRQ5 would result in three bands at 1.7kb, 2.1kb and 2.8kb when
digested with Avail. Nine of the twelve putative clones produced three bands of 2.8kb,
2.1kb and 1.7kb (Fig 3.7a). Clones #4 and #7 produced an identical banding pattern to
pRQ5 of 2.7kb and 2.8kb.
To confirm the LFR/RFR orientation was correct, a diagnostic PCR was performed on
three putative correct clones (clones #1, #2, #3) and one putative negative clone (#7)
across both flanking regions using the LFR 5' primer and the RFR 3' primer (Fig 3.7c).
Clones #1, #2 and #3 produced a PCR product at the predicted length of 2.3kb.
Clone #7 did not produce a PCR product using the LFR/RFR primers. This confirmed




Ml 2 3 4 5 6 7 8 9 10 11 12 M'
An Avail digest of twelve putative constructs containing the LFR cloned upstream of the
RFR in pRQ5. Clones #1-3, #5-6, #8 and #10-12 all exhibit the expected banding pattern for




Vector map of pRQ6 containing the LFR cloned upstream of the RFR. The LFR introduces
a novel Avail site.
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Fig 3.7c
M 1 2 3 7 -ve M
2.3kb
PCR using primers LFR1 and RFR2 on putative clones containing the LFR and RFR from
ZAP1. Clones #1-3 all produced bands for the LFR/RFR PCR product. Clone #7 failed to
produce a band using these primers. Lane 5 (-ve) is the negative PCR control. M =Hindlll
ladder
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3.8- Cloning the sac/kan cassette between the LFR and RFR of pRQ6
The sac/kan cassette was excised from plasmid pDG28 using Bamlil and subsequently
ligated into pRQ6 at the BamW\ restriction site.
Two putative clones were subjected to BamVA restriction analysis. Clone #1 produced
two bands at 6.6kb and 3.9kb indicating the excision of the sac/kan cassette (data not
shown). Clone #1 also conferred kanamycin resistance to E. coli MG1655 strain
AAEC189 when transformed. Clone #1 was designated pRQ7 (Fig 3.8).
Vector map of pRQ7 showing the sac/kan cassette cloned between the LFR and RFR in
pRQ6 between two BamHI sites.
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3.9- Deletion of the fim region from ZAP541
Strain ZAP541 was transformed with the temperature sensitive allelic exchange vector
pRQ40. The exchange of the sac/kan cassette conferred kanamycin resistance and
sucrose sensitivity onto ZAP541. Analysis was performed on two kanamycin resistant
strains that showed impaired growth on sucrose media by PCR using primers fimS VI 5'
and fimS 3' to confirm the deletion of the fim switch (Fig 3.9). E. coli strain MG1655 is
used as a positive control in lane 3. Strain #1 was designated ZAP542.
Fig 3.9
Ml 2 +ve
Diagnostic PCR on two fim region deleted strains. The PCR is specific for the fim switch.
Both strains fail to produce a PCR product. Lane 3 contains the positive control E. coli
MG1655 and produced a band at the expected size for the fim switch. M = lOObp ladder.
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3.10- Construction of the FRIVET synthetic operon
The backbone of the FRIVET system is a synthetic operon containing three genes: fimB,
fimS and bla. A genetic map of the FRIVET operon is shown in Figure 3.10a. A
promoterless copy offimB will be used for its ability to drive inversion of the fim switch
from the 'off to the 'on' orientation.
The fim switch contains a promoter that, in the 'on' orientation drives transcription of
downstream genes, in the fim operon these are the fim structural genes, in the FRIVET
system we will use the reporter gene bla, the product of which confers ampicillin
resistance upon the cell.
Fig 3.10a
Gene map showing the organisation of the three genes in the FRIVET synthetic operon.
The FRIVET operon is constructed between the LFR and RFR for subsequent allelic
exchange.
Construction of the FRIVET backbone will take place on the allelic exchange vector
pRQ4. All three genes will be cloned between the LFR and RFR on pRQ4 at an
intergenic BamHl site in a sequential manner, fimB first, followed by fimS and bla. All
cloning steps will be carried out in the/Sfim E. coli strains AAEC185 and AAEC189.
The promoterless fimB gene will be amplified from MG1655 and the bla gene will be
amplified from the vector pUC18. The 5' primer for fimB contains a novel Xbal site for
subsequent cloning of the ara and other promoters for FRIVET assays.
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The fimS region will be amplified from three distinct vectors/strains. Each of the three
switch regions will be cloned downstream offimB to create three distinct lineages:
A locked 'on' variant of the switch from vector pMM36
A locked 'off variant of the switch from vector pJL2
A variant with a slower rate offimB mediated switching from strain NEC 120
The fim switch in strain NEC120 contains an extra base 'T' in the IRR that results in a 30
fold reduction in fimB mediated switching (Leathart and Gaily, 1998). The cloning




Cloning strategy used to construct the FRIVET backbone lineages using the genes: fimB,
fintS and bla. pRQ4 was used as the template and vectors were constructed in strain
AAEC189.





3.11 - Cloning thefimB gene from MG1655 between the LFR and RFR on pRQ4
The fimB gene was amplified from E.coli MG1655 using primers fimB 5' and fimB 3'.
The resulting fragment was digested with BglW and Bam\ II and ligated with pRQ4. The
correct cloning of the fimB gene into pRQ4 will change the Avail restriction pattern from
1.7kb, 2.1kb and 2.8kb for pRQ4 to 1.7kb, 2.8kb and 2.8kb for pRQ4 + fimB.
Five putative clones were analysed by Avail restriction digest (Fig 3.11b). Clone #4
produced three bands of 1.7kb, 2.8kb and 2.8kb indicating the insertion of a DNA
fragment identical in size to fimB. To confirm the extra DNA as being the fimB gene a
specific PGR was performed using primers fimB 5' and fimB 3' using E. coli MG1655 as
a positive control (+) (Fig 3.11c). Clone 4 produced a PCR product for fimB and was
designated pRQl 1 (Fig 3.11a)
Fig 3.11a
fimB
Vector map of pRQll showing ftmB cloned between the LFR and RFR and a BamH\
restriction site downstream offimB for subsequent cloning offimS and bla.
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Fig 3.11b




^Vflll restriction digest of five putative clones of pRQll. Clone #4 produces a banding
pattern indicating the cloning of a fimB sized DNA fragment. Clones #l-#3 produce
banding patterns identical to pRQ4. M = lkb Ladder.
Fig 3.11c
M 2 4 5 +
683bp
fimB specific PCR on clones #2, #4, and #5. The positive control (+) is an MG1655 DNA
prep, the negative control (-) is water. Clone #4 is confirmed as containing fimB. M =
lOObp ladder.
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3.12 - Cloning the fimS region from pMM36 into pRQll
The fimS region was amplified from plasmid pMM36 using primers fimS 5' VI and fimS
3'. pMM36 contains a copy of fimS locked in the 'on' orientation. The resulting
fragment was digested with Bglll and BamHl and ligated with pRQl 1.
An Avail digest of 3 putative clones against pRQll showed two clones (#2 and #3)
producing a banding pattern of 1.7kb, 2.8kb and 3.5kb (Fig 3.12a). This banding pattern
corresponds to the insertion ofDNA of roughly 700bp into pRQl 1.
To confirm the extra DNA as fimS and to check its orientation a specific PCR was
performed using the primer combinations (1) LFR1 and fimS 5' and (2) RFR2 and fimS 5'
(Fig 3.12c). The first primer set was specific for a fimS insertion in the reverse
orientation with the BamlAl site adjacent to fimB and the promoter in fimS directed
upstream towards fimB. The second primer set was specific for fimS downstream offimB
with the fimS promoter pointing downstream away fromfimB into the RFR.
Clones #2 and #3 produced a PCR product of the expected size with primer set 1 and
clone #1 produced a PCR product for primer set 2. However the Avail banding pattern
for #1 suggests an insertion of a fragment ofDNA larger than 700bp. As this result could




M 1 2 3 pRQll
Avail digest of three putative clones of pRQ12. #2 and #3 produce banding patterns
indicating the cloning of an extra ~700bp DNA. M = lkb Ladder
Avail
Vector map of pRQ12 showing the fimS region cloned downstream offimB. The promoter
in fimS is poining upstream into fimB.
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Fig 3.12c
SET 1 SET 2
M 1 2 3 1 2 3 -
Diagnostic PCR to confirm the cloning of the fimS region into pRQ12 and to check its
orientation respective to fimB. Clones #2 and #3 produce PCR products of the expected
length confirming the cloning of thefimS region into pRQll. M =Hindlll ladder
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3.13 - Cloning the bla gene into pRQ12 to create a transcriptional fusion with the
promoter in fimS.
The bla gene was amplified from pUC18 using primers bla 5' BamYll and bla 3'. The
PCR product was digested with BamWl and cloned downstream of fimS to create a
transcriptional fusion with the fimS promoter. As the bla gene was cloned in using
BamHl sites the orientation of bla was confirmed by patching successful ligation
reactions onto LBA and LBC plates. Six clones were found to be resistant to ampicillin.
To confirm these six clones had the correctfimSr.bla transcriptional fusion construct an
Avail digest was performed on the six putative clones using two ampicillin sensitive
clones and pRQ12 as controls (Fig 3.13b). The bla gene contains an Avail site, thus
correctly cloning the bla gene into pRQ12 in the correct orientation respective to fimS
will result in an Avail banding pattern of 2.8kb, 2.5kb, 1.9kb and 1.7kb. Clones #1 and
#2 match this expected banding pattern. The two ampicillin sensitive controls CI and C2
match the Avail banding pattern for pRQ12. Clones #3 - #6 were ampicillin resistant but
do not show the expected Avail banding pattern.
To further confirm the fimSr.bla fusion a PCR was performed using the 5' fimS VI
primer and the bla 3' primer (Fig 3.13a). Clones #1 and #2 produced a PCR product of
the expected length confirming the creation of the fimSr.bla fusion. Clones #3-#6, CI
and C2 did not produce a PCR product at the expected length and were discarded. Clone
#1 was subsequently designated pRQ13 (Fig 3.13c)
Additionally pRQ13 was sequenced across the region spanning from the LFR to the RFR
to confirm the genetic organisation of the FRIVET operon. Analysis of the sequence data
showed no disruption of any of the ORF's in the FRIVET operon (data not shown).
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Fig 3.13a
M 1 CI C2 -ve M
l.6kb
Fusion PCR specific for the fimS::bla construct. Clones #1 and #2 produced a PCR product
of the expected length at 1.6kb. M = lkb Ladder
Fig 3.13b





Avail digest of six ampicillin resistant pRQ13 clones, #1 and #2 exhibit the correct banding














Vector map of pRQ13 showing the fimSr.bla fusion construct downstream offimB and the
novel AvaW restriction site within bla.
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3.14 - Cloning the fimS region from strain NEC120 into pRQll
The fim switch region was amplified from E. coli strain NEC 120 using primers fimS VI
5' and fimS 3' and the PCR fragment was digested with Bglll and BamHI before ligation
with pRQl 1.
Seven putative clones were analysed by Avail restriction digest (Fig 3.14a). A correct
insertion of fimS would result in an Avail banding pattern of 3.5kb, 2.8kb and 1.7kb
against 2.8kb, 2.8kb and 1.7kb for pRQl 1. Figure 12b shows clones #2 and #3 with the
expected banding pattern for a fimS insertion between the FFR and RFR. To confirm the
presence of fimS and to check its orientation respective to fimB, a diagnostic PCR was
performed using on clones #2 and #3 using two sets of primers: (1) fimB 5' and fimS 3';
(2) fimB 5' and fimS VI 5' (figure 3.14c). Clones #1 and #11 were used as negative
controls and water was used as a PCR control (-) (Fig 3.14c)
Clone #3 produced a positive PCR product with primer set (1) and clone #2 produced a
positive PCR with primer set (2) indicating both orientations of fimS were represented.
Clone #3 was taken subsequently designated pRQ16 (Fig 3.14b).
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Fig 3.14a




AvaW restriction digest on seven putative pRQ16 clones. Compared to pRQll, clones #2
and #3 produce banding patterns indicating the insertion of fimS sized DNA fragment




















M 2 3 11
SET 2
Ml 2 3 11 - M
PCR using fimB and fimS primers to confirm the orientation of fintS repective to fimB.
Clone #3 and clone #2 contain different orientations offimS. M = lOObp Ladder
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3.15 - Cloning bla into pRQ16 downstream offiniS
The bla gene was amplified from pUC18 using primers bla 5' BamW\ and bla 3' and the
resulting PCR product was digested with BamHl and ligated with pRQ16. Eight putative
clones were analysed by BamHl restriction digest to attempt to excise the bla gene. Only
clone #6 excised a band at the expected size for the bla gene (Fig 3.15b).
To confirm bla orientation in clone #6 a PCR was performed using two sets of primers:
(1) fimS VI 5' and bla 5'; (2) bla 5' and RFR2 (Fig 3.15c). Clone #6 produced a PCR
product of the expected size for a fimSr.bla fusion using primer set (2), confirming the





Vector map of pRQ17 showing the orientation of the fimSr.bla fusion and the Xbal
restriction site in fimB for subsequent promoter cloning. The BamHl sites flanking the bla






BantWV restriction digest on clone #6 compared to parent vector pRQ16. A band of 950bp is








Diagnostic PCR on clones #6 and #7 using two sets of primers. Clone #7 failed to excise a
band in the BamHl restriction assay and is included as a negative control. Clone #6
produces a band of the expected size using primer set 2, confirming the cloning of bla in the
correct orientation respective to fintS. As expected clone #7 failed to produce a PCR
product. Water is used as a negative PCR control (-). M = lkb Ladder
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3.16 - CloningfimS from pJL2 into pRQll
The fimS region was amplified from pJL2 using the primers fiimS VI 5' and fimS 3' and
the resulting fragment digested with Bglll and BamUl before ligation with pRQl 1 at the
BamHl site downstream offimB.
A single putative clone was digested with AvaW and its banding pattern compared with
pRQll (Fig 3.16b). The clone produced a banding pattern of 1.7kb, 2.8kb and 3.2kb
corresponding with the expected jump in size of the 2.8kb band in pRQll from2.8kb to
3.2kb indicting an extra 400bp ofDNA inserted between the AvaW sites.
To confirm the presence of the fimS region, and to identify its orientation, a diagnostic
PCR was performed using 2 sets of primers: (I) fimB 5' and fimS 3' new; (2) fimB 5' and
fimS VI 5' (Fig 3.16c). A PCR product of the expected size (1.3kb) was produced using
primer set 1. Clone #1 was designated pRQ23 (Fig 3.16a).
Avail
Vector map of pRQ23. The fimS region is cloned from pJL2 downstream of fimB







AvaW digest on a single putative clone compared against pRQll. The 2.8kb band in pRQll
has risen to 3.2kb, indicating the presence of an extra 400bp. M = lkb ladder
Fig 3.16c
SET 1 SET 2
Ml 1 - M
1.3 kb
PCR using two sets of primers to confirm the orientation offimS respective to fimB. Clone
#1 produces a PCR product at the expected size with primer set 1 indicating the cloning of
fimS in the orientation seen in Fig 13a. M = lkb ladder
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3.17 - Cloning the bla gene downstream offimS in pRQ23
The bla gene was amplified from the vector pUC18 using primers bla 5' BamHl and bla
3' and the resulting PCR product digested with BamHl and ligated with pRQ23.
Eight putative clones were subjected to Avail restriction analysis and compared against
pRQ23 (Fig 3.17b). Clone #7 produced a banding pattern of 1.3kb, 1.7kb, 2.8kb and 3kb
(the 2.8kb and 3kb bands are seen as a doublet). This corresponds to the expected
banding pattern for clones containing the fimSr.bla fusion as the bla gene contains a
novel Avail site at its 3' end thereby increasing the number of bands from three in pRQ23
to four in a pRQ23::Wa clone.
To confirm the cloning of the bla gene a BamHl excision was performed on clone #7 and
compared with clone #6 and pRQ23 (Fig 3.17c). As expected, a band was excised from
clone #7 but not from clone #6 or pRQ23 that matched the correct size for the bla gene.














Avail digest on eight putative pRQ23::6/« clones. #7 produces the expected banding
pattern for a fimSr.bla fusion construct. The 2.8kb and 3kb bands are seen as a doublet,
further resolution of the agarose gel would result in the separation of this doublet. M = lkb
ladder.
Fig 3.17c
M 6 7 pRQ23 M
7.9kb
950bp
BamYll excision digest on clones #6, #7 and pRQ23. Clone #7 excises a b!a sized band at
950bp confirming the presence of bla. Clone #6 and pRQ23 fail to excise a band and
linearize at 7.9kb. M = lkb Ladder.
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3.18- Chapter 3 Discussion
The creation of FRIVET strains for use in in vivo assays requires the construction of a
synthetic operon on an allelic exchange ready, pIB plasmid based background. The
backbone of the FRIVET system was constructed using the components: fimB, bla and
fimS.
All FRIVET constructs were to be placed in single copy at the fim locus in the ZAP 193
background. This was achieved using pRQ40. Plasmid pRQ40 was constructed using
~lkb regions of homology upstream and downstream of the fim operon termed the LFR
and RFR. These fragments were amplified from ZAP 193 and cloned into the temperature
sensitive allelic exchange vector pIB307 to create plasmid pRQ4.
Finally the sac/kan cassette was cloned between the LFR and RFR to create pRQ40. The
sac/kan cassette is important in the process as it allows selection of successful exchange
strains (Blomfield et al, 1991) and as such would be needed for the subsequent exchange
of FRIVET strains into the fim region. The exchange process was successful and the fim
region was deleted from ZAP541 and ZAP544 to create ZAP542 and ZAP545. Strains
were analysed by their antibiotic sensitivity profile and their growth on sucrose
containing media. Additionally a PCR was performed using fimS specific primers on two
strains of ZAP542. As expected both strains failed to produce a PCR product for fimS
against a positive control (strain MG1655) indicating the successful deletion of the fun
region from ZAP541 and the creation of ZAP542.
The fim deletion vector pRQ7 was also constructed using the LFR and RFR from ZAP1
for deletion of the fim region from ZAP1, a category 3 EHEC strain. However, the
exchange process was repeated multiple times yet failed to produce exchange strains with
the correct antibiotic resistance profile. A possible explanation for this could be the LFR
and/or RFR PCR products containing mismatched bases created at the amplification stage.
The standard Taq polymerase has a mismatch rate of about 1 base in 1000. The primer
sequences were also taken from the sequenced EHEC strain EDL933 (Perna et al, 2001)
and not from the actual ZAP1 sequence and as such the two EHEC sequences could
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differ at the flanking regions, resulting in less homology than is needed for successful
allelic exchange.
Due to the successful exchange into the ZAP 193 background, it was decided to
concentrate on ZAP 193 based FRIVET strains and to cease working with the ZAP1
background.
The FRIVET backbone was constructed in a stepwise manner using a pIB307 vector as
the starting point. The first step was the cloning of the fimB gene from MG1655 in
between the LFR and RFR on pRQ4 and the resulting clones were analysed by restriction
digest and PCR to confirm the creation of pRQll. The next cloning step was the
insertion of the three fim switch variants at the BamH\ restriction site downstream offimB
on pRQl 1. The three fimS variants were:
• 'on' orientation from pMM36 - pRQ12
• 'off orientation from pJL2 - pRQ23
• a slower inversion rate 'on' orientation switch from strain NEC 120 - pRQ16
All three switch variants were successfully cloned into the BamWl site downstream of
fimB and results were verified with restriction analysis and diagnostic PCR.
The final step in creating the FRIVET synthetic backbone was the cloning of the bla gene
downstream offimS for each of the three fimS variant lineages. The cloning of bla into
pRQ12 allowed us to select putative clones by screening on ampicillin containing media.
Clones that were resistant to ampicillin therefore would have contained a functioning
fimSr.bla transcriptional fusion where the promoter in fimS drives transcription of the bla
gene. Subsequent restriction digest and diagnostic PCR confirmed the successful cloning
of bla into pRQll. The cloning of the bla gene into pRQ23 and pRQ16 was also
successful, verified by restriction digest and diagnostic PCR.
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The FRIVET system backbone was now constructed. The next step in the construction of
FRIVET strains was to clone promoters of choice to drive fimB expression and to
construct the inhibitory mechanisms needed to control the FRIVET system.
Due to the technical difficulties of constructing the FRIVET operon, many lines of
construction had to be 'dropped' after numerous attempts. Whilst it is important to create
a functioning FRIVET operon, further efforts must be made to construct the various fimS
variants and E. coli 0157:H7 background variants. Without having these variants it will
be much harder to create a controllable FRIVET system or to answer specific questions
about strain differences in E. coli 0157:H7 during infection or colonisation.
94
Chapter 4
Cloning of EHEC promoters into the FRIVET backbone &
Construction of FRIVET Control Plasmids
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4.1 - Introduction
This chapter will focus on two separate elements:
• The cloning of EHEC promoters upstream of fimB into various FRIVET
constructs outlined in chapter 3 to create test FRIVET constructs
• The construction of plasmid constructs designed to control the FRIVET operon.
These constructs will be placed in single copy at a separate locus to the FRIVET
operon.
4.2- Cloning EHEC promoters in front offimB to create FRIVET vectors
The FRIVET backbone consists of a promoterless copy offimB upstream of the fimSv.bla
fusion construct. The 5' fimB primer contains Bglll and Xbal restriction sites as 5' tails
(Fig 4.2). The Bglll site will be used to clone the amplified fimB into the BamHl site on
pRQ4 and the Xbal site will be used to clone promoters of choice upstream of fimB to
create functional transcriptional fusions to fimB. Thus fimB will be under the
transcriptional control of the cloned promoter and consequently fimS inversion rates and
Bla production.
The promoters were cloned into two lineages of FRIVET backbone: pRQ13 and pRQ24.
Both lineages contain wt fim switch regions but the orientation of the FRIVET operon
differs in each lineage. Our limited knowledge of the behaviour of the FRIVET operon




fimB translational start site
I
wt fimB - GCT . AAC . CCA. GCA. CAG. CTA. GTG. CGC. GTC . TG - (19bp) - ATG...
The 5' fimB primer introduces a novel Xbal site 38bp upsteam of the fimB translational
start site. 3 bases are modified from wt sequence in the primer to effect this change.
The four EHEC promoters were initially chosen to be cloned were:
• lee5 - LEE5 (tir, cesT, eae) operon control in EHEC
• fliC - Flagella regulation
• Ipfl - controls EHEC long polar fimbriae production
• loc8 - controls EHEC Loc8 fimbrial production
Our choices reflect a wide variety of EHEC virulence factors. To represent the LEE
pathogenicity island we will use the promoter for the LEE5 operon, responsible for
transcription of the tir, cesT and eae genes. The tir gene product: the translocated intimin
receptor is a translocated effector protein that embeds itself into the host cell membrane
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and acts as a receptor for the eae gene product: the adhesin Intimin. CesT acts as a
chaperone for Intimin.
Bacterial flagella ultrastructure shares many components with type III secretion systems
and flagella regulation may be linked to EHEC pathogenesis as part of a global virulence
gene cascade. E. coli 0157:H7 flagella have also been shown to play a role in
persistence of infection in chickens (Best et al, 2005) and more recently, GrlA, a LEE
encoded positive regulator of LEE gene expression, acts as a negative regulator of
flagellar gene expression (Iyoda et al, 2006).
The promoters for two EHEC specific adhesins will also be studied. The importance of
Lpfl in an EHEC colonisation study is yet to be elucidated but Loc8 was identified in a
signature tagged transposon mutagenesis study as a potentially important adhesin for
EHEC colonisation (Dziva et al, 2004), however studying the activity of these fimbrial
promoters in vivo will allow us to draw futher conclusions about EHEC pathogenesis and
primary attachment.
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4.3 - Cloning the lee5 promoter into pRQ13
The lee5 promoter from strain ZAP 193 was amplified by PCR using primers LEE5 5'
and LEE5 3', digested with Xbal and ligated with Xbal digested pRQ13.
Eleven putative clones were screened by PCR using primers LEE5 5' and fimB 3' (Fig
4.3b) to identify lee5 clones that had inserted in the correct orientation respective to fimB
to create a lee5::fimB transcriptional fusion. The diagnostic PCR yielded one clone, #23,
that produced a positive PCR product for the lee5::fimB construct. The band on the
agarose gel is at the expected size (1.2kb) but is faint. This is due to the two primers not
being designed to be used together. As such one of the primers will anneal to the DNA
with less specificity leading to a weaker, less defined band when run on an agarose gel.
To confirm the result of the PCR an Avail digest was performed on clone #23 and pRQ13
(Fig 4.3c). The change in banding pattern from 1.7kb, 1.9kb, 2.4kb and 2.8kb for pRQ13
to 1.7kb, 2.4kb, 2.4kb and 2.8kb for pRQIOl is due to the extra lee5 promoter DNA
raising the 1.9kb band to 2.4kb. Clone 23 was subsequently designated pRQIOl (Fig
4.3a)







M 17 18 19 20 21 22 23 24 25 26 27 -ve M
I • T. . »
1.2kb
Diagnostic PCR on eleven putative lee5 clones using 5' Iee5 and 3, fimB primer. Clone 23
produces a weak band at the expected size. M = lOObp ladder
Fig 4.3c




^vall digest of clone 23 against pRQ13. The extra lee5 DNA raises the 1.9kb band in
pRQ13 to 2.4kb, seen as a doublet for clone 23. M = lOObp; M' = lkb Ladders.
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4.4 - Cloning thefliC promoter into pRQ13
The fliC promoter region was excised from a lab prepared pTOPO::/7/C clone using Xbal
and gel purified according to manufacturer's protocol. The pTOPO clone contained the
fliC promoter region amplified from ZAP193. The gel purified fragment was ligated with
pRQ13 pre-digested with Xbal.
Eight putative clones were analysed by Avail restriction digest (Fig 4.4a). The Avail
digest of pRQ13 in figure 23b yields a banding pattern of 1.7kb, 1.9kb, 2.5kb and 2.8kb.
Of the eight putative clones analysed with Avail, clones #2 and #4 - #8 produced a
banding pattern of 1.7kb, 2.2kb, 2.5kb and 2.8kb indicating the insertion of 300bp DNA
upstream offimB.
To confirm the presence offliC and to check its orientation with fimB, clones #2 and #4-
#8, were subject to a diagnostic PCR specific for the fliC::fimB fusion using the primers
fliC 3' and fimB 3' (Fig 4.4c). Clone #3 was included as a control. Clones #2, #5, #6
produce a PCR product using the primers for the fliCr.fimB fusion construct and as
expected clone #3 did not produce a PCR product. Clones #4 and #7 also failed to
produce a PCR product and it is likely that these clones contain the fliC promoter region









Avail digest offliC clones. #2, #4-#8 produce banding patterns indicating an extra 300bp









M 2 3 4 5 6 7 8 -ve M'
Diagnostic PCR using 5'y7/C primer and V fimB primer. Clones #2, #5, #6 and #8 produce
PCR products at the expected size of lkb. Clones #4 and #7 are likely to contain the FliC
promoter, but in the reverse orientation. M = lkb; M' = lOObp ladders.
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4.5- Cloning the lee5 promoter into pRQ24
The lee5 promoter was amplified from ZAP 193 using primers LEE5 5' and LEE5 3' and
after digestion with Xbal was ligated with pRQ24.
Putative clones were analysed by Avail restriction analysis (Fig 4.5b). The pRQ24
banding pattern of 1.3kb, 1.7kb, 2.8kb and 3kb is altered in four of the ten clones: #4, #9,
#10 and #12. In these clones' banding patterns the 2.8kb band seen in pRQ24 is raised to
3.3kb confirming the insertion ofDNA in between these Avail sites.
To verify the DNA insertion as the Iee5 promoter a PCR was performed on clones #1, #5,
#9, #10 and #12 using the lee5 5' primer and the fimB 3' primer (Fig 4.5c). Clones #9,
#10 and #12 produce PCR products at the expected size of 1.2kb confirming the result of
the Avail digest. Clones #1 and #5 also produce faint bands in figure 20c. It is possible
that clones #1 and #5 are correct and contain the lee5::fimB fusion construct. The Avail
banding pattern for these clones may not have had the 3kb and 3.3kb bands fully









LFR II 9399 bp
cat
Vector map showing the lee5::fimB fusion construct in pRQ103.
Fig 4.5b
Ml 2 3 4 5 7 8 9 10 12 pRQ24 M'
^4v«II digest of ten putative !ee5 clones. #4, #9, #10 and #12 all exhibit the expected banding
pattern indicating DNA insertion between the LFR and bla. M = lkb; M' = lOObp ladders.
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Fig 4.5c
Ml 5 9 10 12 -ve M
1.3kb
PCR using Iee5 5' and fimB 3' primer. Clones #9, #10 and #12 produce a product at the
expected size (1.3kb). Clones #1 and #5 produce faint bands in contrast to a negative AvaW
digest. The -ve control is water. M = lOObp Ladder.
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4.6 - Cloning the Ipfl promoter into pRQ24
The Ipfl promoter region was amplified from ZAP193 using the primers LPF1 5' and
LPF1 3'. The resultant PCR product was digested with Xbal and ligated with pRQ24
upstream offimB.
Clones were analysed by Avail restriction digest (Fig 4.6b). Clones F and G show the
2.8kb band in pRQ24 raised to 3.3kb indicating the insertion of DNA between two Avail
sites. To confirm the extra DNA as the Ipfl promoter region a fusion specific PCR was
performed on clone F and pRQ24 using primers LPF1 5' and fimB 3' (data not shown).








Vector map of pRQ104 showing the Ipfl promoter upstream offimB.
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Fig 4.6b




Avail restriction digest on 7 putative Ipfl clones. Clones F and G exhibit the expected
banding pattern of 1.3kb, 1.7kb, 3kb and 3.3kb indicating a DNA insertion of roughly
500bp. Clones A-E exhibited identical banding patterns to wt pRQ24. M = lkb; M' =
lOObp ladders.
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4.7 - Cloning the loc8 promoter into pRQ24
The loc8 promoter region was amplified from ZAP 193 using primers loc8 5' and loc8 3'
and ligated with pRQ24 upstream offimB.
Of the ten putative clones analysed by Avail restriction digest in Fig 4.7b, clones #1, #4,
#7 and #8 produced the expected banding pattern for an insertion of DNA between the
LFR and bla.
Clones #1, #4, #7 and #8 were subsequently analysed by diagnostic PCR for the
loc8::fimB fusion construct using the 5' loc8 primer and the 3' fimB primer (Fig 4.7c).
Clones #7 and #8 produce positive PCR products using these primers, indicating the
correct construction of the loc8::fimB fusion. Clones #1 and #4 did not produce PCR
products using these primers. It is likely that these clones do contain the loc8 promoter
region but in the reverse orientation. Thus using the 5' loc8 primer will not yield a
positive PCR. Clone #7 was designated pRQ105 (Fig 4.7a)
Fig 4.7a
cat
Vector map of pRQ105 showing the /oc8 promoter region cloned upstream of fimB on







AvaW digest on ten putative loc8 clones. Clones #1, #4, #7 and #8 show the banding pattern:
1.3kb, 1.7kb, 3kb and 3.3kb indicating a DNA insertion between the LFR and b!a on pRQ24.
M = lkb; M' = lOObp ladders.
Fig 4.7c
1.4kb
Diagnostic PCR on putative loc8 clones using 5' loc8 and 3, fimB primer. Clones #7 and #8
produce a PCR product for the loc8::fimB fusion construct at the expected size of 1.4kb. M
= lkb ladder.
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4.8 - Controlling the FRIVET system
The main aim of each FRIVET experiment is to ascertain the proportion of bacteria that
have switched from ampicillin sensitive to ampicillin resistant as a result of fimS
switching from the 'off orientation to the 'on' orientation. The inoculum for each
experiment therefore has to start with the fiim switch in the 'off orientation. To prevent
unwanted switching whilst preparing the inoculum and after sampling at the end of the
assay, we will use the DNA binding protein PapB to inhibit FimB mediated switching
and thus FRIVET induction, during these periods. A regulator of the pap operon, PapB
has been shown to inhibit the action of FimB on the fim switch, although the exact
mechanism and binding site is yet to be elucidated.
By placing papB under the control of an IPTG inducible promoter in single copy, we can
induce PapB production during inoculum preparation and at the end of the assay during
sampling. We can then be confident that any fiimS switching can only take place during
the assay. The control fusions will be placed in single copy at the lac locus in our
FRIVET test strains. As such we will use the pIB307 plasmid containing the lacl and
lacA genes for allelic exchange into the lac locus (pAJR26).
We will use two IPTG inducible promoters of different strengths:
• /acUV5 promoter - tight regulation, used to control papB in pHMG88
• Ptac promoter - combination of lac and trp promoter regions, IPTG concentration
proportional to Ptac expression
The use of these promoters will provide us with a wide range of potential PapB levels to
inhibit FRIVET induction. The level of PapB needed to inhibit the FRIVET system will
be defined during FRIVET testing.
In addition an IPTG inducible copy offimE was created on a pACYC vector. The ability
of FimE to mediate film switching from the 'on' orientation to the'off orientation will
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also be studied. It will be useful to have two potential inhibitors offim switching as PapB
inhibition has been studied on the native type 1 fimbrial operon. The FRIVET system
may respond to PapB in a different manner and it may become necessary to deploy a
FimE based vector to ensure the inoculum is in the correct fimS orientation prior to
inoculation.
112
4.9 - Cloning the lacU\5::papB fusion into pAJR26
The lacUV5::papB transcriptional fusion construct was amplified by PCR from pHGM88
with using the primers /acUV5 1 and papBA. The resultant PCR fragment was ligated
with pAJR26 at the intergenic BamHl site.
Three putative clones were analysed by PCR using primers papBA and lacA 3' (Fig 4.9b).
All three clones produced a band of the expected size (lkb) indicating correct cloning of






Vector map of pRQ8 showing the lac\JV5::papB fusion construct cloned at the lac IA





Diagnostic PCR on three putative clones using a 3' papB primer and a 3' lacA primer,
three clones produce a PCR product at the expected size of lkb. M = lOObp ladder.
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4.10 - Cloning the Ptac promoter into pAJR26
The Ptac promoter region was amplified from the vector pACTAC using primers 5' Ptac
Bglll and 3' Ptac Bamill. The resulting PCR product was digested with BglM and Bam\ II
before ligation with pAJR26 at the intergenic BamHl site.
Nine putative clones were analysed by restriction digest with Rsal (Fig 4.10b). Clones #7
and #8 produced the expected banding pattern for the Rsal digest as the 933bp band seen
in the Ctrl digest was raised to 1.1 kb for #7 and #8, indicating the insertion of DNA
between these Rsal sites.
To confirm the orientation of the Ptac promoter a PCR was performed with two sets of
primers: (1) lacl 5' and 3' Ptac BamHl; (2) lacA 3' and 3' Ptac BamHl (Fig 4.10c).
Clone #7 produced a strong PCR product using primer set 2 and clone #8 produced a
strong PCR product using primer set 1. Clone #9 produced a PCR product with primer
set 1 and a weaker 'ghost' band for primer set 2 and may represent a correct clone
however the Rsal digest for clone #9 suggests this is not the case. Clone #8 also
appeared to produce a PCR product with primer set 2, although it is likely that this is the
result of lane bleed through from clone #9 when the agarose gel was loaded, resulting in
the false positive. The large ghost band at ~1.5kb seen in lane 1 for clone #7 with primer
setl can likely be attributed to non-specific priming as a result of using non matched






Vector map of pRQ19 showing the Ptac promoter region cloned at the intergenic BamHI
site between /ac/and lacA on pAJR26
Fig 4.10b
M 1 2 3 4 567 89 ctrl M
l.lkb
933bp
Rsal digest on nine putative clones. Clones #7 and #8 show an increase of 170bp in
The 933bp band indicating the insertion of a DNA fragment of that size. The Ctrl is
pAJR26. M = lkb ladder.
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Fig 4.10c
SET 1 SET 2
M 7 8 9 7 8 9 -ve
Diagnostic PCR on clones #7, #8 and #9 using two sets of primers: (1) lacl 5' and 3' Ptac
BamHI; (2) lacA 3' and 3' Ptac BamHl. Clone #7 produced a PCR product of the expected
size with primer set 2. Clone #8 produced a PCR product with primer set 1. M = lkb
ladder.
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4.11 - Cloning the papB gene into pRQ19
The papB gene was amplified from pHMG88 using primers papB3 and papBA and the
resulting PCR product was digested with BamHl and ligated with pRQ19.
Twelve putative clones were digested with BamU\ in an attempt to excise the cloned
papB gene (Fig 4.1 lb). Clones #2, #3, #5-20 and #12 all excised a band at the expected
size for papB.
To confirm the creation of a Ptacv.papB transcriptional fusion on pRQ19 a diagnostic
PCR was performed on all ten of the BamW\ positive clones using a 5' Ptac primer and
the papBA primer (Fig 4.11c). Clones #1, #3, #7, #10 and #12 all produced a PCR
product at the expected size for the Ptacv.papB fusion. Clone #12 was subsequently
designated pRQ20 (Fig 4.1 la)
Fig 4.11a
Vector map of pRQ20 showing the papB gene cloned upstream of the Ptac promoter to
create a Ptac::papB transcriptional fusion.
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Fig 4.11b
Ml 234 56789 10 11 12 prqi9 M
BamHl digest of twelve putative papB clones. Clones #2, #3, #5-#10 and #12 all excise a
band the size ofpapB (500bp). M = lkb ladder.
Fig 4.11c
Ml 23 5 67 8 9 10 12 - M
500bp
Diagnostic PCR using 5' Ptac primer and papBA to screen putative clones for Ptac::papB
fusion construct. Clones #2, #3, #7, #10 and #12 all produced PCR products of the expected
550bp size. M = lOObp ladder.
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4.12 - Exchanging pRQ8 into a ZAP193 background
Using the allelic exchange vector pRQ8 single copy fusions of lac\JV5::papB were made
in the ZAP 193 sac/kan background at the lac locus. To confirm the allelic exchange
process was successful a PCR was performed on six exchange strains using the primers
lacA 3' down and papBA (Fig 4.12a). All six putative exchange strains produced a PCR
product of the expected 800bp size.
To confirm this result was due to the construct being present in single copy on the
chromosome and not residual pRQ8, a pIB specific PCR was performed on the six strains
using primers specific for pIB backbone sequence Fig 4.12b). Controls used were: pIB
lacIA (CI), a stx- lysate (C2) and H2O (C3). All six strains were negative for the PCR
and the positive control CI produced a PCR product as expected. Strain #1 was stored at
-70°C and designated ZAP541.
Fig 4.12a
M 1 2 3 4 5 6 -ve
800bp
Diagnostic PCR on six exchange strains using primers lacA 3' down and papB4. All six




1 2 3 4 5 6 CI C2 C3 M
Diagnostic PCR screen on six exchange strains using primers specific for pIB plasmid
backbone. Controls: CI = pAJR26; C2 = ZAP193 lysate; C3 = water. M = lOObp ladder.
121
4.13 - Exchanging pRQ20 into a ZAP193 background
Strain ZAP 193 sac/kan was transformed with the temperature sensitive allelic exchange
vector pRQ20. After the first 48h of allelic exchange ten kanamycin and
chloramphenicol resistant strains were subject to a diagnostic PCR using primers lacl up
5' and 3' Ptac Xbal (Fig 4.13b). The position of the primers in relation to the primary
exchange construct is shown in Fig 4.13ba
Strain A2 produced a positive PCR product at the expected 1.8kb size and was taken
forward for the second half of the allelic exchange procedure.
Resultant strains that were kanamycin and chloramphenicol sensitive and grew well on
sucrose containing media were designated ZAP544 and stored at -70°C.
Fig 4.13a
lacl up5'
lacl lacl papB pTac lacA
pTac 3' Xba\
Diagrammatic representation of primer position in Fig 3.29a. The lacl up5' primer binds
upstream on the chromosome of the primary integrate ensuring the specificity of the PCR
for integrated vectors only.
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Fig 4.13b
M A1 A2 A3 A4 A5 B1 B2 B3 B4 B5 M
Diagnostic PCR on ten exchange strains using a 5' upstream lacl primer and a 3' Ptac
primer. Strain A2 produced a PCR product at the expected length of 1.8kb. M = lkb
ladder.
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4.14 - Cloning the fimE gene into the pACTAC vector
The fimE gene was amplified from E. coli MG1655 using primers fimE 1 and fimE2. The
resulting fragment was digested with BamRl and ligated with the pACYC184 based
vector pACTAC downstream of Ptac to create a Ptac::fimE fusion.
Eight putative clones were isolated and subjected to restriction digest analysis with Aval
(Fig 4.14a). The pACTAC vector contains a single Aval site and will linearize after
digestion with Aval at 4.4kb. The cloning of fimE introduces a second Aval site and
correct clones will produce 2 bands of 1.2kb and 3.7kb after Aval digestion. Of the eight
clones analysed only clones #5-#7 exhibit this banding pattern. The smeared bands seen
above the 3.7kb band for these clones is likely to be un-digested plasmid at a size of ~5kb.
To verify this result a diagnostic PCR was performed using primers 5' Ptac Hindlll and
FIME2 to identify the clones that contained the VlacwfimE transcriptional fusion
construct (Fig 4.14c). The two negative controls were: pACTAC (-ve) and water (MQ).
Clones #3-#8 all produce PCR products of the expected 800bp length.
This confirms that clones #5-#7 contain the Ptac::fimE fusion construct. Clones #3, #4
and #8 also produce a positive PCR product with these primers yet linearize at 4.4kb after
Aval digest in Fig 4.14a. This anomaly cannot be fully explained so these clones were
discarded. Clone #7 was taken forward and designated pACTAC:;fimE (Fig 4.14b).
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Fig 4.14a
Ml 2 3456 78 pACTAC M
3.7kb
1.2kb
Aval digest of eight putative fimE clones. The fimE gene introduces a novel Aval site
and correct clones will produce two bands at 1.7kb and 1.2kb. Clones #5-#7 produce






Vector diagram of pACTAC: xflmE showing the PtacwfimE transcriptional fusion created
on a pACYC184 based backbone.
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Fig 4.14c
M 1 2 3 4 5 6 7 8 -ve MQ M
950bp
Diagnostic PCR on eight putative fimE clones. Clones #3-#8 all produce PCR products at
the expected size. The-ve control is pACTAC. M=lkn ladder.
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4.15- Chapter 4 discussion
The first aim once the FRIVET backbone had been constructed was to clone EHEC
promoters of choice upstream of fimB to create FRIVET constructs ready for allelic
exchange into ZAP542. The cloned fimB gene from MG1655 used a 5' primer
containing a novel Xba\ site upstream of the fimB translational start site. This Xbal site
was used to clone promoters of choice, thereby creating transcriptional fusions between
the cloned promoter and fimB. The promoters cloned into the FRIVET backbone vectors
were:
• lee5 - LEE5 (tir, cesT, eae) operon control in EHEC
• fliC - Flagella regulation
• Ipfl - controls EHEC long polar fimbriae production
• loc8 - controls EHEC Loc8 fimbrial production
The lee5 promoter was cloned into both the pRQ13 and the pRQ24 background and
putative clones were analysed by restriction digest and diagnostic PCR. The fliC
promoter was cloned into the pRQ13 background and the Ipfl and loc8 promoters were
cloned into the pRQ24 background. Putative clones were again analysed by a mix of
restriction digests and diagnostic PCR. Multiple attempts were made to clone the fliC
promoter into pRQ24 and the Ipfl and loc8 promoters into pRQ13 but these attempts
failed repeatedly. It was decided that as a FRIVET vector now existed for each promoter,
no more effort would be put into creating the full set of FRIVET vectors from the pRQ13
and pRQ24 lineages.
The control of the FRIVET system is of utmost importance to establish a repeating,
dependable in vivo assay. The initial inocula for each experiment must have the fimS set
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to 'off and FRIVET constructs must be locked in their orientations after their recovery
so that they can be analysed for 'off to 'on' switching that took place solely in the assay.
It has been established that the pap operon regulator: PapB, also acts to inhibit FimB
mediated switching of the fun switch (Holden et al, 2001; Xia et al, 2000).
By using PapB at the correct moments in the assay and during the inoculum preparation it
should be possible to 'lock' the switch in the orientation at that time. By placing the
papB gene downstream of an inducible promoter, high concentrations of PapB can be
produced, theoretically locking the switch orientation, at will. A series of IPTG inducible
promoters (/adJV5 and Ptac) was used to create transcriptional fusions with papB. The
fusions were constructed on the temperature sensitive allelic exchange vector pIB307 and
as with the FRIVET operon, the promoterv.papB construct was placed in single copy on
the chromosome of ZAP193 with one difference: the papB constructs were placed at the
lac locus.
Initially, prior to the deletion of the fim locus, the lac region was deleted from ZAP193
using the vector pAJR26::sackan, thereby leaving the sackan cassette at the lac locus for
subsequent exchanges. This strain was then transformed with the lac\JW5::papB (pRQ8)
and the Ptacv.papB constructs (pRQ20) to create strains ZAP541 and ZAP544
respectively. Strains whose antibiotic resistance profiles and sucrose sensitivity assays
were correct were subject to diagnostic PCR to confirm the phenotypic results. The fim
operon was subsequently deleted from these strains to create ZAP542 and ZAP545.
The construction pathway of the two A fim strains can be seen in Fig 4.15.
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Fig 4.15





Construction map of the two Sfim strains: ZAP542 and ZAP545. Each strain has a
different IPTG inducible promoter at lac controlling papB. ZAP542 contains the /acUV5
promoter and ZAP545 contains the Ptac promoter. Both strains contain the sackan cassette
atJim for subsequent allelic exchange of FRIVET vectors
Prior to exchange at the fim locus with FRIVET plasmids, the fim region was deleted
from strains ZAP541 and ZAP544 using the plasmid pRQ40 (see chapter 3).
The IPTG inducible vector pACTAC and the fimE gene from MG1655 were used to
create the pACTACwfimE vector. FimE acts to mediate fim switching from the 'on' to
the 'off orientation and will be used in inhibitory assays with FRIVET strains.
In total five FRIVET vectors were produced with EHEC promoters and two strains were
prepared for FRIVET vector exchange, each strain carrying the papB gene under
transcriptional control of different IPTG inducible promoters.
However it must be remembered that the exact mechanism for PapB inhibition of the Fim
system is not yet known. Without a complete understanding of the mechanism and a
working knowledge of the levels of PapB required it will be difficult to gain complete
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control over wt E. coli 0157:H7 promoters unless prior levels of fimB transcription are
known using RT-PCR or Northern analysis.
Ideally we would have been able to test the level of PapB produced from the two
promoters used in the study prior to single copy exchange at the lac locus and compare
the levels required for inhibition of a native fim system using WT fimB promoters to that




Testing of the FRIVET system
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5.1 - Introduction
The construction of the FRIVET system on a temperature sensitive allelic exchange
vector with a promoterless copy offimB allows the cloning of chosen promoters into this
plasmid background. The newly created vector can then be exchanged in single copy
into an E coli 0157:H7 stx- background. The FRIVET strain can then be tested in vitro
before being used in vivo.
The aim of the FRIVET system is to provide accurate data for the activity of E. coli
0157:H7 promoters in vivo regarding their timing and expression patterns. However due
to the complex nature of the FRIVET 'synthetic operon', testing needs to take place in
vitro beforehand. We need to understand the dynamics of the FRIVET operon and its
levels of tolerance before we deploy the system in vivo. The promoter from the arabinose
operon will be used as a FRIVET test promoter.
The arabinose operon allows E. coli strains to utilize L-arabinose as a carbon source. The
genes of the arabinose operon are distributed at three points on the chromosome. The
uptake of arabinose into the cell is controlled by araE, and at a distinct site on the
chromosome araF, araG and araH. Thus, araE is under the control of a single promoter
and araFGH under the control of a separate promoter. At the third distinct site is the
araC, araBAD complex. At this site araC acts as a positive regulator of the ara operon
and the araBAD genes under the control of the Pbad promoter act on intracellular
arabinose, converting it in a stepwise manner to D-xylulose-5-phosphate. The AraC
protein acts positively to stimulate transcription at Pbad in the presence of arabinose as
well as acting negatively to repress the promoter in the absence of arabinose (Englesberg,
E. et al, 1969). The AraC protein has also been shown to regulate its own synthesis
(Casadaban M.J., 1976) and the ara operon is known to be repressed by the addition of
glucose due to catabolic repression (Greenblatt and Schleif, 1971). In this instance the
addition of glucose lowers the intracellular level of cyclic AMP and cyclic AMP receptor
protein (CRP) which is also required for the induction of the ara operon. The araC,
araBAD complex is represented diagrammatically in Figure 5.1. In the presence of
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inducer AraC binds two control sites upstream of Pbad■ These control sites termed Ii and
I2 are half sites four bases apart. The homodimeric AraC protein occupies both half sites
and transcription occurs from Pbad ■ However in the absence of inducer only a single
subunit of AraC binds to the half site Ii, the other subunit binds to a separate half site
termed O2 at a position upstream of araC.
Genetic map of the ara operon, showing the organization of the the araBAD complex and
the O and I half sites.
As can be seen in Figure 5.1, the binding of AraC to the Ii and O2 half sites stops RNA
polymerase from binding to Pc and Vbad preventing transcription of the araBAD complex.
Guzman et al reported the use of the Vbad promoter to modulate the expression of genes
over a variety of inducer concentrations (Guzman et al 1995). The population expression
profile of a gene at subsaturating levels of inducer can have two explanations.
The percentage level of Vbad expression in each cell in the population is identical to
the percentage expression level in the population as a whole. Each cell is partially
induced.
Each cell in the population is either fully induced or uninduced. The percentage





Siegele et al subsequently reported that the expression from the Pbad promoter was 'all or
none'. Using GFP as a reporter, individual cells were studied under varying
concentrations of inducer. Cells either were fluorescent or not and the proportion of the
fluorescent cells grew larger as the concentration of inducer was raised (Siegele and Hu,
1997). The nature of this 'all or none' response to inducer was linked to the arabinose
transporter AraE. The araE gene is under the transcriptional control of AraC, which
itself is induced by the presence of arabinose. In order for araC expression to occur there
must be a small amount of AraE present to transport inducer inside the cell. If the
amount of AraE is above a threshold level, araC is expressed, resulting in the expression
of the araBAD and araE/araFGH complexes. More AraE production results in more
inducer transported into the cell to further stimulate araC transcription. If however, the
level of AraE inside the cell is below the threshold level, the amount of inducer
transported into the cell is too low to fully activate araC expression and the system
remains repressed. The result is either a fully induced cell or an uninduced cell.
Subsequently researchers have used inducible promoters linked to araE to uncouple the
AraE/AraC dynamic. The researchers found that Vbad expression level was determined
by inducer concentration at an individual cell level (Khlebnikov, et al, 2002).
As the FRIVET system is designed to assay individual cells on an 'all or none' basis in
the population due to the ampicillin selection, this mode of Pbad expression does not
affects its selection as the FRIVET test promoter. The Pbad promoter is still an ideal
choice for initial testing of the FRIVET system as it is relatively 'tight' and can be
controlled by the addition of arabinose and other sugars.
The first step will be the cloning of the ara promoter region from the vector pBAD18
upstream of fimB on the FRIVET vectors to create ara::fimB transcriptional fusions.
These FRIVET test vectors will then be exchanged into the chromosomes of ZAP 193 and
the existing FRIVET papB strains ZAP542 and ZAP544
All three resulting ara FRIVET test strains will be induced with high, medium and low
levels of arabinose in LB and M9 media at both 30°C and 37°C to test the functionality of
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the FRIVET system. These initial tests will validate the arar.fimB transcriptional fusion
construction in the FRIVET vectors as well as indicating the range of induction levels for
the FRIVET system in two media and at two temperatures using three concentrations of
arabinose.
The FRIVET strains will then be tested for papB function. The ability ofpapB to 'lock'
the fim switch will play a crucial role in the control of the FRIVET system for in vivo
assays. The testing protocol for the papB inhibition assays will use two IPTG inducible
promoters of different strengths. Strain ZAP542 contains the /acUV5 promoter fused to
papB in single copy at the lac locus and ZAP544 contains the stronger Ptac promoter
fused to papB in single copy at the lac locus. Each construct will be induced with IPTG
at a final concentration of ImM against various concentrations of arabinose.
Additionally fimE will be used to verify the ability to turn the system from 'on' to 'off
using the pACTACwfimE vector, and glucose will be used to test the FRIVET ara
promoter region responds to catabolite repression.
In order to understand more about ara promoter strength, the ara promoter region will be
cloned in front of gfp+ to create an ara::gfp+ transcriptional fusion. This will then be
used in a series of fluorescence assays designed to assess the population based
transcription level using a range of arabinose concentrations. These assays can be seen in
Figures 5.3a, 5.3b and 5.3c.
The main aims in testing the arabinose driven FRIVET system are:
To validate the construction of the FRIVET operon initially - is it functional?
To validate the ability to create fimB based transcriptional fusions
To define a protocol that is simple and quick to reproduce
To define the role of PapB in the control of fimS
To check the system can be reversed using fimE
To confirm the ara promoter responds to catabolite repression in the FRIVET operon
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Finally the FRIVET system will be tested in vivo using the sheep gut loop animal model
(5.18). In two separate experiments various FRIVET constructs were tested to identify E.
coli 0157:H7 promoter activation of the FRIVET system in an in vivo background.
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5.2 - Construction of an ara::gfp+ reporter vector in a pACYC background
The ara promoter region from pBAD18 was amplified by PCR using the primers ara5'
Xbal and ara 3' Xbal. The resulting PCR fragment was digested with Xba\ and ligated
with pACYC::gfp+ upstream of the gfp+ gene to create an ara::gfp+ transcriptional
fusion.
Ten putative clones were analysed by Rsal restriction digest (Fig 5.2b). The
pACYC::,g/p+ plasmid contains 2 Rsal sites and was used as a comparison to detect
clones containing the promoter insert. The Rsal digest of the control pACYC::gfp+
plasmid results in a banding pattern of 150bp, 550bp, 1.5kb and 2.6kb. The cloning of
the 400bp ara promoter region into pACYC'.'.gfp+ would result in the 2.6kb band being
raised to 3kb. Clones #2, #3, #5-#10 all show this banding pattern indicating the
insertion of a 400bp DNA fragment between these Rsal sites
The ara promoter region also introduces a novel BamHl site in its sequence and therefore
the correct cloning into pACYC:\gfp+ would give 2 bands when digested with BamHl, as
pACYC::gfp+ already contains one site. Additionally as the BamHl site in the ara
promoter is near to the 3' end a BamHl digest will confirm the orientation of the ara
promoter with respect to gfp+. The BamHl banding pattern for the ara::gfp+ fusion
construct in the correct orientation will be 4.2kb, 600bp and 500bp, whereas the banding
pattern for the incorrect orientation will be 4.2kb, 880bp and 250bp. Clones #4- #10
were digested with BamHl and clones #5 and #7-#10 exhibited the correct BamHl
banding pattern for the ara::gfp+ fusion construct in the correct orientation (Fig 5.2c).





Vector map of pRQ30 showing the ara promoter cloned upstream of the gfp+ gene to create
an ara::gfp+ transcriptional fusion.
Fig 5.2b
M123456789 10 ctrl M
3kb
2.6kb
Rsal digest on ten putative pRQ30 clones. The ctrl is pACYC::g/^+. Clones #2, #3 and #5-
10 exhibit the correct banding pattern for an insertion of 400bp DNA upstream of the gfp+
gene. M = lkb ladder.
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Fig 5.2c
M 456 7 8 9 10 M
SrtwiHI digest on seven clones to determine the orientation of the cloned ara promoter.
Clones #5 and #7-10 all exhibit the correct banding pattern for an ara::gfp+ transcriptional
fusion. M = lkb ladder.
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5.3 - Testing pRQ30 arabinose induction using a fluorimeter
The E coli strain AAEC189 was transformed with pRQ30 and subject to a fluostar assy
using a fluorimeter. Three concentrations of arabinose were used to induce pRQ30 at
37°C. The results can be seen in Figures 5.3a, 5.3b and 5.3c.
Fig 5.3a
OD (600nm)
E. coli strain AAEC189 was transformed with pRQ30. 5ml overnight cultures were
prepared in M9-C media. Four flasks of M9-C medium were inoculated with the
overnight cultures to an optical density of 0.05. Arabinose was added to three of the
flasks designated HI, H2 and H3 to a final concentration of 0.02% w/v whilst the fourth
flask remained arabinose free (-). At time points throughout the assay 20pl samples were
measured for their fluorescence levels using a Fluorimeter. These results were plotted
against optical density. All three arabinose flasks produced high levels of fluorescence
by mid exponential phase, the negative control flask produced low levels of fluorescence
for the duration of the assay.
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Fig 5.3b
E. coli strain AAEC189 was transformed with pRQ30. 5ml overnight cultures were
prepared in M9-C media. Four flasks of M9-C medium were inoculated with the
overnight cultures to an optical density of 0.05. Arabinose was added to three of the
flasks designated Ml, M2 and M3 to a final concentration of 0.002% w/v whilst the
fourth flask remained arabinose free (-). All three arabinose flasks reached a
fluorescence level of nearly 8000 at an OD of 0.2. Flask Ml remained at this level for
the duration of the assay whilst flasks M2 and M3 produced higher levels of fluorescence.




E. coli strain AAEC189 was transformed with pRQ30. 5ml overnight cultures were
prepared in M9-C media. Four flasks of M9-C medium were inoculated with the
overnight cultures to an optical density of 0.05. Arabinose was added to three of the
flasks designated LI, L2 and L3 to a final concentration of 0.0002% w/v whilst the fourth
flask remained arabinose free (-). All three arabinose flasks produced low levels of
fluorescence compared with higher arabinose concentrations. The negative control flask
produced low levels of fluorescence for the duration of the assay.
The results seen in Figures 5.3a, 5.3b and 5.3c show that the population is activated in an
inducer concentration dependant manner and that our respective levels of inducer for L,
M and H are sufficient to produce distinguishable fluorescence levels. We can know
begin to construct the FR1VET test strain using the ara promoter.
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5.4 - cloning the ara promoter into pRQ13
Using pBAD18 as a template the ara promoter region was amplified using primers ara 5'
Xbal and ara 3' Xbal. The resulting PCR product and pRQ13 were digested with Xbal
and ligated together.
Putative clones were analysed for ara promoter insertion by Avail restriction digest (Fig
5.4b). The ara promoter PCR product introduces an new Avail site. Therefore positive
clones will show a distinct banding pattern of 2.8kb, 2.5kb, 1.7kb, 1.2kb and 1.3kb.
Twelve putative clones were digested with Avail as seen in Figure 5.4b. Four of the
twelve produced the expected banding pattern: clones #1, #2, #9 and #10.
As the ara promoter was cloned using a single Xbal site and Xbal sites on the 5' and 3'
ara primers a PCR was performed to confirm the orientation of the promoter respective
to fimB using two sets of primers. The first PCR used primers LFR 1 and ara 5' Xbal
and represented the reverse (i.e. incorrect) ara promoter insertion. The second PCR used
primers ara 5' Xbal and fimB 3' and represented the correct orientation for the ara
promoter to create a transcriptional fusion with fimB.
Clones #1, #2. #9 and #10 produced a positive PCR product for both primer sets (data not
shown) indicating both variations of construct were present. It is likely that the parent
strain has acquired both variants of ara::fimB from two separate plasmids, resulting in a
double positive PCR.
Using the same sets of primers a further PCR was performed on clones #2, #5, #6, #7 and
#8 (Fig 5.4c). There remained a possibility that the 1.2kb and 1.3kb bands had not fully
resolved for these clones in the Avail digest. Clone #2 once again produces positive PCR
products for both primer sets as does clone #6. Clones #5, #7 and #8 however produce a
positive PCR product for primer set 2 only (5' ara primer and 3' fimB primer) indicating
the correct orientational insertion of the ara promoter region in pRQ13 to create a



















Vector map of pRQ15 showing the ara promoter region cloned upstream offimB to create
an arar.fimB transcriptional fusion.
Fig 5.4b






Avail digest on twelve putative clones carrying the ara promoter. Clones #1, #2 #9 and #10
all produce the 2.8kb, 2.5kb, 1.7kb, 1.3kb and 1.2kb banding pattern indicating the cloning
of the ara promoter into pRQ13. M = lkb ladder.
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Fig 5.4c
SET 1 SET 2
M 2 5678 - 256 78-M
Diagnostic PCR using two primer sets to determine ara promoter orientation in five
putative clones. Clones #5, #7 and #8 produce positive PCR products using primer set 2 but
do not produce PCR products using primer set 1. The control (-) is water. M = lkb ladder.
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5.5 - Cloning the ara promoter into pRQ17
Using pBAD18 as a template the ara promoter was amplified using primers ara 5' Xbal
and ara 3' Xbal. The resulting PCR product and pRQ17 were digested with Xbal and
ligated together.
Ten putative clones containing the ara promoter region were analysed by Avail
restriction digest and compared to pRQ17 (Fig 5.5b). All ten clones produced a banding
pattern of 2.8kb, 2kb, 1.7kb, 1.3kb and 1.2kb. This banding pattern is consistent with the
correct cloning of the ara promoter into pRQ17 as the ara promoter region contains a
novel Avail site.
Each of the ten clones was subject to a diagnostic PCR to determine the orientation of the
clone ara promoter region using a set of primers for forward orientation (correct) and
reverse orientation (incorrect) respectively: (1) ara 5' Xbal and fimB 3'; (2) ara 3' Xbal
and fimB 3' (Fig 5.5c). Clones B2, CI, C2, Dl, D2, El and E2 all produced a positive
PCR product for the correct ara::fimB transcriptional fusion. However clones C2, Dl,
D2 and El also produced a positive PCR result for the reverse orientation, indicating both
constructs were present in the same plasmid prep. Clone CI was taken forward and

















Vector map of pRQ18 showing the ara promoter cloned upstream of fimB to create an
ara::fimB transcriptional fusion construct.
Fig 5.5b






AvaW digest on ten putative clones. All ten clones produced the expected banding pattern
consistent with the insertion of DNA in pRQ17. M = lkb ladder.
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Fig 5.5c
M A1 A2 B1 B2 CI C2 D1 D2 El E2 pRQI7 M
SET 1
M A1 A2 B1 B2 CI C2 D1 D2 El E2 prqi? M
SET 2
Diagnostic PCR using two primer sets on ten putative clones. Clones B2, CI and E2
produce PCR products for primer set 1 but not for primer set 2 indicating the correct
cloning of the ara promoter region into pRQ17. M = lkb ladder.
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5.6 - Exchanging pRQ15 into ZAP542
Strain ZAP542 was transformed with the temperature sensitive allelic exchange vector
pRQ15 to create a FRIVET ara testing construct with lac\J\5::papB at the lac locus.
Putative strains that were kanamycin sensitive and grew well on sucrose containing
media were stored at -70°C. However for a FRIVET assay to function the fim switch
must start in the 'off orientation. As fimS on pRQ15 was originally cloned from pMM36
we would expect the fim switch in these putative strains to be in the 'on' orientation
The fim switch orientation in seven isolates was confirmed as 'on' by'PGR using primers
fimS VI 5' bla 3' and digesting the 1.6kb PCR product with Hinfl before running on an
agarose gel (Fig 5.6). Using arabinose at a concentration of 0.04% w/v an 'on' to 'off
switching assay was performed to isolate an 'off variant of strain #1. The resultant strain
was designated ZAP543 and stored at -70°C.
To ascertain the correct concentration of ampicillin needed for the FRIVET assays a
series of LB agar plates were made with varying concentrations of ampicillin. The
concentrations were 5pg/ml, lOpg/ml, 15pg/ml, 20pg/ml, 25pg/ml, 30pg/ml, 35pg/ml,
40pg/ml, and 50pg/ml. Serial dilutions of ZAP543 were spread onto these LBA plates
and growth recorded. ZAP543 grew at concentrations of 5pg/ml and lOpg/ml but failed
to grow at higher ampicillin concentrations. Further plates were made with 7.5pg/ml and
12.5pg/ml ampicillin. ZAP 543 failed to grow on the 12.5pg/ml plate. The experiment
was repeated a further two times and the same results were observed. Subsequently the
concentration of ampicillin in the FRIVET assays was set at lOpg/ml.
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Fig 5.6





Hinjl digestion of 1.6kb PCR product from seven putative pRQ15 exchange strains. All
seven strains exhibit Hinjl banding pattern for the 'on' orientation. Briefly, the 7
strains were subject to PCR using primers FRIVET bla diag and FRIVET JintS diag.
The resulting 1.1 kb PCR product was purified and subject to restriction digest with
Hinjl. DNA bands at 672bp/182bp indicate JintS in the 'on' orientation. Bands at
389bp/466bp indicateJintS in the 'off orientation.
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5.7 - Exchanging pRQ15 into ZAP544
ZAP544 was transformed with the temperature sensitive allelic exchange vector pRQ40
and subjected to allelic exchange. Putative strains confirmed as receiving the sac/kan
cassette (phenotype Afim sac/kan) were termed ZAP545 and transformed with pRQ15.
After allelic exchange two strains that exhibited kanamycin and chloramphenicol
sensitivity and good growth on sucrose containing media were subjected to diagnostic
PCR using the LFR up 5' primer and the ara 3' primer (Fig 5.7).
Strain #1 produced a PCR product of the expected size (1.5kb) and was subjected to an
'on' to 'off switching assay: The strain was grown in LB media in the presence of
arabinose to an OD of 0.9. The culture was then diluted onto LB agar and incubated
overnight. Colonies were subsequently patched onto LB and LBA plates to isolate the
'off variants. These 'off variants were designated ZAP 546 and stored at -70°C.
The inhibitory concentration of ampicillin was found to be lOpg/ml and this
concentration was used in subsequent FRIVET assays with ZAP546.
Fig 5.7
M 1 2 -ve M
Diagnostic PCR on two putative ZAP546 strains using primers specific for an upstream
region of LFR and the 3,ara primer. Strain #1 produces a PCR product of the expected
1.5kb size. The -ve control is ZAP545. M = lkb ladder.
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5.8 - Exchanging pRQ15 into ZAP193
ZAP193 was initially transformed with pRQ40 and subjected to allelic exchange to create
the Afim sackan strain: ZAP547. Putative strains were analysed by their antibiotic
resistance profile and growth on sucrose containing media. Strains that fit the phenotypic
profile were transformed with pRQ15. Again putative strains were analysed by their
antibiotic resistance patterns and sucrose growth. Strains that exhibited the correct
phenotypic profile were designated ZAP548.
The inhibitory concentration of ampicillin was found to be 1 Opg/ml and this
concentration was used in subsequent FRIVET assays with ZAP548.
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5.9 - Induction of ZAP548 with varying concentrations of arabinose at 37°C in M9
media
The FRIVET test strain ZAP548 was subject to FRIVET assays using three levels of




Four flasks of M9 medium were inoculated with overnight cultures of ZAP548 to an
optical density of 0.05. Arabinose was added to three flasks designated HI, H2 and H3
to a final concentration of 0.02% w/v. The fourth flask remained arabinose free (-). The
% ampicillin resistance exhibited in each culture was plotted against optical density.
lOOpl aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot determined by direct plating. All three flasks
exhibited similar levels of FRIVET induction during the assay. The negative control








Four flasks of M9 medium were inoculated with overnight cultures of ZAP548 to an
optical density of 0.05. Arabinose was added to three flasks designated Ml, M2 and M3
to a final concentration of 0.002% w/v. The fourth flask remained arabinose free (-).
1 OOjul aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot determined by direct plating. All three flasks
exhibited similar levels of FRIVET induction during the assay. The negative control
flask (-) did not exhibit any resistance to ampicillin in the absence of arabinose inducer.
154
Fig 5.9c
Four flasks of M9 medium were inoculated with overnight cultures of ZAP548 to an
optical density of 0.05. Arabinose was added to three flasks designated LI, L2 and L3 to
a final concentration of 0.0002% w/v. The fourth flask remained arabinose free (-).
lOOpl aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot determined by direct plating. All three flasks
exhibited very low levels of FRIVET induction with a maximum ampicillin resistance
level of 2% reached by flask L3 at an OD of 0.63. The negative control flask (-) did not
exhibit any resistance to ampicillin in the absence of arabinose inducer.
The results for these three FRIVET assays for ZAP548 show that the FRIVET operon
functions as a synthetic unit when under the control of the ara promoter and furthermore
seems to be subject to similar population dynamics seen with the pRQ30 testing of the
ara promoter by responding to a varying concentration of arabinose inducer..
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5.10 - Induction of ZAP543 with varying levels of arabinose concentration in LB
broth at 37°C.
ZAP543 (lac\J\5::papB @ lac) was induced with three concentrations of arabinose in
LB broth in a FRIVET assay. The results can be seen in Figure 5.10.
Fig 5.10
Four LB broths were inoculated with ZAP543 and induced with concentrations of
arabinose of 0.0004% w/v, 0.004% w/v, 0.04% w/v and no arabinose (-) at 37°C.
Samples were taken at regular intervals and analysed for proportion of recovered colonies
that were resistant to ampicillin. The % ampicillin resistance exhibited in each culture
was plotted against optical density. It is evident that as higher concentrations of
arabinose were used the proportion of ampicillin resistant bacteria detectable increased.
The control flask (-) population did not exhibit any resistance to ampicillin in the absence
of arabinose inducer.
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5.11 - Induction of ZAP546 with varying concentrations of arabinose at 37°C and
30°C.
ZAP546 (VVdcwpapB @ lac) was subject to a FRIVET assay using varying arabinose
concentrations in LB broth at 37°C (Fig. 5.1 la) and 30°C (Fig. 5.1 lb).
Fig 5.11a
Four LB broths were inoculated with overnight cultures of ZAP546 to an optical density
of 0.05. Arabinose was added to a final concentration of 0.02% w/v, 0.002% w/v and
0.0002% w/v to three of the flasks. 100pl aliquots of culture were removed from all
flasks at multiple time points and the % of ampicillin resistant bacteria determined by
direct plating. The % ampicillin resistance exhibited by each culture was relative to the
concentration of arabinose added. The negative control flask (-) population did not
exhibit any resistance to ampicillin in the absence of inducer.
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Fig 5.11b
Four LB broths were inoculated with an overnight culture of ZAP546 to an optical
density of 0.05. Arabinose was added to a final concentration of 0.02% w/v, 0.002% w/v
and 0.0002% w/v in the three flasks. The fourth flask had no arabinose added. lOOpl
aliquots of each culture were removed at multiple time points and the % of ampicillin
resistant bacteria in each aliquot was determined by direct plating. The % ampicillin
resistance from each flask remained at 0% until mid exponential phase when the 0.02%
w/v and 0.002% w/v flasks showed increased ampicillin resistance. The 0.0002% w/v
flask remained 'off for the duration of the experiment. The negative control flask (-)
population did not exhibit any resistance to ampicillin in the absence of arabinose inducer.
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5.12 - Induction of ZAP546 with varying concentrations of arabinose at 37°C in M9
media
ZAP546 (PtacwpapB @ lac) was subject to three FRIVET assays using varying
concentrations of arabinose inducer. The results can be seen in Figures 5.12a, 5.12b and
5.12c.
Fig 5.12a
Three flasks of M9 medium were inoculated with overnight cultures of ZAP546 to an
optical density of 0.05. Arabinose was added to a final concentration of 0.02% w/v to
two flasks. The third had no arabinose added (-). lOOpl aliquots of each culture were
removed at multiple time points and the % of ampicillin resistant bacteria in each aliquot
was determined by direct plating. The % ampicillin resistance increased to 73% and 84%
for both flasks by early exponential phase and rose to 100% for both flasks by mid
exponential phase until stationary phase. The negative control flask (-) population did




Three flasks of M9 medium were inoculated with overnight cultures of ZAP546 to an
optical density of 0.05. Arabinose was added to a final concentration of 0.002% w/v to
two flasks. The third had no arabinose added. 100pl aliquots of each culture were
removed at multiple time points and the % of ampicillin resistant bacteria in each aliquot
was determined by direct plating. The % ampicillin resistance increased to 60% and 70%
for both flasks by early exponential phase and rose to 72% and 84% respectively by mid
exponential phase. The negative control flask (-) population did not exhibit any




Three flasks of M9 medium were inoculated with overnight cultures of ZAP546 to an
optical density of 0.05. Arabinose was added to a final concentration of 0.0002% w/v to
two flasks. The third had no arabinose added. lOOpl aliquots of each culture were
removed at multiple time points and the % of ampicillin resistant bacteria in each aliquot
was determined by direct plating. The % ampicillin resistance increased to -22% for
both flasks by early exponential phase and remained at that level until stationary phase.
The negative control flask (-) population did not exhibit any resistance to ampicillin in
the absence of arabinose inducer.
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5.13 - Using PapB to suppress FRIVET induction in ZAP543 at 37°C in LB broth
ZAP543 (/acUV5\:papB @ lac) was subject to an FRIVET inhibition assay to measure
the effect of PapB on the FRIVET system. IPTG was added to direct the production of
PapB from the lacUW5::papB fusion @ the lac locus. The results of this assay can be
seen in Figure 5.13.
Fig 5.13
Two LB broths were inoculated from a ZAP543 overnight culture to an optical density of
0.05. Arabinose was added to both flasks to a final concentration of 0.04% w/v. In
addition ImM IPTG (final concentration) was added to one of the flasks to induce the
lac\JV5::papB transcriptional fusion at the lac locus on ZAP543. The IPTG/arabinose
culture demonstrated 'locking' of the FRIVET system until mid exponential phase when
inversion of the fim switch was detected. The control flask exhibited a steady increase in
levels of arabinose mediated FRIVET expression.
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5.14 - Suppression of FRIVET induction in ZAP546 at 37°C
ZAP546 (Ptacv.papB @ lac) was subject to an FRIVET inhibition assay to measure the
effect of PapB on the FRIVET system. IPTG was added to direct the production of PapB
from the Ptacv.papB fusion @ the lac locus. Figure 5.14a shows the assay as performed





Four LB broths were inoculated with overnight cultures of ZAP546 to an optical density
of 0.2. Arabinose was added to a final concentration of 0.04% w/v, 0.04% w/v and
0.0004% w/v to three flasks. The fourth had no inducer added (-). IPTG was added to a
flask with 0.04% w/v arabinose to a final concentration of ImM IPTG. 100pl aliquots of
each culture were removed at multiple time points and the % of ampicillin resistant
bacteria in each aliquot was determined by direct plating. The two positive control flasks
with 0.04% w/v and 0.0004% w/v arabinose exhibited increase in ampicillin resistance
relative to the concentration of arabinose. The flask containing 0.04% arabinose and
IPTG showed decreased FRIVET induction compared to control until stationary phase at
which point cultures from both the arabinose/IPTG flask and the 0.04% arabinose control
flasks exhibited similar levels of ampicillin resistance. The negative control flask (-)




Three flasks of M9 media were inoculated with overnight cultures of ZAP546 to an
optical density of 0.05. Arabinose was added to a final concentration of 0.002% w/v to
two flasks. The third had no arabinose added (-). IPTG was added to one of the 0.002%
w/v arabinose flasks to a final concentration of ImM. . 100pl aliquots of each culture
were removed at multiple time points and the % of ampicillin resistant bacteria in each
aliquot was determined by direct plating. The IPTG/arabinose flask exhibited 30%
ampicillin resistance at an optical density of 0.2 against 47% for the positive control.
However, by mid exponential phase the IPTG/arabinose flask showed a higher ampicillin
resistance % than the control although both flasks exhibited similar levels of ampicillin
resistance by stationary phase. The negative control flask (-) population did not exhibit
any resistance to ampicillin in the absence of arabinose inducer.
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5.15 - Transformation of ZAP546 with pHMG88 to suppress FRIVET induction
The results seen in 5.13 and 5.14 show that the level of PapB in these assays failed to
suppress the activity of the FRIVET system. The next logical step was to increase the
level of PapB in the cell and to observe if the concentration of PapB was the defining
factor in the PapB/Fim switch interaction. This was achieved by the transformation of
ZAP546 with pHMG88, a medium copy plasmid containing the IPTG inducible
lac\J\5::papB transcriptional fusion. By adding IPTG, PapB would be produced both
from the chromosomal Ptacv.papB fusion on ZAP546 and from pHMG88 resulting in
high concentrations of PapB in the cell. The assay was performed with three
concentrations of arabinose inducer in M9 media at 37°C. The results can be seen in

























Three flasks of M9-T medium were inoculated with overnight cultures of
ZAP546::pHMG88 to an optical density of 0.05. Arabinose was added to a final
concentration of 0.0002% w/v to two flasks. The third had no arabinose added (-). IPTG
was added to one of the 0.0002% w/v arabinose flasks to a final concentration of ImM.
lOOpl aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot was determined by direct plating. The
positive control 0.0002% w/v flask reached an ampicilin resistance of 8% at an OD of 0.5
rising to 12% at an OD of 1.05. The IPTG/arabinose culture demonstrated 'locking' of
the FRIVET system and remained 'off for the duration of the assay. The negative




Three flasks of M9-T medium were inoculated with overnight cultures of
ZAP546::pHMG88 to an optical density of 0.05. Arabinose was added to a final
concentration of 0.002% w/v to two flasks. The third had no arabinose added (-). IPTG
was added to one of the 0.002% w/v arabinose flasks to a final concentration of ImM.
lOOpt aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot was determined by direct plating. The
positive control 0.002% w/v flask reached an ampicilin resistance of 52% at an OD of 0.2
rising to 66% at an OD of 0.48 and 68% at an OD of 1.1. The IPTG/arabinose flask
exhibited significantly decreased FRIVET induction and reached a maximum ampicillin
resistance percentage of 1.3% during the assay. The negative control flask (-) population
did not exhibit any resistance to ampicillin in the absence of arabinose inducer.
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Fig 5.15c
Three flasks of M9-T medium were inoculated with overnight cultures of
ZAP546::pHMG88 to an optical density of 0.05. Arabinose was added to a final
concentration of 0.02% w/v to two flasks. The third had no arabinose added (-). IPTG
was added to one of the 0.02% w/v arabinose flasks to a final concentration of ImM.
lOOpl aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot was determined by direct plating. The
positive control 0.02% w/v flask reached maximum ampicilin resistance of 98% at an OD
of 1.1. The IPTG/arabinose flask exhibited significantly decreased FRIVET induction
and only reached a maximum ampicillin resistance percentage of 3.1% during the assay.
The negative control flask (-) population did not exhibit any resistance to ampicillin in
the absence of arabinose inducer.
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The results in Figures 5.17a, 5.17b and 5.17c clearly show the inhibition of FRIVET
induction with the addition of pHMG88. To test whether the prescence of the plasmid
itself was making a difference ZAP546 was transformed with pACYC184 and the assay
from Figure 5.17a repeated (data not shown). No inhibition of FRIVET induction was
observed. We can conclude that PapB appears to function to inhibit the FRIVET operon
at a threshold level, and that this level is not reached with the use of the lac\J\5 and Ptac
promoters in single copy.
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5.16- Inhibition of the FRIVET system using pACTAC::fimE at 37°C in M9-C
media
ZAP546 (Viacv.papB @ lac) was transformed with pACTAC:;//w£ to observe the effects
of FimE on the FRIVET system. It was expected that the FRIVET system may need
another level of control not using PapB. This pACYC184 based vector contains a
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Three flasks of M9-C medium were inoculated with overnight cultures of
ZAP546::pACTAC::y?w£' to an optical density of 0.05. The remaining flask was
inoculated with an overnight culture of ZAP546::pACTAC to an optical density of 0.05.
Arabinose was added to a final concentration of 0.02% w/v to three flasks. The fourth
was designated the negative control and remained free of arabinose (-). IPTG was added
to two of the 0.02% w/v arabinose flasks to a final concentration of lmMlOOpl aliquots
of each culture were removed at multiple time points and the % of ampicillin resistant
bacteria in each aliquot was determined by direct plating. The positive control 0.02%
w/v flask only reached a maximum ampicilin resistance of 29% at an OD of 0.8, however
the pACTAC control flask reached a 100% ampicillin resistance level at a similar OD.
The pACTACv.fimE flask exhibited decreased FRIVET induction compared to the
pACTAC control flask reaching a maximum ampicillin resistance percentage of 24%
during the assay. The negative control flask (-) population did not exhibit any resistance
to ampicillin in the absence of arabinose inducer.
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5.17 - Repression of the FRIVET system with supplemental glucose
ZAP546 (PtacwpapB @ lac) was grown in the presence and absence of glucose to
observe the effects of glucose repression on the ara based FRIVET test system. The
results can be seen in Figure 5.17.
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Fig 5.17
Three flasks of M9 medium were inoculated with overnight cultures of ZAP546 to an
optical density of 0.05. Arabinose was added to a final concentration of 0.02% w/v to
two flasks. The third was designated a negative control and remained arabinose free (-).
Glucose was added to one of the arabinose flasks to a final concentration of 0.2% v/v.
100pl aliquots of each culture were removed at multiple time points and the % of
ampicillin resistant bacteria in each aliquot was determined by direct plating. The
positive control 0.02% w/v flask reached an ampicilin resistance level of 94% at an OD
of 1.1. The arabinose/glucose flask exhibited significantly decreased FRIVET induction
levels compared to the arabinose only flask reaching a maximum ampicillin resistance
percentage of 1.4% during the assay. The negative control flask (-) population did not
exhibit any resistance to ampicillin in the absence of arabinose inducer.
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5.18 - Using LEE5 FRIVET constructs in a sheep gut loop animal model of infection
ZAP545 was transformed with the FRIVET plasmids pRQ103, 104 and 105 to create the
strains VLAFRIVET::LEE5, VLAFRIVET:://?/7 and VLAFRIVET: :loc8 respectively.
Using the method outlined in chapter 2 a ligated gut loop assays was performed on 2
sheep at the VLA, Weybridge, UK using the three VLAFRIVET strains.







































An overnight culture of VLAFRIVET: :LEE5 grown in LBNal was used to inoculate a
single gut loop segment in sheep #1 and sheep #2. After 6h the segment was excised and
cut open. Faecal content and the endothelial lining were processed separately and a
FRIVET ampicillin assays was performed on each sample. The results show negligible












































An overnight culture of VLAFRIVET: :lpfl grown in LBNal was used to inoculate a
single gut loop segment in sheep #1 and sheep #2. After 6h the segment was excised and
cut open. Faecal content and the endothelial lining were processed separately and a
FRIVET ampicillin assays was performed on each sample. The results as shown in Fig





































An overnight culture of VLAFRIVET:\loc8 grown in LBNal was used to inoculate a
single gut loop segment in sheep #1 and sheep #2. After 6h the segment was excised and
cut open. Faecal content and the endothelial lining were processed separately and a
FRIVET ampicillin assays was performed on each sample. The results for the two assays
show minimal FRIVET activation for the loc8 promoter in this assay.
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5.19 - Chapter 5 discussion
Having chosen the arabinose inducible promoter as the FRIVET test promoter, the first
step was to establish a working range of arabinose concentrations to be used in the
FRIVET assays. For this an ara::gfp+ fusion was constructed on a pACYC background,
subsequently termed pRQ30. The strain AAEC189 was transformed with pRQ30 and
used to inoculate a series ofM9-C flasks. Using a Fluorimeter, the fluorescence value of
each culture was measured and plotted against optical density. The results demonstrate a
good range of values using the arabinose concentrations (final) as follows:
• High (H) - 0.02% w/v
• Medium (M) - 0.002% w/v
• Low (L) - 0.0002% w/v
The negative control also demonstrated the tight regulation of the ara promoter in the
absence of arabinose inducer. These values were subsequently taken forward for use in
the FRIVET assays.
The functional testing of the FRIVET operon was extremely important in order to
validate the operon as a working unit and to define the working limits in an in vitro assay.
Testing in vitro at this stage will allow us to predict possible issues with the system and
controlling it.
Initially the ara FRIVET vectors pRQ15 and pRQ18 were constructed from pRQ13 and
pRQ17 respectively. The ara promoter region from the arabinose inducible vector
pBAD18 was amplified and cloned upstream of fimB at the novel Xbal site. Putative
clones were analysed by restriction digest and diagnostic PCR to confirm the creation of
the ara::fimB transcriptional fusion.
With the ara FRIVET vectors now constructed the next step was the allelic exchange into
three Afim backgrounds:
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• ZAP542 - Afim; lac\JW5::papB at lac
• ZAP545 - Afim; Ptacv.papB at lac
• ZAP547 - Afim
The ara FRIVET vector pRQ15 was exchanged into each background and phenotypic
testing confirmed the creation of new FRIVET strains for each background. Additionally
diagnostic PCR was carried out on ZAP546 strains to confirm the results of the
phenotypic analysis. As the orientation of the fim switch in pRQ15 is 'on' (fimS from
pMM36) arabinose was used to induce fim switching and 'off strains were reovered and
stored for subsequent in vitro testing. The resulting FRIVET test strains were:
• ZAP543 - ara::FRIVET at fim; lac\J\5::papB at lac
• ZAP546 - ara./FRIVET at fim; PtacwpapB at lac
• ZAP548 - ara.:FRIVET at fim
Each Afim strain was also transformed with pRQ18 and subjected to allelic exchange. No
strains were recovered in the first attempt and due to the success with the exchange of
pRQ15 into the Afim backgrounds it was decided to halt allelic exchange of pRQ18 into
the Afim backgrounds.
Initial arabinose testing used three concentrations of arabinose termed low (L), medium
(M) and high (H) as previously defined using the ara::gfp+ fusion. These arbitrary
concentrations equated to a final arabinose concentration of 0.0002% w/v (L), 0.002%
w/v (M) and 0.02% w/v (H). The one exception was Figure 5.10. In this assay ZAP543
was induced with levels of arabinose equating to final concentrations of 0.0004% w/v (L),
0.004% w/v (M) and 0.04% w/v (H).
ZAP548 was induced with arabinose in M9 medium alone, ZAP546 was induced in M9
medium and LB medium and ZAP543 was induced in LB medium alone. For the
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majority of assays the change in the media showed a negligible change in results, both
media produced consistent reproducible results with all three strains. However there
were some inconsistencies with using LB medium. In some assays, very low levels of
ampicillin resistance were seen, even with high levels of inducer. As LB medium can
differ from supplier to supplier and each component may differ in composition, each
batch of LB medium used in an assay may be subtlety different and could affect
arabinose induction levels, especially if other carbon sources are present in the medium.
For this reason LB was not used for subsequent FRIVET testing, even though it provides
a distinct time advantage over M9 medium for bacterial growth.
As expected ZAP548 produced ampicillin resistance levels in proportion to the level of
inducer added. Each assay was carried out in triplicate, and the results indicate
reproducible consistent results for each arabinose concentration. Also importantly in the
absence of inducer the FRIVET operon remained 'silent', that is, no induction was
observed. This suggests that without promoter led fimB activation, fimS does not invert,
and is not under the control of other unknown regulators or recombinases that may affect
fimS switching.
It is clear from these results however that whilst the FRIVET system always responded to
arabinose as an inducer, it was difficult to obtain completely reproducible results. Two
reasons for this are: FRIVET tests were performed in 2 types of media: LB and M9. The
results from the LB assays demonstrated a degree of variation in ampicillin resistance
levels over a number of individual assays. The relative benefits of using LB for the
FRIVET assays seem to be outweighed by the variation we see in arabinose induction
using different batches of LB and as mentioned previously FRIVET assays were
performed in M9 media as well. However there was still a degree of variability in the
percentage of the population that were ampicillin resistant as demonstrated in Figs 5.9a
and 5.9b. In these assays ZAP548 was induced with two concentrations of arabinose:
0.02% and 0.002% respectively. Three flasks were used in each assay and we noted
variation in the percentage of ampicillin resistance over the course of the assay for each
flask. In fig 5.9a, there was a 30% range difference in ampicllin resistance at TP2
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(OD600=~0.2), a difference that dropped to 10% by TP4 (OD600=~0.7). As the media
used was defined M9 there must be other reasons for the variability we see in the in vitro
FRIVET assays other than the presence of alternative carbon sources in the medium.
Another reason for the variability seen could be the FRIVET sampling method. The
method used to measure the percentage ampicillin resistance could have generated a
degree of variability with the counting of ampicillin resistant colonies on the LBA plates.
The presence of 'satellite' ampicillin sensitive colonies growing in close proximity to
ampicillin resistant P-lactamase producing colonies may have provided false positives.
The overall ampicillin resistance percentage in the population will therefore be artificially
high. Moreover the extent of this false positive will be different for each individual plate
and flask, furthering the chance of wide variability in the results of a FRIVET assay using
the same concentration of inducer. Great care was taken to count only fully mature
colonies (satellite colonies can exhibit a "sick" phenotype on plates). Analysis of the
fimS orientation in each individual colony would give us an accurate readout of the
ampicillin resistance levels in the population.
ZAP543 and ZAP546 were also both induced with L, M, and H levels of arabinose in LB
medium. Both strains produced very similar results for each arabinose level as seen in
Figure 5.10 and Figure 5.11a. At this stage we can be confident therefore that the Ptac
promoter is at least as 'tightly' regulated as the lacU\5 promoter. If the Ptac promoter
was driving low level constitutive expression ofpapB we would expect to see a decrease
in FRIVET induction for ZAP546 relative to ZAP543. There was a concern that the Ptac
promoter might be 'leaky' as other studies in the laboratory had indicated such a finding
(Dai Wang, personal communication).
To see the effects of low temperature on the FRIVET system, ZAP546 was induced at
30°C using the three levels of inducer. Overall induction levels were much delayed, each
flask not responding to inducer levels until an OD-0.5 as opposed to 0.1 for 37°C (Figure
5.11b). This result indicates a lower level of induction from the ara promoter at lower
temperatures.
182
The induction of ZAP546 in M9 medium produced a different set of results to ZAP548 in
the same medium at the same arabinose inducer levels. Overall, the level of induction
was higher in the ZAP546 flasks than in the ZAP548 flasks. The assays were repeated
again to verify these results and the same difference was observed (data not shown). The
main difference between ZAP546 and ZAP548 is the Ptacv.papB construct at lac in
ZAP546. We would not expect the difference between the two strains to be as a result of
PapB being produced from a 'leaky' Ptac promoter in M9 medium. If PapB was being
produced we would expect a slightly lower induction level in ZAP546 than in ZAP548
which is not the case. It is likely that the differences are strain dependent; however it was
decided to continue with arabinose testing and IPTG inhibition assays.
ZAP543 was induced with 0.04% w/v arabinose and ImM IPTG to ascertain the
inhibitory effects of PapB when induced from the /<7cUV5 promoter. Looking at Figure
5.13 we see that PapB appears to have a strong inhibitory action on FimB mediated
switching until mid exponential phase (OD~ 0.5). At this point induction inhibition
appears to be lifted and the rate of induction becomes faster than the un-inhibited control
flask. This result suggests that the levels of PapB were initially high enough to inhibit
the actions of FimB. However as the assay continued FimB levels were high enough to
overcome PapB inhibition and switching started. This result suggests that PapB can work
to inhibit the FRIVET operon from switching if it can occupy the preferential binding site
prior to FimB levels becoming high, and if PapB levels can remain at a high level.
When ZAP546 was tested in a similar IPTG inhibition assay to ZAP543, the result was
similar, if not to the same level. Induction levels were lower at mid and late exponential
phase for the IPTG flask against the positive control, and ampicillin resistance levels
eventually reached the same point at an OD~l .5. This result is not as expected. The Ptac
promoter driving papB expression in ZAP546 should provide a higher level of free PapB
than the /<2cUV5 promoter in ZAP543. Accordingly, there should be more evidence of
FRIVET inhibition for ZAP546. A possible explanation was the LB broth used having a
subtlety different composition for each assay. The same assay was repeated for ZAP546
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in M9 medium (Figure 5.14b). The result shows no inhibitory effect by PapB after early
exponential phase.
Given the dynamics of the ara promoter in populations, it was hypothesised that the
levels of FimB in each cell induced by arabinose was too high for the levels of PapB in
that cell expressed from the Ptac promoter. It was decided to transform ZAP546 with
pFIMG88, a pACYC based plasmid carrying the lacU\5::papB fusion. This plasmid had
been successful in UPEC type 1 fimbriae inhibition assays in the laboratory (N. Holden,
personal communication) and was initially used to study pap operon regulation (Forsman
etal, 1989).
The transformed ZAP546 strain was grown in the presence of arabinose at the three
predefined concentrations and IPTG was added to a final concentration of ImM. The
results in Figures 5.15a, 5.15b and 5.15c clearly show the 'locking' of the FRIVET
system in the 'off orientation when measured against a positive control. This set of
results seems to confirm our hypothesis based on a 'threshold' level for PapB in an ara
based FRIVET system. By inducing pHMG88, the combined levels of PapB from the
plasmid and the single copy Ptac::joapB fusion at lac were enough to competitively
inhibit FimB mediated switching. However, if PapB levels dropped below the threshold,
FimB mediated switching can occur, as seen in Figures 5.13 and 5.14b.
Whilst this observation is important with regards to initial ara testing of the FRIVET
system, we do not expect the same issues with EHEC promoters. The population based
nature of the ara promoter in each cell results in an articially high concentration of PapB
needed to inhibit FRIVET induction. Further testing using FRIVET test strains
containing EHEC promoters will be carried out to ascertain the levels of promoter
induction.
The FRIVET system was also tested for its response to FimE and glucose. The fimE
gene from MG1655 was cloned into the IPTG inducible vector pACTAC downstream of
the Ptac promoter. In a FRIVET assay using ZAP546, the results indicate that FimE acts
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to inhibit fimS switching when compared to a positive control transformed with the
pACTAC vector only (Figure 5.16). Similarly, the addition of glucose to the FRIVET
assay to a final concentration of 0.2% w/v significantly inhibits FRIVET induction when
compared to a positive control (Figure 5.17).
Figures 5.18a, 5.18b and 5.18c show the results of a sheep ligated gut loop experiment
carried out on two sheep with three FRIVET strains using the LEE5, Ipfl and loc8
promoters. As we see there is little to no FRIVET activation seen in these assays. The
PBS serial dilutions for each assay were carried to the 10"5 plate and the 10"3, 10"4 and
10"5 dilutions were plated onto LBNalAmp and LBNal plates. The results shown are for
the 10~4 dilution plate. However the 10"3 and 10~5 plates were also counted and the
results were similar to those shown in Figures 5.18a, b and c with little or no activation
seen for the FRIVET system (data not shown).
There are a number of reasons as to the relative failure of these assays to validate the
FRIVET system as a novel in vivo technology. The first is that the animal model and
method chosen was not ideal for the purpose of elucidating the role of these E. coli
0157:H7 promoters in its natural bovine host. Previous studies has shown the site of
colonisation of E. coli 0157:H7 to be the terminal recto anal junction (Naylor et al, 2005).
The tissue types at this site differ markedly from those in the ascending spiral colon used
for the ligated gut loops. A study using E. coli 0157:H7 in the same animal model
showed sparse and small A/E lesions as determined by microscopy. No change in this
result was found with increasing bacterial cell density or pre-inoculation growth
conditions (Wales et al, 2002).
Additionally the VLAFRIVET strains were tested in vitro at the same time using a
variety of media in an attempt to prove the E. coli 0157:H7 promoters driving the
FRIVET operon in these strains was functionally operating and responding to
environmental signals. None of the VLAFRIVET strains exhibited any FRIVET
activation in these assays. Fluoremeter assays using a LEE5::g^?+ fusion on a pACYC
backbone showed enhanced fluorescence when transferred from an LB overnight culture
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to an MEM media (data not shown). However, VLAFRIVET::LEE5 failed to respond to
the same media change to any significant degree.
Without fully understanding the nature of the FRIVET operon when driven by a wild
type E. coli 0157:H7 promoter the FRIVET system will be unable to answer many of the
questions about the biology of E. coli 0157:H7 in an in vivo environment. Combining
the issues seen with FRIVET strains based on E. coli 0157:H7 promoters and the
FRIVET operon and a lack of reproducibility in the results seen in the ara in vitro assays
we can conclude that much more work is needed to establish a solid FRIVET operon that
functions in vitro and a choice of E. coli 0157:H7 promoters that allow us to fully test a





The aims of this thesis were fourfold:
1) To construct a working FRIVET operon containing the invertible fim
element that is able to direct transcription of the downstream bla gene
and respond to FimB.
2) To test the limits of the FRIVET operon using a suitable test promoter
and appropriate control points and to define a reproducible
experimentally robust screening method
3) To construct E coli 0157:H7 promoter based FRIVET constructs for
use in in vitro and in vivo assays to enable us to understand E coli
0157:H7 promoter activity in an animal model
4) To use constructed FRIVET strains in an in vivo experiment. The
animal model and strain to be used will be decided closer to the time.
Current animal models such as the sheep gut loop (ligated chambers in
the ascending spiral colon) may be deployed.
Although there were numerous technical difficulties in creating the synthetic FRIVET
operon, the first two aims were completed successfully. The FRIVET operon was tested
using the arabinose inducible promoter: ara. With hindsight, the population induction
patterns of the ara promoter was not ideal for measuring promoter activation levels at a
cellular level and for defining the appropriate levels of any control gene needed (in this
case papB). However, the ara promoter was chosen in lieu of an IPTG inducible
promoter.
Ideally I would have used Ptac or /acUV5 as a FRIVET test promoter. However,
knowing that a papB based control fusion would be needed at lac, and that control fusion
would need to be quiescent in the in vivo assays, it was decided to use an IPTG inducible
promoter for this role, disallowing it as a FRIVET test promoter.
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PapB failed to 'lock' to inversion offimS as a single copy fusion construct with the pTac
promoter but increasing the levels of PapB by adding pHMG88, a pACYC based vector
containing a lac\JW5::papB fusion, exhibited the locking of the fim switch, validating our
hypothesis that PapB acts as a competitive inhibitor of FimB mediated switching at a
certain threshold level. Evidently the level produced by the single copy fY&cwpapB
fusion at lac in the FRIVET strain was sub-threshold. Introducing more PapB into the
system pushed the PapB levels over this threshold, resulting in the 'locking' of the fim
element. EHEC promoters that provided a lower threshold for PapB inhibition may have
been controllable from a single copy papB construct however I was unable to test this
hypothesis as no functional in vivo FRIVET strains were constructed.
The ability to control the FRIVET system, specifically the orientation of the fim switch,
after collection from the in vivo system is vital for reproducible results and an accurate
record of promoter activation in the animal model. To this end for the FRIVET system to
work, PapB must be able to function against a particular E coli 0157:H7 promoter. The
inability to produce a single copy papB control system for the FRIVET system was a
major problem and further work will need to be carried out in order to provide a means of
controlling FRIVET induction.
The failure to create functional and stable single copy fusions using E coli 0157:H7
promoters was largely due to technical difficulties and time constraints. In the future
alternative allelic exchange methods could be attempted to create single copy E coli
0157:H7 FRIVET strains.
Once this technical hurdle has been overcome however, the FRIVET system is well
placed to produce original and exciting data concerning E. coli 0157:H7 virulence gene
activity in an in vivo environment. The first step towards the success of the FRIVET
system is to understand the working parameters of the E. coli 0157:H7 FRIVET strains,
such as those used in the VLA sheep assays. Results from these assays make it clear that
more initial work is needed on the strains to fully understand their range of dynamics in
vitro, before in vivo work can commence. The initial experiments using this strain would
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focus on testing the functional limits of this promoter in response to known
environmental conditions in vitro such as MEM medium and aerobic/anaerobic
conditions. Once a degree of control is achieved with this strain then the functionality of
PapB can be assessed. It is my expectation that PapB should function to inhibit FimB
mediated switching in the LEE5::FRIVETstrain, and that papB can be placed under
control of an IPTG or arabinose inducible promoter for this to occur.
Research in our laboratory confirms that LEE5 is upregulated on cell contact with Hela
cells, and as such the LEE5::FRIVET strain would be tested using a similar experimental
design and setup. Temporal control of multiple promoters can be tested at this juncture
using multiplt FRIVET strains.
Data recorded at this stage will allow us to ascertain the suitability of the LEE5 and other
FRIVET strains for animal experiments. Whilst the in vitro experiments cannot
accurately reproduce the environmental signals present in the animal, we can hope to gain
an understanding of the promoter fired FimB levels during FRIVET assays. There is a
risk that the FRIVET system is too sensitive and operates on a 'hair trigger', that is, small
levels of promoter activation will be enough to mediate switching in the majority of cells.
The ability to 'tune' RIVET systems has been demonstrated before (Lee et al, 1999). We
would be able to utilise a unique clal restriction site within fimB to introduce changes to
the fimB shine-dalgarno site. By modifying the fimB Shine-dalgarno site, we can bring
FimB levels down and add further control to the FRIVET system.
The FRIVET system was also tested in an animal model using the ligated gut loop
method on adult sheep. The results of the assay using key E. coli 0157:H7 promoters
indicated little or no FRIVET activation. The same strains also failed to exhibit any
FRIVET induction in a series of in vitro assays using permissible media and growth
conditions. The animal model used was also likely to be not ideal for E. coli 0157:H7
virulence gene activation. Previous studies had shown the ligated sheep gut loops as a
poor model for E. coli 0157:H7 A/E lesion formation (Wales et al, 2002).
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Once a more suitable animal model is found and we have a greater understanding of the E.
coli 0157:H7 FRIVET strains and the variability seen in the ara in vitro assays, a range
of in vivo assays can be performed using the FRIVET constructs. In its most basic guise,
a FRIVET experiment would start with the oral inoculation of the animal model and the
collection of faecal samples for FRIVET analysis after suitable time has elapsed. This
assay will allow us to ascertain whether the promoter being tested was activated at any
timepoint during the colonisation process, a 'history' or 'memory' of gene activity will be
retained by the cell for future analysis. Promoters that are known to have an active role
in colonisation of the bovine GI TR such as LEE5 and LEE4 would be expected to show
ampicillin resistant populations for their respective FRIVET strains. Other promoters
such as fliC and Ipf, have a less than clear role in bovine colonisation, and as such
FRIVET analysis would prove extremely useful in unravelling the initial factors
responsible for E. coli 0157:H7 persistance in the bovine host.
However it must be noted that the FRIVET system can only provide a yes/no for
promoter activation in the animal model. Specific controls would have to be employed to
discount the global gene activation or false positives during the infection and sampling
process. The use of a fimS orientation PCR on individual colonies from sampling plates
would give a clear result of the percentage of the population that have exhibited FRIVET
activation. However, this PCR screening method increases the complexity and the time
of the assay. One of the advantages of FRIVET was a simple, quick and reproducible
screening method.
Additionally the FRIVET system would likely have to be 'tuned' for each E. coli
0157:H7 promoter to achieve the correct 'trigger pressure' for the promoter in vivo.
Without extensive in vitro workup, the FRIVET system could either be too 'soft' for the
promoter, leading to false positives as very low levels of environmental signals could
activate the FRIVET system even if they were biologically irrelevant to the promoters
role in E. coli 0157:H7 infection. Conversely the FRIVET system could be too 'hard',
leading to low or zero levels of FRIVET activation and false negatives. These specific
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issues cannot be controlled for at the time of the assay. They need to be unravelled
during the in vitro workup for each E. coli 0157:H7 FRIVET promoter.
The natural evolution of the basic FRIVET assay would involve analysis of bacteria
recovered from different sites along the GI tract via post-mortem processing. This will
allow us to analyse the timing of individual E. coli 0157:H7 gene expression. By
subjecting multiple E. coli 0157:H7 FRIVET strains to this assay we can build a solid
picture of how E. coli 0157:H7 regulates its virulence genes in a colonisation model. For
example: are LEE4 and LEE5 co-ordinately regulated in vivo as in vitro and is the T3SS
basal apparatus present prior to LEE4/LEE5 activation; does E. coli 0157:H7 use Lpf as
an initial adhesin and is FliC involved in the attachment process? By analysing FRIVET
activation levels at various points in the GI tract we can link the yes/no answers the
FRIVET system gives us to build a better view of E. coli 0157:H7 pathogenesis in the
host.
Whilst the FRIVET system is a novel and potentially powerful tool for elucidating
bacterial in vivo gene dynamics, it is not the 'all in one' in vivo tool for answering all the
key in vivo questions for E. coli 0157:H7 infection or colonisation process. The power
in the FRIVET system will lie in its use in conjunction with other in vivo and in vitro
methods such as micro-arrays and fluorescence microscopy. These methods could
potentially be employed directly from bacterial samples during post mortem or from
faeces. Micro-array data allows us to see the upregulation of any number of genes during
an infection process or at a particular juncture in the GI tract. Additionally the use of
fluorescence microscopy to analyse E. coli 0157:H7 promoters linked to fluorescence
proteins such as gfp and rfp can be used to measure gene activation in a population, or to
identify A/E lesion formation on tissue samples taken during post-mortem.
It was postulated during the research phase of this thesis to integrate our knowledge of
fluorescence reporter systems and the FRIVET system to build a modified FRIVET
operon that could be analysed by fluorescence microscopy. This operon, named the
'traffic light' FRIVET system, uses two fluorescence proteins: gfp and rfp either side of
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the fim switch in place of bla. As fimS contains a promoter that can direct upstream
transcription when in the 'off orientation (no FimB production) and downstream
transcription when in the 'on' orientation (FimB produced) we can analyse the activation
of the FRIVET system by noting the switch from cells fluorescing red to fluorescing
green under microscopy. The traffic light FRIVET system is outlined in Figure 6.1.
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Fig 6.1 - Proposed traffic light FRIVET model













The FRIVET traffic light model is based on the promoter in fimS driving transcription in
either direction depending on its orientation. At that start of the experiment fimS is in the
'off orientation, the ftmS promoter will direct transcription of rfp and the cells will be red
under fluorescence microscopy. During the assay fimB will be activated leading to the
invesion of fimS. The promoter now directs the downstream transcription of gfp and the
cells appear green under fluorescence microscopy. By taking timepoint samples during the
assay we can measure the induction offimB at a single cell level in a population.
The use of the FRIVET system in conjunction with other in vivo methods will allow a
clearer picture of the virulence gene dynamics of E. coli 0157:H7 in the host to be
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formed. Modifications to the basic FRIVET model to incorporate other reporter genes
such as fluorescence proteins as seen in traffic light FRIVET allow us to gain further
understanding of the promoter being investigated.
FRIVET on its own will help to answer some basic in vivo questions, but to gain the






Adu-Bobie, J., Trabulsi, L.R., Carneiro-Sampaio, M.M., Dougan, G. and Frankel, G.
Identification of immunodominant regions within the C-terminal cell binding domain of
intimin alpha and intimin beta from enteropathogenic Escherichia coli.
Infect Immun. (1998) (12):5643-9
Angelini, F., Menard, A., Asencio, C., Marais, A. and Megraud, F.
Construction of replicative and integrative plasmids for setting up the in vivo expression
technology in Helicobacter pylori.
Plasmid (2004) 51(2): 101-7
Ball, H.J., Finlay, D., Burns, L. and Mackie, D.P.
The detection of verocytotoxins in bacterial cultures from human diarrhoeal samples with
monoclonal antibody-based ELISAs.
Res Vet Sci (1994) 57(2):225-32
Bartoleschi, C., Pardini, M.C., Scaringi, C., Martino, M.C., Pazzani, C. and Bernardini,
M.L.
Selection of Shigella flexneri candidate virulence genes specifically induced in bacteria
resident in host cell cytoplasm.
Cell Microbiol (2002) 4(9):613-26
Baumler, A.J. and Fleffron, F.
Identification and sequence analysis of IpfABCDE, a putative fimbrial operon of
Salmonella typhimurium.
J Bacteriol (1995) 177(8):2087-97
197
Baumler, A.J., Tsolis, R.M. and Heffron, F.
The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's
patches.
PNAS (1996) 9;93(l):279-83
Best, A., La Ragione, R.M., Sayers, A.R. and Woodward, M.J.
Role for flagella but not intimin in the persistent infection of the gastrointestinal tissues
of specific-pathogen-free chicks by shiga toxin-negative Escherichia coli 0157:H7.
Infect. Immun. (2005) 73(3): 1836-46
Blomfield, I.C., McClain, M.S., Princ, J.A., Calie, P.J. and Eisenstein, B.I.
Type 1 fimbriation and fimE mutants of Escherichia coli K-12
J. Bacteriol. (1991) 173: 5298-307
Blomfield, I.C., Calie, P.J., Eberhardt, K.J., McClain, M.S. and Eisenstein, B.I.
Lrp stimulates phase variation of type 1 fimbriation in Escherichia coli K-12
J. Bacteriol. (1993) 175: 27-36
Blomfield, I.C., Kulasekara, D.H. and Eisenstein, B.I.
Integration host factor stimulates both FimB- and FimE- mediated site specific DNA
inversion that controls phase variation of type 1 fimbriae expression in Escherichia coli
Mol. Microbiol. (1997) 23: 705-17
Blomfield, I.C.
The regulation of pap and type 1 fimbriation in Escherichia coli
Adv. Microbial Physiol. (2001) 45: 1-27
198
Boudeau, J., Barnich, N. and Darfeuille-Michaud, A.
Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's
disease is involved in bacterial invasion of intestinal epithelial cells.
Mol Microbiol. (2001) 39(5): 1272-84.
Burns, L.S., Smith, S.G.J, and Dorman, C.J.
Interaction of the FimB integrase with the fimS invertible DNA element in Escherichia
coli in vivo and in vitro
J. Bacteriol. (2000) 182: 2953-9
Bustamante, V.H., Santana, F.J., Calva, E. and Puente, J.L.
Transcriptional regulation of type III secretion genes in enteropathogenic Escherichia
coli: Ler antagonizes H-NS-dependent repression.
Mol Microbiol. (2001) 39(3):664-78.
Camilli, A. and Mekalanos, J.J.
Use of recombinase gene fusions to identify Vibrio cholerae induced during infection
Mol. Microbiol. (1995) 18: 671-83
Campellone, K.G., Rankin, S., Pawson, T., Kirschner, M.W., Tipper, D.J. and Leong,
J.M.
Clustering of Nek by a 12-residue Tir phosphopeptide is sufficient to trigger localized
actin assembly.
J Cell Biol. (2004) 164(3):407-16.
199
Casadaban, M.J.
Regulation of the regulatory gene for the arabinose pathway, araC
J Mol Biol, (1976) Jul; 104 (3):557-66
Cornick, N.A., Booher, S.L. and Moon, H.W.
Intimin facilitates colonization by Escherichia coli 0157:H7 in adult ruminants.
Infect Immun. (2002) 70(5):2704-7.
Chiu, H-J. and Syu, W-J.
Functional analysis of EspB from enterohaemorrhagic Escherichia coli
Microbiology (2005) 151: 3277-86
Creasey, E.A., Delahay, R.M., Bishop, A.A., Shaw, R.K., Kenny, B., Knutton, S. and
Frankel, G.
CesT is a bivalent enteropathogenic Escherichia coli chaperone required for translocation
of both Tir and Map.
Mol Microbiol (2003) 47( 1 ):209-221
Dahan, S., Wiles, S., La Ragione, R.M., Best, A., Woodward, M.J., Stevens, M.P., Shaw,
R.K., Chong, Y., Knutton, S., Phillips, A. and Frankel, G.
EspJ is a prophage-carried type III effector protein of attaching and effacing pathogens
that modulates infection dynamics.
Infect Immun (2005) 73(2):679-686
200
Daniell, S.J., Delahay, R.M., Shaw, R.K., Hartland, E.L., Pallen, M.J., Booy, F., Ebel, F.,
Knutton, S. and Frankel, G.
Coiled-coil domain of enteropathogenic Escherichia coli type III secreted protein EspD is
involved in EspA filament-mediated cell attachment and hemolysis.
Infect Immun (2001) 69(6):4055-4064
Dean-Nystrom, E.A., Bosworth, B.T., Cray, W.C.Jr. and Moon, H.W.
Pathogenicity ofEscherichia coli 0157:147 in the intestines of neonatal calves.
Infect Immun (1997) 65(5): 1842-1848
Dean-Nystrom, E.A., Bosworth, B.T., Moon, H.W., and O'Brien, A.D.
Escherichia coli 0157:H7 requires intimin for enteropathogenicity in calves.
Infect Immun (1998) 66(9):4560-4563
Dviza, F., van Diemen, P.M. Stevens, M.P., Smith, A.J. and Wallis, T.S.
Identification of Escherichia coli 0157:H7 genes influencing colonisation of the bovine
gastrointestinal tract using signature-tagged mutagenesis
Microbiology (2004) 150: 3631-45
Dubnau, E., Fontan, P., Manganelli, R., Soares-Appel, S. and Smith, I.
Mycobacterium tuberculosis genes induced during infection of human macrophages.
Infect Immun (2002) 70(6):2787-2795
El-Labany, S., Sohanpal, B.K., Lahooti, M., Akerman, R. and Blomfield, I.C.
Distant cis-active sequences and sialic acid control the expression offimB in Escherichia
coli K-12
Mol. Microbiol. (2003)49: 1109-18
201
Elliott, S. J., Wainwright, L. A., McDaniel, T. K., Jarvis, K. G., Deng, Y. K., Lai, L. C.,
McNaniara, B. P., Donnenberg, M. S. and Kaper, J. B.
The complete sequence of the locus of enterocyte effacement (LEE) from
enteropathogenic Escherichia coli E2348/69.
Mol Microbiol (1998) 28:1-4
Elliott, S. J., Yu, J. and Kaper, J. B.
The cloned locus of enterocyte effacement from enterohemorrhagic Escherichia coli
0157:H7 is unable to confer the attaching and effacing phenotype upon E. coli K-12.
Infect Immun (1999) 67:4260-4263.
Elliot, S.J., Sperandio, V., Giron, J.A., Shin, S., Mellies, J.L., Wainwright, L., Hutcheson,
S.W., McDaniel, T.K. and Kaper, J.B.
The Locus of Enterocyte Effacement (LEE)-Encoded Regulator Controls Expression of
Both LEE- and Non-LEE-Encoded Virulence Factors in Enteropathogenic and
Enterohemorrhagic Escherichia coli
Infect Immun (2000) 68(11):6115-6126
Forsman, K., Goransson, M. and Uhlin, B.E.
Autoregulation and multiple DNA interactions by a transcriptional regulatory protein in E.
coli pili biogenesis
EMBO J. (1989) 8: 1271-7
Frankel, G., Phillips, A.D., Rosenshine, I., Dougan, G., Kaper, J.B. and Knutton, S.
Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements
Mol. Microbiol. (1998) 30: 911-21
202
Friedberg, D., Umanski, T., Fang ,Y. and Rosenshine I.
Hierarchy in the expression of the locus of enterocyte effacement genes of
enteropathogenic Escherichia coli.
Mol Microbiol. (1999) 34 : 941-52.
Gahan, C.G. and Hill, C.
The use of listeriolysin to identify in vivo induced genes in the gram-positive intracellular
pathogen Listeria monocytogenes.
Mol Microbiol. (2000) (2):498-507.
Gaily, D.L., Bogan, J.A., Eisenstein, B.I. and Blomfield, I.C.
Environmental regulation of the fim switch controlling type 1 fimbrial phase variation in
Escherichia coli K-12: Effects of temperature and media
J. Bacteriol. (1993) 175: 6186-93
Gaily, D.L., Leathart, J. and Blomfield, I.C.
Interaction of FimB and FimE with the fim switch that controls the phase variation of
type 1 fimbriation in Escherichia coli
Mol. Microbiol. (1996) 21: 735-38
Gammage, S.D., Patton, A.K., Strasser, J.E., Chalk, C.L. and Weiss, A.A.
Commensal bacteria influence Escherichia coli 0157:H7 persistence and shiga toxin
production in the mouse intestine
Infect Immun. (2006) 74: 1977-83
203
Garmendia, J., Phillips, A.D., Carlier, M.F., Chong, Y., Schuller, S., Marches, O., Dahan,
S., Oswald, E., Shaw, R.K., Knutton, S. and Frankel,. G.
TccP is an enterohaemorrhagic Escherichia coli 0157:H7 type III effector protein that
couples Tir to the actin-cytoskeleton.
Cell Microbiol. (2004) 6(12): 1167-83.
Garmendia, J., Frankel, G. and Crepin, V.F.
Enteropathogenic and enterohaemorrhagic Escherichia coli infections: translocation,
translocation, translocation
Infect Immun. (2005) 73: 2573-85
Godaly, G., Frendeus, B., Proudfoot, A., Svensson, M., Klemm, P. and Svanborg, C.
Role of fimbriae-mediated adherence for neutrophil migration across Escherichia coli-
infected epithelial cell layers.
Mol Microbiol. (1998) 30(4):725-35.
Greenblatt, J. and Schleif, R.
Arabinose C protein: regulation of the arabinose operon in vitro
Nat New Biol. 1971 Oct 6; 233 (40) : 166-70
Gruenheid, S., Sekirov, I., Thomas, N.A., Deng, W., O'Donnell, P., Goode, D., Li, Y.,
Frey, E.A., Brown, N.F., Metalnikov, P., Pawson, T., Ashman, K. and Finlay, B.B.
Identification and characterization ofNleA, a non-LEE-encoded type III translocated
virulence factor of enterohaemorrhagic Escherichia coli 0157:H7.
Mol Microbiol. (2004) 51:1233-49.
204
Gunther, N.W. 4th, Lockatell, V., Johnson, D.E. and Mobley, H.L.
In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during
experimental urinary tract infection.
Infect Immun. (2001) 69(5):2838-46.
Guzman, L. M., Belin, D., Carson, M. J., and Bewick, J.
Tight regulation, modulation and high level expression vectors containing the arabinose pBAD
promoter.
Journal ofBacteriology (1995) 177: 4121-4130.
Handfield, M., Lehoux, D.E., Sanschagrin, F., Mahan, M.J., Woods, D.E. and Levesque,
R.C.
In vivo-induced genes in Pseudomonas aeruginosa.
Infect Immun. (2000) 68(4):2359-62.
Hayashi, T., Makino, K., Ohnishi, M., Kurokawa, K., Ishii, K., Yokoyama, K., Han, C.G.,
Ohtsubo, E., Nakayama, K., Murata, T., Tanaka, M., Tobe, T., Iida, T., Takami, H.,
Honda, T., Sasakawa, C., Ogasawara, N., Yasunaga, T., Kuhara, S., Shiba, T., Hattori, M.
and Shinagawa, H.
Complete genome sequence of enterohemorrhagic Escherichia coli 0157:H7 and
genomic comparison with a laboratory strain K-12.
DNA Res. (2001) 28;8(1): 11-22. Erratum in: DNA Res (2001) 27;8(2):96.
Hensel, M., Shea, J.E., Gleeson, C., Jones, M.D., Dalton, E. and Holden, D.W.
Simultaneous identification of bacterial virulence genes by negative selection
Science (1995) 269(5222):400-3
205
Holden, N.J., Uhlin, B.E. and Gaily, D.L.
PapB paralogues and their effect on the phase variation of type 1 fimbriae in Escherichia
coli.
Mol Microbiol. (2001) 42(2):319-30.
Holden, N.J. and Gaily, D.L.
Switches, cross-talk and memory in Escherichia coli adherence
J. Med. Microbiol. (2004) 53: 585-93
Holden, N.J., Totsika, M., Mahler, E., Roe, A.J., Catherwood, K., Lindner, K., Dobrindt,
U. and Gaily, D.L.
Demonstration of regulatory cross-talk between P fimbriae and type 1 fimbriae in
uropathogenic Escherichia coli
Microbiology (2006) 152: 1143-53
Hoey, D.E., Currie, C., Else, R.W., Nutikka, A., Lingwood, C.A., Gaily, D.L. and Smith,
D.G.
Expression of receptors for verotoxin 1 from Escherichia coli 0157 on bovine intestinal
epithelium.
J Med Microbiol. (2002) 51(2): 143-9.
Iyoda, S., Koizumi, N., Satou, H., Lu, Y., Saitoh, T., Ohnishi, M. and Watanabe, H.
The GrlR-GrlA Regualtory System Coordinately Controls the Expression of Flaggelar
and LEE-Encoded Type III Protein Secretion Systems in Enterohemorrhagic Escherichia
coli
J. Bacteriol 2006 188 16 p 5682-5692
206
Iwanaga, M., Yamamoto, K., Higa, N., Ichinose, Y., Nakasone, N. and Tanabe, M.
Culture conditions for stimulating cholera toxin production by Vibrio cholerae 01 El Tor
Microbiology and Immunology (1986) 30: 1075-83
Kanack, K.J., Crawford, J.A., Tatsuno, I., Karmali, M.A. and Kaper, J.B.
SepZ/EspZ is secreted and translocated into HeLa cells by the enteropathogenic
Escherichia coli type III secretion system.
Infect Immun. (2005) 73(7):4327-37.
Kaper, J.B.
Enterohaemorrhagic Escherichia coli
Curr. Op. in Microbiol. (1998) 1:103-8
Kenny, B., DeVinney, R., Stein, M., Reinscheid, D.J., Frey, E.A. and Finlay, B.B.
Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into
mammalian cells.
Cell. (1997) 91(4):511-20.
Kenny, B. and Jepson, M.
Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host
mitochondria.
Cell Microbiol. (2000) (6):579-90.
207
Khan, A., Datta, S., Das, S.C., Ranamurthy, T., Khanam, J., Takeda, Y., Bhattacharya,
S.K. and Nair, G.B.
Shiga toxin producing Escherichia coli infection: current progress and future challenges
Indian J. Med. Res. (2003) 118: 1-24
Khlebnikov, A., Skaug, T. and Keasling, J.D.
Modulation of gene expression from the arabinose-inducible araBAD promoter.
J. Ind Microbiol Biotechnol. (2002) (l):34-7.
Klemm, P.
Two regulatory fim genes, fimB and fimE control the phase variation of type 1 fimbriae in
Escherichia coli
EMBO J. (1986) 5, 1389-93
Knutton, S., Rosenshine, I., Pallen, M.J., Nisan, I., Neves, B.C., Bain, C., Wolff, C.,
Dougan, G. and Frankel, G.
A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved
in protein translocation into epithelial cells.
EMBO J. (1998) (8):2166-76.
Kresse, A.U., Rohde, M. and Guzman, C.A.
The EspD protein of enterohemorrhagic Escherichia coli is required for the formation of
bacterial surface appendages and is incorporated in the cytoplasmic membranes of target
cells.
Infect Immun. (1999) (9):4834-42.
208
Kulasekara, D.H. and Blomfield, I.C.
The molecular basis for the specificity offimE in the phase variation of type 1 fimbriae of
Escherichia coli K-12
Mol. Microbiol. (1999)31: 1171-81
Laaberki, M-H., Janabi, N., Oswald, E. and Repoila, F.
Concert of regulators to switch on LEE expression in enterohaemorrhagic Escherichia
coli 0157:H7: Interplay between Ler, GrlA, HNS and RpoS
Int. J. Med. Microbiol. (2006)
Lai, Y.C., Peng, H.L. and Chang, H.Y.
Identification of genes induced in vivo during Klebsiella pneumoniae CG43 infection.
Infect Immun. (2001) (11):7140-5
Leathart, J.B.S. and Gaily, D.L.
Regulation of type 1 fimbrial expression in uropathogenic Escherichia coli:
heterogeneity of expression through sequence changes in the fim switch region
Mol. Microbiol. (1998) 28: 371-81
Lee, S.H., Butler, S.M. and Camilli, A.
Selection for in vivo regulators of bacterial virulence
PNAS (2001) 98: 6889-94
Lee, S.H., Hava, D.L., Waldor, M.K. and Camilli, A.





Role of verotoxin receptors in pathogenesis.
Trends Microbiol. (1996) (4): 147-53
Livny, J. and Friedman, D.I.
Characterising spontaneous induction of Stx encoding phages using a selectable reporter
system
Mol. Microbiol. (2004) 51: 1691-704
Low, A.S., Holden, N., Rosser, T., Roe, A.J., Constantinidou, C., Hobman, J.L., Smith,
D.G.E., Low, J.C. and Gaily, D.L.
Analysis of timbrial gene clusters and their expression in enterohaemorrhagic
Escherichia coli 0157:H7
Env. Microbiology (2006)
Low, A.S., Dziva, F., Torres, A.G., Martinez, J.L., Rosser, T., Naylor, S., Spears, K.,
Holden, N., Mahajan, A., Findlay, J., Sales, J., Smith, D.G.E., Low, J.C., Stevens, M.P.
and Gaily, D.L.
Cloning, expression and characterisation of fimbrial operon F9 from enterohaemorrhagic
Escherichia coli 0157:H7
Infection and Immunity (2006) 74: 2233-44
Lowe, A.M., Beattie, D.T. and Deresiewicz, R.L.
Identification of novel staphylococcal virulence genes by in vivo expression technology.
Mol Microbiol. (1998) (5):967-76.
210
Mahan, M.J., Slauch, J.M. and Mekalanos, J.J.
Selection of bacterial virulence genes that are specifically induced in host tissues.
Science. (1993) (5095):686-8.
Marches, O., Nougayrede, J.P., Boullier, S., Mainil, J., Charlier, G., Raymond, I., Pohl, P.,
Boury, M., De Rycke, J., Milon, A. and Oswald, E.
Role of tir and intimin in the virulence of rabbit enteropathogenic Escherichia coli
serotype O103:H2.
Infect Immun. (2000) (4):2171-82.
Marches, O., Ledger, T.N., Boury, M., Ohara, M., Tu, X., Goffaux, F., Mainil, J.,
Rosenshine, I., Sugai, M., De Rycke, J. and Oswald, E.
Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called
Cif, which blocks cell cycle G2/M transition.
Mol Microbiol. (2003) (5): 1553-67.
Marches, O., Wiles, S., Dziva, F., La Ragione, R.M., Schuller, S., Best, A., Phillips, A.D.,
Hartland, E.L., Woodward, M.J., Stevens, M.P. and Frankel, G.
Characterisation of two non-locus of enterocyte effacement-encoded type-Ill translocated
effectors, NleC and NleD, in attaching and effacing pathogens
Infection and Immunity (2005) 73: 8411-7
Martinez, J.J., Mulvey, M.A., Schilling, R.D., Pinker, J.S. and Hultgren, S.J.
Type 1 pilus-mediated invasion of bladder epithelial cells
EMBO J (2000) 19:2803-2812
211
McClain, M.S., Blomfield, I.C. and Eisenstein, B.I.
Roles offimB and fimE in site specific DNA inversion associated with phase variation of
type 1 fimbriae in Escherichia coli
J. Bacteriol. (1991) 173: 5304-14
McDaniel, T.K., Jarvis, K.G., Donnenberg, M.S. and Kaper, J.B.
A genetic locus of enterocyte effacement conserved among diverse enterobacterial
pathogens.
Proc Natl Acad Sci USA. (1995) 28;92(5):1664-8
Mead, P.S., Slutsker, L., Dietz, V., McCaig, L.F., Bresee, J.S., Shapiro, C., Griffin, P.M.
and Tauxe, R.V.,
Food-related illness and death in the United States
Emerging Infectious Disease 1999 5, 607-625
Mellies, J.L., Elliott, S.J., Sperandio, V., Donnenberg, M.S. and Kaper, J.B.
The Per regulon of enteropathogenic Escherichia coir, identification of a regulatory
cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-
encoded regulator (Ler).
Mol Microbiol. (1999) (2):296-306.
Merrell, D.S. and Camilli, A.
Detection and analysis of gene expression during infection by in vivo expression
technology
Phil. Trans. R. Soc. Lond. B (2000) 355: 587-99
212
Michino, H., Araki, K., Minami, S., Takaya, S., Sakai, N., Miyazaki, M., Ono, A. and
Yanagawa, H.
Massive outbreak of Escherichia coli 0157:H7 infection in schoolchildren in Sakai City,
Japan, associated with consumption of white radish sprouts.
Am J Epidemiol. (1999) (8):787-96.
Mundy, R., Jenkins, C., Yu, J., Smith, H. and Frankel, G.
Distribution of espl among clinical enterohaemorrhagic and enteropathogenic
Escherichia coli isolates.
J Med Microbiol. (2004) (Pt 11):1145-9.
Nataro, J.P. and Kaper, J.B.
Diarrheagenic Escherichia coli.
Clin Microbiol Rev. (1998) (1): 142-201. Review. Erratum in: Clin Microbiol Rev (1998)
(2):403.
Naylor, S.W., Low, J.C., Besser, T.E., Mahajan, A., Gunn, G.J., Pearce, M.C.,
McKendrick, I.J., Smith, D.G. and Gaily, D.L.
Lymphoid follicle-dense mucosa at the terminal rectum is the principal site of
colonization of enterohemorrhagic Escherichia coli 0157:H7 in the bovine host.
Infect Immun. (2003) (3): 1505-12.
Naylor, S.W., Gaily, D.L. and Low, J.C.
Enterohaemorrhagic E. coli in veterinary medicine.
Int J Med Microbiol. (2005) (6-7):419-41. Review.
213
Naylor, S.W., Roe, A.J., Nart, P., Spears, K., Smith, D.G.E., Low, J.C. and Gaily, D.L.
Escherichia coli 0157:H7 forms attaching and effacing lesions at the terminal rectum of
cattle and colonisation requires the LEE4 operon
Microbiology (2005) 151: 2773-81
O'Connell, C.B., Creasey, E.A., Knutton, S., Elliott, S., Crowther, L.J., Luo, W., Albert,
M.J., Kaper, J.B., Frankel, G. and Donnenberg, M.S.
SepL, a protein required for enteropathogenic Escherichia coli type III translocation,
interacts with secretion component SepD
Mol. Microbiol. (2004) 52: 1613-25
O'Gara, J.P. and Dorman, C.J.
Effects of local transcription and H-NS on inversion of the fim switch of Escherichia coli
Mol. Microbiol. (2000) 36: 457-66
O'Loughlin, E. V., and Robins-Browne, R. M. (2001).
Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells.
Microbes and Infection. 3: 493-507.
Olsen, P.B. and Klemm, P.
Localisation of promoters in the fim gene cluster and the effect of H-NS on the
transcription offimB and fimE
FEMS Microbiol. Lett. (1994) 116: 95-100
214
Olsen P.B., Schembri, M.A., Gaily, D.L. and Klemm, P.
Differential temperature modulation by H-NS of the fimB and fimE recombinase genes
which control the orientation of the type 1 fimbrial phase switch
FEMS Microbiol. Lett. (1998) 162: 17-23
Osbourn AE, Barber CE, Daniels MJ.
Identification of plant-induced genes of the bacterial pathogen Xanthomonas campestris
pathovar campestris using a promoter-probe plasmid.
EMBO J. (1987) (l):23-8.
Oshima, T., Ito, K., Kabayama, H. and Nakamura, Y.
Regulation of lrp gene expression by H-NS and Lrp proteins in Escherichia coir.
dominant negative mutations in lrp.
Mol Gen Genet. (1995) (5):521-8.
Osorio, C.G., Crawford, J.A., Michalski, J., Martinez-Wilson, H., Kaper, J.B. and Camilli,
A.
Second generation recombination based in vivo expression technology for large scale
screening for Vibrio cholerae genes induced during infection of the mouse small intestine
Infect Immun. (2005) 73: 972-80
Quitard, S., Dean, P., Maresca, M. and Kenny, B.
The enteropathogenicEsr/zenc/zh? coli EspF effector molecule inhibits PI-3 kinase-
mediated uptake independently of mitochondrial targeting
Cell Microbiol. (2006) 8(6), 972-981
215
Perna, N.T., Mayhew, G.F., Posfai, G., Elliott, S., Donnenberg, M.S., Kaper, J.B. and
Blattner, F.R.
Molecular evolution of a pathogenicity island from enterohemorrhagic Escherichia coli
0157:H7.
Infect Immun. (1998) (8):3810-7.
Perna, N.T., Plunkett, G. 3rd, Burland, V., Mau, B., Glasner, J.D., Rose, D.J., Mayhew,
G.F., Evans, P.S., Gregor, J., Kirkpatrick, H.A., Posfai, G., Hackett, J., Klink, S., Boutin,
A., Shao, Y., Miller, L., Grotbeck, E.J., Davis, N.W., Lim, A., Dimalanta, E.T.,
Potamousis, K.D., Apodaca, J., Anantharaman, T.S., Lin, J., Yen, G., Schwartz, D.C.,
Welch, R.A. and Blattner, F.R.
Genome sequence of enterohaemorrhagic Escherichia coli 0157:H7.
Nature. (2001) 409(6819):529-33. Erratum in: Nature (2001) 410(6825):240.
Phillips, A.D., Navabpour, S., Hicks, S., Dougan, G., Wallis, T. and Frankel, G.
Enterohaemorrhagic Escherichia coli 0157:H7 target Peyer's patches in humans and
cause attaching/effacing lesions in both human and bovine intestine.
Gut. (2000) (3):377-81.
Rediers, H., Rainey, P.B., Vanderleyden, J. and de Mot, R.
Unravelling the secret lives of bacteria: Use of in vivo expression technology and
differential fluorescence induction promoter traps as tools for exploring niche-specific
gene expression
Microbiol. Mol. Biol. Rev. (2005) 69: 217-61
216
Reece, S., Simmons, C.P., Fitzhenry, R.J., Matthews, S., Phillips, A.D., Dougan, G. and
Frankel, G.
Site-directed mutagenesis of intimin alpha modulates intimin-mediated tissue tropism and
host specificity.
Mol Microbiol. (2001) (l):86-98.
Riley, L.W., Remis, R.S., Helgerson, S.D., McGee, H.B., Wells, J.G., Davis, B.R.,
Hebert, R.J., Olcott, E.S., Johnson, L.M., Hargrett, N.T., Blake, P.A. and Cohen, M.L.
Hemorrhagic colitis associated with a rare Escherichia coli serotype.
New England Journal of Medicine (1983) 308:681-5
Ritchie, J.M., Thorpe, C.M., Rogers, A.B. and Waldor, M.K.
Critical roles for stx2, eae, and tir in enterohemorrhagic Escherichia coli-induced
diarrhea and intestinal inflammation in infant rabbits.
Infect Immun. (2003) (12):7129-39.
Robinson, C. R., Sinclair, J.F., Smith, M.J. and O'Brien, A.D.
Shiga toxin of enterohemorrhagic Escherichia coli type 0157:H7 promotes intestinal
colonisation
PNAS (2006) 103:25, 9667
Roe, A.J. and Gaily, D.L.
Enteropathogenic and enterohaemorrhagic Escherichia coli and diarrhoea
Curr. Opin, Infect, Dis. (2000) 13: 511-7
217
Roe, A.J., Currie, C., Smith, D.G.E. and Gaily, D.L.
Analysis of type 1 fimbriae expression in verotoxigenic Escherichia coli: A comparison
between serotypes 0157 and 026
Microbiology (2001) 147: 145-52
Roe, A.J., Yull, H„ Naylor, S.W., Woodward, M.J., Smith, D.G. and Gaily, D.L.
Heterogeneous surface expression ofEspA translocon filaments by Escherichia coli
0157:H7 is controlled at the posttranscriptional level.
Infect Immun. (2003) (10):5900-9.
Roe, A.J., Naylor, S.W., Spears, K.J., Yull, H.M., Dransfield, T.A., Oxford, M.,
McKendrick, I.J., Porter, M., Woodward, M.J., Smith, D.G.E. and Gaily, D.L.
Co-ordinate single-cell expression of LEE4- and LEE5- encoded proteins of Escherichia
coli 0157:H7
Mol. Microbiol. (2004) 54: 337-52
Roesch, P.L. and Blomfield, I.C.
Leucine alters the interaction of the leucine-responsive regulatory protein (Lrp) with the
fim switch to stimulate site-specific recombination in Escherichia coli
Mol. Microbiol. (1998) 27: 751-61
Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989).
Molecular Cloning: A Laboratory Manual, 2nd edition (New York: Cold Spring Harbour
Laboratory Press).
218
Sanchez-SanMartin, C., Bustamante, V.H., Calva, E. and Puente, J.L.
Transcriptional regulation of the orfl9 gene and the tir-cesT-eae operon of
enteropathogenic Escherichia coli.
J Bacteriol. (2001) (9):2823-33.
Schwan, W.R., Seifert, H.S. and Duncan, J.L.
Growth conditions mediate differential transcription of fun genes involved in phase
variation of type 1 pili
J. Bacteriol. (1992) 174: 2374-5
Schwan, W.R., Seifert, H.S. and Duncan, J.L.
Analysis of the fimB promoter region involved in type 1 pilus phase variation in
Escherichia coli.
Mol Gen Genet. (1994) (5):623-30.
Sharma, V.K. and Zuerner, R.L.
Role of hha and ler in transcriptional regulation of the esp operon of enterohaemorrhagic
Escherichia coli 0157:H7
J. Bacteriol. (2004) 186: 7290-301
Shaw, R.K., Smollett, K., Cleary, J., Garmendia, J., Straatman-Iwanowska, A., Frankel,
G. and Knutton, S.
Enteropathogenic Escherichia coli type III effectors EspG and EspG2 disrupt the
microtubule network of intestinal epithelial cells.
Infect Immun. (2005) (7):4385-90.
219
Siegele, D.A. and Hu, J.C.
Gene expression form plasmids containing the araBAD promoter at subsaturating inducer
concentrations represents mixed populations
PNAS (1997) 94 (15) : 8168-72
Sinclair, J.F. and O'Brien, A.D.
Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma
of enterohemorrhagic Escherichia coli 0157:H7.
J Biol Chem. (2002) 277(4):2876-85. Epub 2001 Nov 9.
Smith, D.G.E., Naylor, S.W. and Gaily, D.L.
Consequences ofEHEC colonisation in humans and cattle
Int. J. Med. Microbiol. (2002) 292: 169-83
Smith, S.G.J, and Dorman, C.J.
Functional analysis of the FimE integrase of Escherichia coli K-12: Isolation of mutant
derivatives with altered DNA inversion preferences
Mol. Microbiol. (1999) 34: 965-79
Snyder, J.A., Haugen, B.J., Buckles, E.L., Lockatell, C.V., Johnson, D.E., Donnenberg,
M.S., Welch, R.A. and Mobley, H.L.
Transcriptome of uropathogenic Escherichia coli during urinary tract infection.
Infect Immun. (2004) (11):6373-81.
220
Snyders J.A., Haugen, B.J., Lockatell, C.V., Maroncle, N., Hagan, E.C., Johnson, D.E.,
Welch, R.A. and Mobley, H.L.
Coordinate expression of fimbriae in uropathogenic Escherichia coli.
Infect Immun. (2005) (11):7588-96.
Snyder, J.A., Lloyd, A.L., Lockatell, C.V., Johnson, D.E. and Mobley, H.L.
Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis
isolate during urinary tract infection.
Infect Immun. (2006) (2): 1387-93.
Sohanpal, B.K., El-Labany, S., Lahooti, M., Plumbridge, J.A. and Blomfield, I.C.
Integrated regulatory responses offimB to H-acetylneuraminic (sialic) acid and GlcNAc
in Escerichia coli K-12
PNAS (2004) 101: 16322-7
Spears, K.J., Roe, A.J. and Gaily, D.L.
A comparison of enteropathogenic and enterohaemorrhagic Escherichia coli pathogenesis
FEMS Microbiol. Lett. (2006) 255: 187-202
Spears, P.A., Schauer, D.A. and Orndorff, P.E.
Metastable regulation of type 1 piliation in Escherichia coli and isolation and
characterisation of a phenotypically stable mutant
J. Bacteriol. (1986) 168: 179-85
221
Sperandio, V., Li, C.C. and Kaper, J.B.
Quorum-sensing Escherichia coli regulator A: a regulator of the LysR family involved in
the regulation of the locus of enterocyte effacement pathogenicity island in
enterohemorrhagic E. coli.
Infect Immun. (2002) 70(6):3085-93.
Stevens, M.P., Roe, A. J., Vlisidou, I., van Diemen, P.M., La Ragione, R.M., Best, A.,
Woodward, M.J., Gaily, D.L. and Wallis, T.S.
Mutation of toxB and a truncated version of the efa-1 gene in Escherichia coli 0157:H7
influences the expression and secretion of locus of enterocyte effacement-encoded
proteins but not intestinal colonization in calves or sheep.
Infect Immun. (2004) (9):5402-l 1.
Tatsuno, I., Horie, M., Abe, H., Miki, T., Makino, K., Shinagawa, H., Taguchi, H.,
Kamiya, S., Hayashi, T. and Sasakawa, C.
toxB gene on pOI57 of enterohemorrhagic Escherichia coli 0157:H7 is required for full
epithelial cell adherence phenotype.
Infect Immun. (2001) (11):6660-9.
Toru Tobe, Scott A. Beatson , Hisaaki Taniguchi, Hiroyuki Abe, Christopher M. Bailey,
Amanda Fivian, Rasha Younis, Sophie Matthews, Olivier Marches, Gad Frankel, Tetsuya
Hayashi, and Mark J. Pallen
An extensive repertoire of type III secretion effectors in Escherichia coli 0157 and the
role of lambdoid phages in their dissemination
PNAS (2006) 103: 40, 14941-14946
222
Tu, X., Nisan, I., Yona, C., Hanski, E. and Rosenshine, I.
EspH, a new cytoskeleton-modulating effector of enterohaemorrhagic and
enteropathogenic Escherichia coli.
Mol Microbiol. (2003) (3):595-606.
Viswanathan, V. K., Koutsouris, A., Lukic, S., Pilkinton, M.,
Simonovic, I., Simonovic, M. and Hecht, G.
Comparative Analysis of EspF from Enteropathogenic and Enterohemorrhagic
Escherichia coli in Alteration of Epithelial Barrier Function
Infec Immun. (2004) 72: 3218-3227
Vlisidou, I., Dziva, F., La Ragione, R.M., Best, A., Garmendia, J., Hawes, P., Monaghan,
P., Cawthraw, S.A., Frankel, G., Woodward, M.J. and Stevens, M.P.
Role of intimin-tir interactions and the tir-cytoskeleton coupling protein in the
colonisation of calves and lambs by Escherichia coli 0157:H7
Infect Immun. (2006) 74: 758-64
Wachter, C., Beinke, C., Mattes, M. and Schmidt, M.A.
Insertion of EspD into epithelial target cell membranes by infecting enteropathogenic
Escherichia coli.
Mol Microbiol. (1999) (6):1695-707.
Wolff, C., Nisan, I., Hanski, E., Frankel, G. and Rosenshine, I.
Protein translocation into host epithelial cells by infecting enteropathogenic Escherichia
coli.
Mol Microbiol. (1998) (1): 143-55.
223
Woodward, M.J., Best, A., Sprigings, K.A., Pearson, G.R., Skuse, A.M., Wales, A.,
Hayes, C.M., Roe, J.M., Low, J.C. and La Ragione, R.M.
Non-toxigenic Escherichia coli 0157:H7 strain NCTC12900 causes attaching-effacing
lesions and eae-dependent persistence in weaned sheep.
Int J Med Microbiol. (2003) (4):299-308.
Wray, C., McLaren, I.M., Randall, L.P. and Pearson, G.R.
Natural and experimental infection of normal cattle with Escherichia coli 0157.
Vet Rec. (2000) 147(3):65-8.
Wu, Y., Lee, S.W., Hillman, J.D. and Progulske-Fox, A.
Identification and testing of Porphyromonas gingivalis virulence genes with a pPGIVET
system.
Infect Immun. (2002) (2):928-37.
Xia, Y., Gaily, D., Forsman-Semb, K. and Uhlin, B.E.
Regulatory cross-talk between adhesin operons in Escherichia coli: inhibition of type 1
fimbriae expression by the PapB protein.
EMBO J. (2000) (7): 1450-7.
Xie, Y., Yao, Y., Kolisnychenko, V., Teng, C-H. and Kim, K.S.
HbiF regulates type 1 fimbriation independently of FimB and FimE
Infect Immun. (2006) 74: 4039-47
224
Yanisch-Perron, C., Vieira, J. and Messing, J.
Improved Ml3 phage cloning vectors and host strains: nucleotide sequences of the
M13mpl8 and pUC19 vectors.
Gene 1985; 33 (1): 103-19
Young GM, Miller VL.
Identification of novel chromosomal loci affecting Yersinia enterocolitica pathogenesis.
Mol Microbiol. (1997) (2):319-28.
Zhang, L., Chaudhuri, R.R., Constantinidou, C., Hobman, J.L., Patel, M.D., Jones, A.C.,
Sarti, D., Roe, A.J., Vlisidou, I., Shaw, R.K., Falciani, F., Stevens, M.P., Gaily, D.L.,
Knutton, S., Frankel, G., Penn, C.W. and Pallen, M.J.
Regulators encoded in the Escherichia coli type III secretion system 2 gene cluster
influence expression of genes within the locus for enterocyte effacement in
enterohemorrhagic E. coli 0157:H7.














of the major virulence factors of
EHEC 0157. (1) Chromosomal DNA
contains pathogenicity islands (red
and yellow) such as the locus for
enterocyte effacement (LEE) that
is largely responsible for the
attaching and effacing phenotype.
Additional virulence traits are
carried by the large p0157 plasmid.
(2) The LEE encodes a type III
secretion system that allows the
injection of bacterial proteins into
target cells, thereby allowing
intimate attachment. (3) Initial
bacterial binding to host cells or
bacterial spread following
attachment may be mediated by
fimbriae. (4) Bacterial motility is
driven by the presence of flagellae
that may enhance penetration of
host defences, including mucus,
thereby aiding initial attachment to
host tissue. (5) Finally. £ co//0157
carries a phage-encoded AB toxin
known asShiga-like toxin (SLT) or
verotoxin (VT), which can have
multiple effects dependent on host






the bovine terminal rectum,
(a) Location of lymphoid follicles
(LF) after acetic acid treatment of
terminal rectal mucosa. AC, anal
canal; REC, region of bacterial
colonization, (b) H&E stain of a
lymphoid follicle (LF) and follicle-
associated epithelium (FAE) at the
terminal rectum, (c) Microcolony
of EHEC 0157: H7 (green)
Situated Dn LAE.
COURTESY D.L. GALLY
EHEC0157:H7 -getting to the
bottomof theburger bug
Robert J. 0.Quantrell, StuartW. Naylor,
AndrewJ. Roe, Kevin Spears & David L. Gaily
•Enterohaemorrhagic E. coli (EHEC) emerged asa human pathogen in the 1980s through aseri s of food-borne outbreaks. Its notoriety
stems from the severe disease it can cause, especially in
the very young and the elderly. EHEC contain integrated
bacteriophage genomes capable ofexpressing a potent
toxin known as verotoxin (VT) or shiga-like toxin (SLT)
that destroys blood vessels by killing endothelial cells.
Damage to blood vessels in the gastrointestinal tract
leads to the characteristic bloody diarrhoea associated
with this infection. Kidney damage and failure can also
be precipitated by the toxin and the very young are more
susceptible, due in part to a higher toxin receptor level in
the kidney. Fig. 1 outlines the key virulence-associated
factors produced by the organism.
EHEC in cattle
There is now considerable evidence that ruminants,
particularly cattle, are the direct or indirect source of
most human infections. In the UK, North America and
Japan, the main serogroup associated with disease is
EHEC Ol 57 :H7. Unlike in humans, EHEC Ol57 :H7
does not cause overt disease in cattle and can be
considered a commensal. The overall aim ofour research
is to understand how EHEC 0157:H7 colonizes cattle so
that interventions can be designed to remove it from this
primary host and therefore prevent transmission
to humans. A key requirement is to determine where
and how EHEC 0157:H7 persists in the bovine gastro¬
intestinal tract, as this is a prerequisite to finding the
factors involved in bacterial persistence and designing
interventions.
The bottom line
Cattle orally dosedwith 109EHECO157:H7 shed up to
106 bacteria per gram faeces for at least 4 weeks. In our
work to localize the bacterium in cattle, the first few
post-mortems ofanimals shedding high levels ofEHEC
Ol 57 :H7 in their faeces failed to find significant levels
at any site within the gastrointestinal tract, including
the contents. As a result of this observation, attention
turned to the terminal rectum of the animal, with
subsequent work demonstrating that the bacteria
were really only colonizing the final few centimetres
of the gut at the terminal rectum adjacent to the anal
canal. EHEC 0157:H7
was coating the faeces
as the animal defaecated
and this was proven by
sampling the surface versus
the core of the faecal stool
(when such separation is
possible). The bacteria
are therefore being taken
in orally and more or
less ignoremetres ofgastro¬
intestinal tract and then
colonize in a narrow band
adjacent to the anus (this
research was supported
by a Veterinary Fellowship
from DEFRA and was
subsequently known as
The Fellowship ofthe Ring\).
This remarkable tropism
explained why others
had missed the site in the
past and opened up the
possibility of simple




i The molecular basis of colonization
Attention then turned to the molecular basis of this
tropism. Examination of the site of EHEC Ol 57 :H7
colonization was not shared by the generic E. coli
population and revealed a region containing a high
concentration of sub-mucosal lymphoid follicles (Fig.
2a). These follicles contain B and T lymphocytes that
signal alterations to the epithelium above these
structures. This follicle-associated epithelium (FAE)
is characterized by a
reduction in the levels of
mucus-secreting goblet
cells and the presence of
cells with shortened micro¬
villi. These cells are similar
to M-cells found in the
small intestine that sample
lumenal antigens. In
conjunction with work
carried out using human
gastrointestinal explants,
this research indicates
that EHEC 0157:H7 is
likely to interact initially
with M or M-like cells
in both humans and
cattle. Similarly, members
of the Enterobacteriaceae —
Salmonella, Shigella and other pathotypes of E. coli —
have been shown to use M-cells as an initial point of
interaction with their host.
The obvious downside to contacting M-cells is that
their usual function is to take up foreign particles.
Bacteria such as Salmonella have the capacity to take
advantage of this internalization, but this does not
appear to be the case for EHEC 0157:H7 as it is
predominantly extracellular. In common with these
other enteric pathogens, EHEC has a type III secretion
system that enables the injection of bacterial proteins
into host cells (see Figs 1, 5 and 6). The most obvious
consequence of this is the formation of attaching and
effacing lesions (Fig. 3) and this secretion system is
essential for colonization and persistence in cattle.
Another fundamental role for this system could be in
disabling the M-cell on contact to then allow
colonization of the epithelium in that area. This is
analogous to the type III secretion system of Yersinia
spp. that is able to rapidly disable macrophages and
prevent phagocytosis. One hypothesis to explain the
EHEC Ol 57:H7 tropism is that the type III secretion
system is only primed for action by signals present in
the lower gastrointestinal tract, thus allowing this
specific region to be colonized rather than FAE at higher
sites in the gastrointestinal tract. Subsequent spread
and persistence of the bacteria at the terminal rectal site
will require other components such as flagellae and
fimbriae as well as the capacity to multiply in the mucus
layer.
EPECvs EHEC in cattle
In contrast to the related but non-toxigenic entero-
pathogenic E. coli (EPEC), EHEC OI57:H7 does not
cause disease in cattle and can colonize and potentially
recolonize animals for long periods (weeks). This
long-term shedding relies on preventing both an
TOP LEFT:
Fig. 3. A/E lesions in the bovine
spiral colon induced by a human
EHEC 0111 ;H- strain (E43035N)




Fig. 4 Expression of tir::egfp
in f. coliOKI: H7 on contact with
cultured EBL cells. Cells were
incubated with bacteria before
fixation at the time points indicated,
(b). (d) and (f) show expression of
A//:: ep//7at 0 min (b). 15 min with
EBL contact (d) and 15 min without
EBL contact (f). (a), (c) and (e) show
bacterial phase contrast images at 0
min (a), 15 min with EBL contact (c)
and 15 min without EBL contact (e).
COURTESY D.L.GALLY
LOWER LEFT:
Fig. 5. Model illustrating primed
expression of type III secretion on
colonization of the bovine terminal
rectum, (1) Transition through the
majority of the bovine gastrointestinal
tract without epithelial interaction.
(2) In the lower gastrointestinal
tract a combination of environmental
cues, including higher bacteria
levels and quorum sensing, lead to
expression of the basal type III
secretion apparatus. At this time
the mRNA for the EspADB translocon
may also be produced. (3) With a
further signal, such as cell contact,
the mRNA is translated and EspA
filaments are produced. Transcription
of certain type III secreted effector
proteins occurs and intimin is
expressed and inserted into the
bacterial outer membrane (4 & 5).
Secretion of effector proteins may
occur in a co-ordinated manner,
controlled by both expression
patterns and differential affinities
of effector proteins for shared
chaperones that escort the secreted
proteins to the apparatus and out of
the bacterial cell. (6) Cytoskeletal
rearrangements occur as a
consequence of the activities of the
injected effector proteins and
the interaction of intimin with the
translocated intimin receptor (Tir).
The result is an intimately attached
bacterium and an attaching and
effacing (A/E) lesion. (7) From this
initial binding site the bacteria
spread to colonize the surrounding
epithelium using a combination of
flagellae, fimbriae and type III






Fig. 6. (a) EHEC 0157:H7
responds to host environmental
signals and expresses adhesins on
its outer membrane, (b) EHEC
0157: H7 binds to microvilli on the
host-cell surtace. (c) LEE4
(EspADB translocon) mRNA (shown
in blue) is translated in situ at the
Inner membrane of the TTSS. The
resultant Esp proteins are then
exported through the needle
complex. In this way translation
and secretion are coupled.
(d) EHEC 0157: H7 producesa
long EspA filament that allows the
injection of the translocated
intimin receptor (Tir) into the host
cell where it inserts into the
membrane. EHEC 0157: H7 then
binds tightly to the host cell via this
Tir-intimin interaction, (e) Host-
cell cytoskeletal rearrangements
result in EHEC 0157: H7 embedding
in the host-cell membrane as part
of the formation of an attaching
and effacing (A/E) lesion.
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inflammatory response and an adaptive immune
response on colonization. Multiple factors contribute to
this biology.
1.The very restricted site of colonization may limit
responses in comparison to generalized colonization of
the gut, orgastrointestinal tract.
2. In vitro, most EHEC isolates limit expression of
important surface antigens such as the type III
translocation filaments and intimin; this is in stark
contrast to EPEC strains characterized to date that
show less restricted expression.
3. The regulation in EHEC 0157:H7 has evolved to
allow rapid expression of these type III secretion-
related factors on contactwith host cells (Fig. 4).
4. Other EHEC factors such as VT/SLT appear to inhibit
pro-inflammatory cytokine expression.
Having described EHECOl 57: H7 as a commensal in
cattle earlier in the article, it is clear that this belies a
complex multifactorial interaction with the bovine host
that leads to colonization by stealth. Transfer this
bacterium to humans as an incidental host and the
consequences can be devastating. This difference
primarily lies with the receptor distribution for the
VT/SLT in the two hosts, but also is likely to reflect their
differences in colonization patterns, gene expression
and signalling pathways. Fig. 5 illustrates the initial
sequential interactions envisaged currently
• EH EC 0157: H7 - the movie
We have worked with a UK-based animation company
Biovisual (www.biovisual.co.uk) to produce a full-
length animation representing the key stages ofEHEC
Ol 57:H7 interaction with the host. Biovisual produces
custom animations that aim to summarize complex
microbiological processes in a 3D environment. Still
images illustrating steps in the process are shown
in Fig. 6 and the full animation can be viewed at
the Biovisual website or at our laboratory homepage
(www.vet.ed.ac.uk/zap/research/movie.htm).
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